Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 1 of 84A Mul
ticentre, Randomized, Double-blinded, Placebo -controlled, Parallel Group, Single-
dose Design to Determine the Efficacy and Safety of Nerinetide in Participants with Acute 
Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding  Thrombolysis 
(ESCAPE -NEXT  Trial)  
PROT
OCOL NA-1-009 
Versi
on 6.0 
DATE : 01 June 2022  
Compou
nd: Nerinetide (NA-1) 
Coord
inating Centre 
University of Calgary 
Health Authority File Number:  
Eudra CT 2020 -002360 -30 
US IND 
clinicaltrials.gov number  118,087 
[STUDY_ID_REMOVED]  
Foothills Medical Centre
[ADDRESS_615508]
Toronto, Ontario, Canad a M5V 1E7
Personal Protected Data
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 3 of 84DOCUMENT HISTORY  
Document  Date  
Original Protocol /Version 1.[ADDRESS_615509] 2020  
Version 4.0  26 November 2020  
Version 5.0  18 November 2021  
Version 6.0  01 June  2022  
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 4 of 84Table of Contents 
SIGNATURES OF APPROVAL  ........................................................................................................................ 2  
1 PROTOCOL SUMMARY  ........................................................................................................ 8  
1.1 SYNOPSIS  .............................................................................................................................................  8 
1.2 COORDINATING CENTRE AND SPONSOR .......................................................................................... 18 
2 INTRODUCTION  ................................................................................................................... 19  
2.1 BACKGROUND  ...................................................................................................................................  19 
2.1.1  NERINETIDE (NA-1): A POST-SYNAPTIC DENSITY [ADDRESS_615510] OF ALTEPLASE ON NERINETIDE  21 
2.1.3  THROMBECTOMY AS A STROKE TREATMENT  21 
2.1.4  TREATMENT OF STROKE WITH NERINETIDE IN NON-HUMAN PRIMATES  22 
2.1.5  PREVIOUS CLINICAL TRIALS  22 
2.2 STUDY RATIONALE  ...........................................................................................................................  23 
2.3 BENEFIT /RISK ASSESSMENT  ............................................................................................................ 24 
2.3.1  RISK ASSESSMENT  24 
2.3.2  BENEFIT ASSESSMENT  24 
2.3.3  OVERALL BENEFIT : RISK CONCLUSION  25 
3 TRIAL OBJECTIVES  ............................................................................................................ 26  
3.1 OBJECTIVES  ......................................................................................................................................  26 
3.1.1  PRIMARY OBJECTIVE  27 
3.1.2  SECONDARY OBJECTIVES  27 
3.1.3  TERTIARY OBJECTIVES  27 
3.1.4  SAFETY OBJECTIVES  27 
3.1.5  1-Y EAR FOLLOW UP ANALYTIC SUB-TRIAL OBJECTIVES 28 
3
.2 OUTCOMES  ........................................................................................................................................  28 
3.2.1  PRIMARY EFFICACY OUTCOME  28 
3.2.2  SECONDARY EFFICACY OUTCOMES  28 
3.2.3  TERTIARY OUTCOMES  28 
3.
2.4 1-Y EAR FOLLOW UP ANALYTIC SUB-TRIAL OUTCOMES 29 
3.
2.5 SAFETY OUTCOMES  29 
4 TRIAL DESIGN  ...................................................................................................................... 30  
4.1 OVERALL DESIGN  ............................................................................................................................. 30 
4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN  ..................................................................................  30 
4.3 JUSTIFICATION FOR THE TARGET STUDY POPULATION  ................................................................ . 32 
4.4 JUSTIFICATION FOR DOSE ................................................................................................................ 33 
4.5 END OF STUDY DEFINITION .............................................................................................................. 33 
5 STUDY POPULATION  .......................................................................................................... 34  
5.1 INCLUSION CRITERIA  .......................................................................................................................  34 
5.2 EXCLUSION CRITERIA  ......................................................................................................................  34 
5.3 LIFESTYLE CONSIDERATIONS  ..........................................................................................................  35 
5.4 SCREEN FAILURES  ............................................................................................................................  35 
5.5 STUDY ENROLMENT PROCESS  ......................................................................................................... 35 
5.5.1  IMAGING  36 
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 5 of 845.5.2  CONSENT PROCESS  37 
5.5.3  PHYSICAL EXAMINATIONS  37 
6 STUDY INTERVENTIONS AND CONCOMITANT THERAPY  .................................... 38  
6.1 STUDY INTERVENTION ADMINISTRATION  .......................................................................................  38 
6.2 PREPARATION / HANDLING / STORAGE / ACCOUNTABILITY  ............................................................. 38 
6.2.1  STORAGE AND ACCOUNTABILITY  39 
6.2.2  DISPOSITION OF STUDY DRUG SUPPLIES  39 
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING  ................................................  40 
6.3.1  PROCEDURE FOR BREAKING THE RANDOMIZATION CODE 40 
6.4 STUDY INTERVENTION COMPLIANCE  ..............................................................................................  41 
6.5 DOSE MODIFICATION  .......................................................................................................................  41 
6.6 CONTINUED ACCESS TO STUDY INTERVENTION AFTER THE END OF THE STUDY  .........................  41 
6.7 TREATMENT OF OVERDOSE  .............................................................................................................  41 
6.8 CONCOMITANT THERAPY  ................................................................................................................ 42 
6.8.1  RESCUE MEDICINE /TREATMENT  42 
6.9 ENDOVASCULAR INTERVENTION AND STROKE CARE .................................................................... 43 
7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ................................................................................... 44  
7.1 DISCONTINUATION OF STUDY INTERVENTION  ................................................................................  44 
7.2 PARTICIPANT DISCONTINUATION /WITHDRAWAL FROM THE TRIAL  .............................................  [ADDRESS_615511] TO FOLLOW UP  ........................................................................................................................ 44 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................................................. 46  
8.1 EFFICACY ASSESSMENTS ..................................................................................................................  46 
8.1.1  THE MODIFIED RANKIN SCALE  46 
8.1.2  MORTALITY RATE 46 
8.1.3  WORSENING OF STROKE  46 
8.1.4  VOLUME OF STROKES  46 
8.1.5  THE NATIONAL INSTITUTES OF HEALTH STROKE SCALE  47 
8.
1.6 BARTHEL INDEX  47 
8.1.7  EQ-5D-5L 47 
8.2 SAFETY  ASSESSMENTS  .............................................................................................................. 47 
8.2.1  VITAL SIGNS  47 
8.2.2  CLINICAL SAFETY LABORATORY ASSESSMENTS  47 
8.2.3  PREGNANCY TESTING  48 
8.3 ADVERSE EVENTS (AE S), SERIOUS ADVERSE EVENTS (SAE S), AND OTHER SAFETY REPORTING
48 
8.
3.1 TIME PERIOD AND FREQUENCY FOR COLLECTING AE AND SAE  INFORMATION  48 
8.3.2  METHOD OF DETECTING AES AND SAE S 48 
8.3.3  FOLLOW -UP OF AES AND SAE S 49 
8.3.4  REGULATORY REPORTING REQUIREMENTS FOR SAE S 49 
8.3.5  PREGNANCY  50 
8.4 PHARMACOKINETICS ........................................................................................................................ 50 
9 STATISTICS  ........................................................................................................................... 52  
9.1 SAMPLE SIZE DETERMINATION  ....................................................................................................... 52 
9.2 ANALYSIS SETS ................................................................................................................................ . 52 
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 6 of 849.3 STATISTICAL ANALYSIS  ................................................................................................................... 53 
9.3.1  GENERAL CONSIDERATIONS  53 
9.3.2  EFFICACY ANALYSIS  55 
9.3.3  ANALYSES OF SAFETY  59 
9.3.4  PHARMACOKINETICS  59 
9.4 INTERIM ANALYSIS  ...........................................................................................................................  60 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ... 61  
10.1  APPENDIX 1: REGULATORY , ETHICAL , AND STUDY OVERSIGHT CONSIDERATIONS  ..................  61 
10.1.1  REGULATORY AND ETHICAL CONSIDERATIONS  61 
10.1.2  FINANCIAL DISCLOSURE  61 
10.1.3  INFORMED CONSENT PROCESS  62 
10.1.4  DATA PROTECTION  62 
10.1.5  COMMITTEES STRUCTURE  63 
10.1.6  DISSEMINATION OF CLINICAL STUDY DATA 63 
10.1.7  DATA QUALITY ASSURANCE  63 
10.1.8  SOURCE DOCUMENTS  64 
10.1.9  STUDY AND SITE START AND CLOSURE  65 
10.1.10  PUBLICATION POLICY  66 
10.1.11  AUDITS AND INSPECTIONS  67 
10.2  APPENDIX 2: CLINICAL LABORATORY TESTS AND IMAGING  .......................................................  68 
10.2.1  CLINICAL LABORATORY TESTS  68 
10.2.2  IMAGING  68 
10.3  APPENDIX 3: ADVERSE EVENTS : DEFINITIONS AND PROCEDURES FOR RECORDING , 
EVALUATING , FOLLOW -UP, AND REPORTING  .......................................................................................... 69 
10.3.1  DEFINITION OF AE 69 
10.3.2  DEFINITION OF SAE 70 
10.3.3  RECORDING AND FOLLOW -UP OF AE AND/OR SAE  71 
10.3.4  REPORTING OF SAE S 73 
10.
4 APPENDIX 4: COLLECTION OF PREGNANCY INFORMATION  .........................................................  74 
10.5  APPENDIX 5: ABBREVIATIONS ........................................................................................................  75 
10.6  APPENDIX 6: COUNTRY -SPECIFIC REQUIREMENTS  ......................................................................  77 
10.6.1  ADDITION TO CONSENT PROCESS - SECTION 5.5.2  77 
10.6.2  ADDITION TO REMOTE SOURCE DOCUMENT VERIFICATION - SECTION 10.1.7  77 
11 REFERENCES  ...................................................................................................................... 78  
12 INVESTIGATOR’S AGREEMENT  ................................................................................... 81  
13 ADDENDUM  ......................................................................................................................... 82  
13.1  CO VID- 19 CONSIDERATIONS  ........................................................................................................  82 
13.2  ASSESSMENT QUESTIONNAIRES  .....................................................................................................  84 
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 7 of 84Tables and Figures  
F
igure 1: Inhibition of NO Production by [CONTACT_479409] (NA -1) via Perturbation of NMDA Receptor 
PSD-95 Interactions  ........................................................................................................................ 21  
Tab
le 1-1: Schedule of Activities - Main Trial  ................................................................................ 16  
Table 1 -2: Schedule of Activities: [ADDRESS_615512] .......... 17  
Table 3 -1: Objectives and Endpoints  .............................................................................................. 26  
Table 6 -1: Study Interventions ........................................................................................................ 38  
Table 9 -1: Statistical Analysis Methods  ......................................................................................... 55  
Table 10 -1: Protocol-Required Safety Laboratory Assessments  .................................................... 68  
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 8 of 841 PROTOCOL SUMMARY 
1.1 Synopsis  
Title  A Multicentre, Randomized, Double -blinded, Placebo -controlled, Parallel 
Group, Single-dose Design to Determine the Efficacy and Safety of 
Nerinetide in Participants  with Acute Ischemic Stroke Undergoing 
Endovascular Thrombectomy Excluding Thrombolysis  
Trial Code  ESCAPE -NEXT (NA -1-009) 
Trial Design  This study is a Phase 3, randomized, multicentre, blinded, placebo -
controlled, parallel group, single-dose design with a single interim analysis for safety and efficacy . Because AIS is a medical emergency, t
he 
trial is designed to enable the administration of standard -of-care  
treatments without delay in order to save the life of the person concerned, restore good health or alleviate suffering.  
At total of up to 850 male and female p articipants  aged 18 years and older 
harboring an acute ischemic stroke who are selected for endovascular 
revascularization without intravenous or intra-arterial thrombolytic therapy will be given a single, 2.6 mg/kg (up to a maximum dose of 270 mg) intravenous dose of nerinetide or placebo. Randomization will be stratified by [CONTACT_479410] ≤4.5 hours (yes/no) and done with  stochastic minimization to balance baseline factors within  
strata.  Outcomes of the main trial will be evaluated throughout a [ADDRESS_615513] report will be based on the completion of Day 90 visits for the main trial.  The second report will be following the completion of the 1-Year  follow up for the analytic sub-trial.  
Trial Objectives  
for Main Trial  The primary objective is  to determine the efficacy of the neuroprotectant, 
nerinetide in : 
•Reducing global disability in participants with acute ischemicstroke (AIS)
The secondary objectives are to determine the efficacy of nerinetide in: 
1) Reducing mortality rate
2) Reducing worsening of stroke*
3) Re
ducing functional dependence
4) Improving neurological outcome
*Worsening of stroke is defined as (A) progression, or hemorrhagic
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 9 of 84transformation of  the index stroke , as documented by [CONTACT_479411]  (a) life -threatening requiring intervention and/or (b) results in 
increased disability as gauged by a ≥[ADDRESS_615514] NIHSS 
during hospi[INVESTIGATOR_26109] (B) results in death  from the index stroke. 
Th
e tertiary  objectives are to determine the efficacy of nerinetide in: 
•Decreasing infarct volume
•Improving activities of daily living
•Reducing dependency or death
•Improving excellent functional outcome
•Improving health related quality of life
The safety objectives are to determine the safety in participant s with acute 
ischemic strokes of a single 2.6 mg/kg dose (up to a maximum dose of 
270 mg) of intravenous nerinetide,  based on serious adverse events 
(SAEs) and 90 -day mortality.  
Efficacy 
Outcomes for Main Trial The primary outcome is : 
•The proportion of participants with independent functioning on themodified Rankin Scale ( mRS), as defined by a score of 0-2, at Day
90.
The secondary outcomes include:  
1) M ortality rate, as defined by [CONTACT_479412] (%) for mortality over the
90-day study period.
2)
Proportion of participants exhibiting a worsening of their index
stroke. Worsening of stroke is defined as (A) progression, or
hemorrhagic transformation of the index stroke , as documented by
[CONTACT_479413] (a) life-threatening requiring interventionand/or (b) results in increased disability as gauged by a ≥[ADDRESS_615515] NIHSS during hospi[INVESTIGATOR_26109] (B) results indeath  from the index stroke.
3) A shift of one or more categories to reduced functional dependence
analyzed across the whole distribution of outcomes on the mRS at
Day [ADDRESS_615516] randomization.
4)Proportion of participants with good neurological outcome, as
defined by a score of 0-[ADDRESS_615517]
randomization.
Tertiary outcomes include:  
•Volume of stroke as measured by  [CONTACT_479414] (MRI
preferred).
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 10 of 84•Proportion of participant s with functional independence in
activities of daily living, as defined by a score of ≥ 95 on the Barthel
Index (BI) at Day [ADDRESS_615518] randomization.
•Proportion of participants with reduced moderate or severe
disability or death, as defined by a score of 4-[ADDRESS_615519] randomization.
•Proportion of participant s with excellent functional outcome , as
defined by a score of 0-[ADDRESS_615520] randomization.
•Health -related quality of life, as measured by [CONTACT_20367] -5D-5L at Day
90.
Trial Objectives 
for Analytic 
Sub-Trial at 1-Year Follow-up There will be a n analytic 1-Year  follow -up sub-trial investigating the 
long-term effects of nerinetide treatment .  
The primary objective is to determine the efficacy of the neuroprotectant, nerinetide at 1-Y ear post randomization  in:  
•Reducing global disability in participants with acute ischemicstroke (AIS).
The secondary objectives are to determine the efficacy of nerinetide in:  
•Reducing mortality rate
•Improving activities of daily living
•Improving health related quality of life
Efficacy 
Outcomes for 1-Year Follow -up  The primary outcome  of the 1-Year follow -up is: 
•The proportion of participant s with independent functioning on the
modified Rankin Scale (mRS), as defined by a score of 0-[ADDRESS_615521] randomization.
The secondary outcomes include:  
•A reduction in mortality rate, as defined by [CONTACT_479412] (%) for
mortality over the 1-Year study follow-up period.
•The proportion of participant s with independent function on
activities of daily living defined on the Barthel Index (BI) with ascore of ≥ [ADDRESS_615522] randomization.
•Health -related quality of life, as measured by [CONTACT_20367] -5D-5L at 1-
Year post randomization.
Safety Outcomes 
for Main Trial  Safety outcomes include: 
•Serious adverse events  (SAEs) to Day 90.
•90-day mortality .
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 11 of 84Additional Safety outcomes include:  
•Adverse events (AEs)  to Day 30.
•Discontinuations due to AEs.
•Baseline and Day [ADDRESS_615523]-dose study drug laboratory tests.
•Baseline and post-dose (to Day 2 ) study drug vital signs.
Number of  
Participants  Up to 850 male and female participants  harboring AIS and who are 
selected for endovascular revascularization without intravenous  or intra -
arterial  thrombolytic therapy will be enrolled.  
Inclusion/ 
Exclusion 
Criteria  Inclusion Criteria  
1)Acute ischemic stroke (AIS) select ed for emergency  endovascular
treatment .
2) Age 18 years or greater.
3)Onset (last-known-well) time to randomization time within 12 hours.
4)Disabling stroke defined as a baseline National Institutes of Health
Stroke Score (NIHSS)
a.NIHSS > 5 for internal carotid artery ( ICA) and M1-middle
cerebral artery (MCA) occlusion or
b. NIHSS > 10 for M2-MCA occlusion.
5)Confirmed symptomatic intracranial occlusion at one or more of thefollowing locations: Intracranial carotid I/ T/L, M1 or M2 segment
MCA.  Tandem extracranial carotid and intracranial occlusions  are
permitted .
6)Pre-stroke (24 hours prior to stroke onset) independent functional
status in activities of daily living with modified Barthel Index (BI) ≥95. Patient must be living without requiring nursing care.
7) Qualifying imaging performed less than 2 hours prior to
randomization.
8) Consent process completed as per national laws and regulation and the
applicable ethics committee requirements.
Exclusion Criteria 
1)Treated  with a tissue  plasminogen activator (e.g., alteplase or
tenecteplase) within 24 hours before randomization.
2)Determination  by [CONTACT_1963] , based on current treatment
guidelines  and medical evidence, that treatment with a plasminogen
activator  is indicated .
3) L arge core of established infarction defined as ASPECTS 0 -4.
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 12 of 844)Absent or poor collateral circulation on qualifying imaging  (e.g.,
Collateral score of 0 or 1).
5)Any intracranial hemorrhage on the qualifying imaging.
6) Planned use of an endovascular device not having approval or
clearance by [CONTACT_479415].
7) Endovascular thrombectomy procedure is completed as defined by [CONTACT_479416] 2c/3 reperfusion or completion of groin / arterial
closure.
8)Clinical history, past imaging or clinical judgment suggesting that the
intracranial occlusion is chronic or there is suspected intracranialdissection such that there is a predicted lack of success withendovascular intervention.
9) Estimated or known weight > 120 kg (264 lbs).
10)Pregnancy/Lactation; female, with positive urine or serum beta human
chorionic gonadotropin (β -hCG) test, or breastfeeding.
11) Known prior receipt of nerinetide for any reason, including prior
enrolment in this ESCAPE -NEXT trial.
12) Severe known renal impairment defined as requiring renal
replacement therapy (hemo- or peritoneal dialysis ).
13)Severe or fatal comorbid illness that will prevent improvement orfollow up.
14)Inability to complete follow -up treatment to Day 90.
15)Participation in another clinical trial investigating a drug, medicaldevice, or a medical procedure in the 30 days preceding trial
inclusion.
Countries  Global, multicent re trial 
Treatment  Nerinetide  2.6 mg/kg ( up to a maximum dose of 270 mg or matching 
placebo volume) will be administered as a single 10±1minute intravenous infusion using an infusion pump starting after randomization.   
Consent  Initial Informed Consent  
Participants or their legally authorized representative will be required to sign a statement of informed consent that meets the requirements of applicable national laws and regulation and the ethics committee.  
See Appendix 10.6.1 for additional country specific details.  
Regained Capacity Consent  
If the original consent process involved anyone other than the participant, 
and if required by [CONTACT_104130], consent will be sought for the 
Version: 6.0  Protocol NA -1-009 
Date: [ADDRESS_615524] 
regained capac ity.  
Note: Electronic consent tools may be used for initial and regained 
capacity consent, as permitted under national laws and regulations and the applicable Independent Review Boards/Ethics Committee.  
Randomization 
Method Treatment will be assigned using 1:1 randomization ( nerinetide: placebo)  
with a stratification based on  time from stroke onset to randomization of 
less than or equal to  4.5 hours (yes/no) and a randomized minimization 
algorithm to minimize the contribution of imbalances in baseline factors (age, sex,  baseline NIHSS score, 
baseline ASPECT score, occlusion 
location , time from qualifying imaging to randomization, and site ).  
Duration of 
Treatment Participants  will receive a single [ADDRESS_615525] of care. At Day 30 and Day 90 it is preferred that 
participants will return to clinic. If an in- clinic visit is not possible, the 
participant  can be contact[CONTACT_479417]  (preferred) or by [CONTACT_756] 
(last option). 
For the purpose of the analytic 1-Year  sub-trial, p articipants  will be 
contact[CONTACT_479418]. 
The end of the study is defined as the date of the last contact  [CONTACT_479419] 1-Year  follow up.   
Laboratory 
Tests If the participant  is female and is of childbearing potential, a pregnancy 
test (urine or serum point-of -care pregnancy test) must be completed  and 
a negative test result  obtained prior to inclusion in the trial. 
In order to support the assessment of safety, baseline ( pre-dose) and post-
dose (Day 2 ) hematology, electrolytes  and chemistry laboratory results 
will be reported and analysed.   
Assessment of 
Efficacy and 
Power  The primary estimand will be the adjusted unconditional population 
difference in the mRS response (i.e., mRS score of 0-2) proportions between treatment conditions (nerinetide vs. placebo) in the target patient population at Day 90. Deaths occurring over the Day 90 period will be considered as non-responses.  
Assuming a 50% overall responder rate for the placebo group population (as observed in the ESCAPE-NA1 trial ), there will be approximately 
91.3%power to detect an 11.4% absolute effect difference between 
response rate (proportion of responders, with Day 90 mRS in the range 0 
to 2 with nerinetide and placebo, at alpha level 0.25 one-sided ( 0.05 2-
sided ), using the planned sample size of 850 evaluable subjects, 
randomized 1:1, per group [EaST v6.5, 2022]. 
Version: 6.0  Protocol NA -1-009 
Date: [ADDRESS_615526] at 60% information (primary 
endpoint), i.e.,  when approximately [ADDRESS_615527] 
reached their primary endpoint assessment. The cumulative alpha spent at 
the interim analysis is 0.004 and final analysis 0.025, one-sided (0.05 2-sided); the stoppi[INVESTIGATOR_3073] Z scale are 2.668 (interim) and 1.981 (final) and on the p-value scale 0.004 (interim) and 0.021 (final), all on the assumption that the interim is conducted at 60% information.  
Statistical 
Assumptions  The primary and secondary efficacy endpoint analyses will be conducted 
on the intent-to -treat (ITT) population, defined as all randomized 
participant s, regardless of treatment actually received.   The primary 
analysis will be repeated on the Per Protocol (PP) population.  An ITT analysis will also be conducted for the secondary endpoints, with participant grouped according to the randomized (intended) treatment. 
The pi[INVESTIGATOR_479348] a 
logistic regression model with fixed effects including the treatment group , 
the stratification covariate of time from stroke onset to  randomization ≤ 
4.5 hours (yes/no) and the randomized minimization factors (age, sex, baseline NIHSS score, occlusion location, time from qualifying  imaging 
to randomization, baseline ASPECT score, sex, and pooled site), and an interaction term of treatment by [CONTACT_479410]. If the interaction term is not significant at the level of 0.05  it will be 
removed from the model.  
The analysis for the secondary estimands with binary endpoints will be based on the ITT population following the same methods as the primary (logistic regression based, with the odds ratios along with the 95% CI reported in addition to the primary Ge et al, 2011 method results) and secondary (two sample proportion test) analyses of the primary estimand. Mortality analysis will be additionally supported using time-to -death 
survival function analysis, both unadjusted shown using Kaplan-Meier analysis  and adju sted via Cox proportional hazards regression. 
For the secondary estimand of the “mRS shift analysis”, the first step in the analysis will be an analysis with mRS score 5 and 6 combined, using a proportional odds model to derive the common odds of improvement (“shift”) along the mRS scale. It will be adjusted for the same covariates as the primary analysis. The mRS shift analysis will only be conducted as part of the fixed sequence testing sequence provided that the proportional odds assumption is found to be valid on testing. If it is found to be inval id, the remaining secondary endpoints will be analyzed in the fixed 
testing sequence specified without the mRS shift analysis; i.e. it will be removed from the fixed sequence testing sequence. Adjustment will include the same variables as the specified in the adjusted logistic regression model for the primary estimand.  
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 15 of 84The secondary outcome of NIHSS scores  at Day 90  will be dichotomized 
into 0-2 (indicating a good neurological outcome) versus >2 (indicating 
otherwise). The proportion of participant  achieving a good neurological 
outcome at Day [ADDRESS_615528] brain imaging in 
the nerinetide versus placebo control participants will be assessed using an unadjusted two-tailed Student’s t-test  and supported bya linear 
regression that includes the stratification and minimization variables . 
Secondary outcomes will be assessed in a pre-defined hierarchical order.  
The tertiary outcomes comprising proportions of responders will be analyzed similarly to the primary outcome or will be assessed descriptively .  
Three separate efficacy analysis timepoints are planned for this trial. The first analysis will be at the interim analysis planned at 60% information on the primary endpoint. The second analysis timepoint will be based on the completion of Day [ADDRESS_615529] analysis will 
be following the completion of the 1 -Year follow up. 
For the safety analysis, the frequency of SAEs, SAEs resulting in death, AEs and discontinuations due to AEs will be summarized .   
Independent 
Data Monitoring Committee An Independent Data Monitoring Committee (IDMC) will monitor patient 
safety and scientific integrity during the trial.  
The interim analys is for efficacy during the trial will also be assessed by  
[CONTACT_31849]. The interim efficacy analysis will be performed after approximately [ADDRESS_615530] complete the Day 90 follow -up, at 
60% information on the primary endpoint.  
Bioanalytical Sampling  Plasma samples from up to 100 participants in North America ( Canada 
and the US) will be collected for potential pharmacokinetic assessment. 
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 16 of 84Table 1-1: Schedule of Activities - Main Trial 
Visit /Contact  V1 V2 V3 V4 V5 V6 
Day Day [ADDRESS_615531]-EVT  Day 2/3  Day 61 or 
discharge  Day 302 Day 902 
Window  (~2 h)  (18-56 h)  (±5 d)  (-21 to +7d)  
Informed consent  X 
Regained capacity informed consent3 X X X X 
History and physical examination  X 
Weight4 X 
Vital Signs (BP, HR, Temp erature ) 5 X X X 
Randomization/  
Study drug administration  X 
Mortality  X X X X X 
NIHSS  X X X X X X 
mRS6 X X X X 
Barthel Index  X X X 
EQ-5D-5L X 
Qualifying  Imaging  X 
Endovascular Procedure  X 
MRI/NCCT head7 X 
Laboratory Assessments  X8 X 
Pregnancy test9 X 
Pharmacokinetic samples10 X 
AE Collected to Day 30  
SAE  Collected to Day 90  
Prior medications  X 
Concomitant medications  Collected to Day 6 or discharge  
1.Visit will occur at Day 6 or hospi[INVESTIGATOR_479349] 6.
2.At Day 30 and Day 90 it is preferred that participant s will return to clinic.  If a in clinic visit is not possible the participant can
be contact[CONTACT_479420]  (preferred) or by [CONTACT_756] (last option).
3.If the original process involved anyone other than the participant (and if required), site staff will make ongoing efforts until: (1)
regained capacity consent is obtained from participant, (2) death, or (3) completion of the Day 90 assessment.
4.At baseline estimated or actual weight will be collected. If an estimated weight was collected at baseline, actual weight should
be collected as soon as feasible and prior to discharge . 
5.Vital signs (BP, HR only) will be recorded immediately before and after completion of the study drug infusion, temperature will 
be collected  at baseline only if standard of care.
6.Historical (pre -stroke) mRS score can be collected at any time .
7.MRI head may be supplanted by [CONTACT_479421].
8.Blood should be drawn at baseline, but results are not required prior to randomization. Results from primary hospi[INVESTIGATOR_307] (within 8hours) are accepted.
9.If the participant is female and is of childbearing potential a pregnancy test (urine or serum point-of -care pregnancy test) must
be completed and the result must be negative; this is the only mandatory laboratory test prior to randomization.
10.PK samples will be collected from up to 100 participants: pre-dose and at 10, 20, 30 and 60 min after the start of study drug
administration.
d = days; h = hours  
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 17 of 84Table 1-2: Schedule of Activities: 1-Y ear Follow Up  Telemedicine or Telephone [CONTACT_112684] 
[CONTACT_112684]  V7 
1-Year  Follow  up
Day Day 365  
Window  (±30 d)  
Mortality  X 
EQ-5D-5L X 
mRS  X 
Barthel Index  X 
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 18 of 841.2 Coordinating Centre and Sponsor  
Coordinating Centre  
Overall [CONTACT_15957]ordinating 
Investigator: 
[CONTACT_15957]-Coordinating  
Investigator 
[CONTACT_2728]:  
Sponsor Medical Oversight  
Imaging Adjudication  
Pharmacokinetic  Analysis  
Personal Protected Data
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 19 of 84 2 INTRODUCTION  
2.1 Background  
Stroke is a leading cause of mortality and neurological disability worldwide 1-3. When  blood flow 
to the brain is interrupted during a stroke , some brain cells die immediately, while others remain 
at risk for death. These damaged cells make up t he ischemic penumbra  and can linger in a 
compromised state for periods varying from minutes to several hours 4-6.   Given that there is a 
critical time, a “therapeutic window”, which may vary from minutes to a few hours in which cerebral ischemia can be reversed or mitigated , stroke should be treated as a medical emergency  
and treatment should commence without delay in order to save the life of the person concerned, 
restore good health and alleviate suffering .  
Brain tissue is rapi[INVESTIGATOR_479350]
8 and  early intervention is critical 
to improve stroke  outcome. Alteplase, recombinant tissue plasminogen activator, is  the only 
approved pharmacological treatment for acute ischemic stroke (AIS) and must be administered  
within 3 -4.5 hours of symptom onset, and only in those patients for which the possibility of 
hemorrhagic stroke was excluded. According to the 2017 claims data only 10% of all ischemic 
strokes in the [LOCATION_003] are treated with alteplase.    
Endovascular thrombectomy (EVT) is being used with or without alteplase to retrieve blood clots in AIS caused by [CONTACT_93974] (LVO)
9. Even with EVT, only about 10% patients return 
to normal after their AIS9, and only approximately half reach functional independence10.  
Therefore, although reperfusion therapi[INVESTIGATOR_479351], there remains a significant 
unmet medical need. Such a need would be fulfilled by a neuroprotective therapy – one that 
enhances the brain’s resilience to ischemia. However, at present , no approved neuroprotective 
pharmacotherap y exist s. 
Nerinetide ( NA-1) is a first in class neuroprotectant that is designed to address the major unmet 
medical need for treatments that reduce the functional disability produced by [CONTACT_479422]. It reduces the vulnerability of ischemic brain tissue to hypoperfusion by [CONTACT_479423]. Nerinetide is intended, alone or in combination with available therapi[INVESTIGATOR_014], to treat acute stroke, a serious and life- threatening disease.    
For this reason, nerinetide  is being developed as a drug for use in emergency situations  aimed at 
reducing global disability in patients with acute ischemic stroke.   Nerinetide may provide 
significant benefit for the treatment of acute cerebral ischemia if administered to stroke patients who present to medical attention before infarction is complete. The rapid progression of 
irreversible brain injury in most acute strokes implies a short window of clinical efficacy of any 
treatment, including nerinetide.  T he ability to identify patients with salvageable brain using the 
criteria used in the ESCAPE trial
[ADDRESS_615532] of reperfusion therapi[INVESTIGATOR_014]. The  preclinical and clinical data support this notion.  
A detailed description of the chemistry, pharmacology, efficacy, and safety of nerinetide is 
provided in the Investigator’s Brochure.  
 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 20 of 84 2.1.1 Nerinetide (NA -1): A Post-synaptic Density 95 Inhibitor  
Nerinetide ( NA-1) is a first in class neuroprotectant that is designed to address the major unmet 
medical need for treatments that reduce the functional disability produced by [CONTACT_479422]. It reduces the vulnerability of ischemic brain tissue to hypoperfusion by [CONTACT_479423]. Nerinetide is intended, alone or in combination with available therapi[INVESTIGATOR_014], to treat acute stroke, a serious and life- threatening disease.  
Nerinetide (NA -1) is a novel synthetic peptide composed of two parts: a [ADDRESS_615533] -synaptic density protein 95 (PSD -95), and an [ADDRESS_615534] -synaptic density protein-95 (PSD -95), which binds both 
the N -methyl -D-aspartate receptors (NMDARs) and neuronal nitric oxide synthases (nNOS) at 
excitatory synapses to form the NMDAR/PSD -95/nNOS complex that efficiently translates 
NMDAR overactivation to NO production during cerebral ischemia. Nerinetide inhibits the protein-protein interaction between PSD -[ADDRESS_615535] on other known NMDAR functions , but results in decreases in downstream 
neurotoxic signaling (i.e., NO production). Figure 1 summarizes the mechanism of inhibition of nitric oxide (NO) by [CONTACT_479424] ( NA-1).  
Based on pharmacokinetic studies, the plasma half -life of nerinetide at doses in the therapeutic 
range is in the 6 -15 minute range.  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 21 of 84  
Figure 1: Inhibition of NO Production by [CONTACT_479409] ( NA-1) via Perturbation of NMDA 
Receptor PSD -[ADDRESS_615536] nerinetide after residues 3 , 4, 5, 6, 7, 9, 11 and 
12 from the N -terminus  (https://web.expasy.org/peptide_cutter/ ). Similar  cleavage products were  
observed after incubating nerinetide with plasmin in  vitro18. Incubating nerinetide with alteplase 
in rat or human plasma reduced the n erinetide content in both. Concurrent administration of 
nerinetide and alteplase to rats caused a significant lowering of nerinetide levels18.  
2.1.3  Thrombectomy As a Stroke Treatment  
Medical devices may be used with or without alteplase to retrieve blood clots in large cerebral arteries that cause severe brain ischemia (“endovascular thrombectomy”)
9. The evidence that 
endovascular therapy (EVT) is effective in improving neurological outcome is strongest in patients who have the combination of an LVO as well as direct or indirect imaging evidence of salvageable brain (an ischemic penumbra) at the time of treatment initiation.  Current generation 
devices  are intended for patients whose AIS is caused by a LVO, and  produce higher rates of 
reperfusion than alteplase in  such  appropriately selected patients.  However, even with EVT, only 
about 10% patients return to normal as defined by [CONTACT_479425] (mRS) = 0 after their 

Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615537] there is no significant difference in outcomes between patients who were 
treated with EVT only as compared with those who received combined thrombolysis with 
alteplase and EVT19-21.  
Although reperfusion therapi[INVESTIGATOR_479352]/or EVT improve stroke prognosis, a 
significant need remains to reduce the overall number of AIS patients who have poor outcomes. As such, stroke remains a serious condition, with an unmet medical need.  
2.1.[ADDRESS_615538] whether nerinetide is beneficial when administered later in the setting of a prolonged temporary middle cerebral artery occlusion (tMCAO ), [ADDRESS_615539] volumes as compared with 
placebo as evaluated on MRI (T2-weighted M RI:  at 48 hours: p=0.006; DWI MRI at 48 hours: 
p=0.004; T2-weighted MRI at 14 Days: p=0.003).   
Animals treated with nerinetide exhibited improved non-human primate stroke score (NHPSS ) 
scores throughout the 14-day observation period days [p=0.004, two-way repeated measures 
analysis of variance ] and trended to better performance in the six -well and the valley staircase 
tasks
22. There were no statistically significant differences in any of the physiological parameters 
(including MAP) at any of the measured time points for the nerinetide versus placebo treated animals.    
More detailed information on these and other non-human primate studies are  provided in the 
Investigator’s Brochure.   
2.1.[ADDRESS_615540] been completed to date.  
The results of a Phase 1 trial conducted in healthy volunteers indicate that nerinetide is well 
tolerated  when administered in doses ranging between 0.02 and 2.60 mg/kg and a dose of 2.6 
mg/kg was selected for further clinical trials .  No serious adverse events ( SAEs) or 
discontinuations due to adverse events  were reported in the trial .   
In the  Phase [ADDRESS_615541] clinical trial using a dose of 2.60 mg/kg in patients undergoing 
endovascular repair of brain aneurysms, both unruptured and ruptured, the data suggest a 
treatment effect of nerinetide on the procedurally – induced stroke s.  The treatment effect was 
most evident when evaluat ing lesion counts using DWI or FLAIR imaging, and also in 
exploratory analyses  when evaluat ing lesion volume  in the mITT population . The treatment effect 
was most pronounced in participant s who suffered from a ruptured brain aneurysm, in whom 
infarct numbers and infarct volumes were reduced.  Exploratory analyses suggested that stroke 
volumes were also reduced when analyses accounted for delayed strokes, or for the non-normality of the data. There were three deaths during this trial , two in the placebo group and one  in the 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 23 of 84 nerinetide  group. The SAEs leading to death were all severe and unrelated to study drug. T here 
were no other discontinuations due to adverse events . Overall, nerinetide (NA-1) 2.60 mg/kg was 
well-tolerated and no safety concerns were identified in any of the patient groups  in the trial. 
The selectio n of the single IV dose of 2.60 mg/kg is based on the safety and tolerability profile of 
nerinetide  observed in the Phase 1 and 2 clinical trial s.  
In the ESCAPE -NA1 trial, treatment with single 2.6 mg/kg IV  dose of nerinetide  did not achieve 
the primary endpoint of the trial  in all participant s with ischemic stroke due to large vessel 
occlusion and who were selected for EVT, with and without intravenous alteplase. Among 
participant s who were not treated with alteplase, a treatment effect  was observed. Specifically, 
there was a benefit in the nerinetide group on the proportion of participant s achieving an mRS 0 -2 
at 90 days (59.4% for nerinetide participant s vs. 49.8% for placebo participant s) (O dds 
Ratio  = 1.657; 95% CI  1.055, 2.603; p =  0.028). There was also a reduction in mortality rate i n the 
participant s receiving nerinetide with an absolute  reduction in mortality rate of 7.5% (relative 
difference of 39.7%; p = 0.041, Fisher’s Exact Test ) without an increase in severe disability (i.e., 
mRS 4 or 5). Other measures of function, including the NIHSS and BI trended in the same direction, in favor of nerinetide. Lastly, treatment with nerinetide resulted in a significant reduction in median infarct volumes in the  nerinetide  group (p = 0.048).  
The results of the safety analysis from the ESCAPE -NA1 trial indicate that nerinetide was  well 
tolerated when given as a single IV  dose of 2.6 mg/kg with most adverse events occurring with a 
similar frequency in the drug and placebo groups. The only exception to that was an increase in serous hypotension immediately (within 2 hours) following the administration of nerinetide (6 SAEs in nerinetide vs. 0 in placebo). These cases were reported resolved within 2 days . There  
were n o other differences in other im portant safety outcomes observed.  When nerinetide is 
administered without alteplase there were fewer deaths and a fewer number of neurological serious adverse events (including stroke in evolution, ischemic stroke and hemorrhagic transformation). When nerinetide is administered with alteplase there were no differences in 
important safety outcomes observed between the nerinetide and placebo groups .  
2.[ADDRESS_615542] volumes in the nerinetide- treated group. The effectiveness of nerinetide on improving 
functional independence, mortality, and infarction volumes in the no -alteplase stratum was not 
seen in the stratum treated with alteplase. This is consistent with the hypothesi s that nerinetide 
Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615543]  acute strokes impli es a 
short window  of clinical efficacy of any treatment, including nerinetide.   
2.3 Benefit/Risk Assessment  
More detailed information about the chemistry, pharmacology, efficacy, safety and expected benefits and risks  of nerinetide  is provided in the Investigator’s Brochure.   
2.3.1 Risk Assessment  
Based on the clinical data available for nerinetide to date,  the major possible  risk for the proposed 
use is : 
• Higher rate of (transient) hypotension due to a transient elevation of blood histamine   
• Effect modification by [CONTACT_479426]   
2.3.[ADDRESS_615544] of possible benefits to the trial participants in ESCAPE-NEXT : 
• improved functional outcome (mRS 0-2) 
• reduced stroke mortality  
• improved good neurologic outcome (NIHSS 0-2)  
• reduced chance of stroke worsening  
• improved functional independence (BI>95)  
• contribut ion to the process of developi[INVESTIGATOR_479353], treatment with nerinetide may slow the progression of ischemic brain damage, providing more time during which endovascular thrombectomy may be of benefit to the patient. This is of even greater relevance during the global COVID-19 pandemic for the following reasons:  
a) There is a necessity to protect hospi[INVESTIGATOR_33717] , resulting in additional hospi[INVESTIGATOR_479354] e the exposure of the 
clinical stroke team to a potentially COVID -19 positive stroke patient (there is no time for 
COVID-19 testing to be completed) . 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 25 of 84 b)  There is a necessity to protect the patient , resulting in additional hospi[INVESTIGATOR_479355]/her from hospi[INVESTIGATOR_479356] (e.g., CT scanner) used on other patients . 
These necessities  slow down emergency stroke care workflows , potentially causing undue delays 
in the emergency stroke care of all AIS patients, not just those who may have been exposed to COVID-19. Thus, the possibility that nerinetide, by [CONTACT_479427], mitigates such delays may be of direct benefit to treated patients. Further details related to COVID -19 considerations are provided in Section 13.1.  
2.3.3 Overall Benefit: Risk Conclusion 
The potential risks identified in association with  nerinetide  are justified by [CONTACT_479428] s with acute ischemic stroke.  
Overall, nerinetide administered as a single intravenous dose was well tolerated at doses up to and 
including 2.6 mg/kg, and no safety concerns have been identified in any of the patient groups in the clinical trials.   
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 26 of 84 3 TRIAL OBJECTIVES  
3.1 Objectives  
Table 3-1: Objectives and Endpoints  
Objectives  Endpoints  
Primary   
Reducing global disability in participant s 
with acute ischemic stroke (AIS).  The proportion of participant s with independent 
functioning on the modified Rankin Scale (mRS), as defined by a score of 0-2 at Day 90.
 
Secondary   
Reducing mortality rate . Proportion of participant mortality over the 90 -
day study period.  
Reducing worsening of stroke  Proportion of participants with a worsening of 
stroke  over the 90-day study period.  
Reducing functional dependence . A shift of one or more categories to reduced 
functional dependence analyzed across the whole distribution of outcomes on the mRS at Day 90. 
Improving neurological outcome . Proportion of participant s with a score of 0 -2 on 
the NIHSS at Day 90. 
Tertiary/Exploratory   
Decreasing infarct volume . Volume of stroke as measured by [CONTACT_479429] (MRI preferred).  
Improving activities of daily living . Proportion of participant s with a score of ≥ 95 on 
the Barthel Index (BI) at Day 90.  
Reducing dependency or death . Proportion of participants with a  score of 4 -6 on 
the mRS at Day 90 . 
Improving excellent functional outcome.   Proportion of participant s with a score of 0 -1 on 
the mRS at Day 90 . 
Improving health related quality of life . Health -related quality of life, as measured by [CONTACT_72553]-5D-5L at Day 90.  
Safety   
To determine the safety based on serious 
adverse events (SAEs) .  Proportion of participant s with serious adverse 
events to Day 90.  
90-day mortality . Proportion of participant s alive at 90 -day. 
 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 27 of 84 1-Year Follow Up  
Objectives  Endpoints  
Reducing global disability in participant s with 
acute ischemic stroke (AIS).  Proportion of participant s with independent 
functioning on the modified Rankin Score  
(mRS ) score of 0-2 at 1-Year . 
Reducing mortality rate . Proportion of participant  mortality  at 1-Year . 
Improving activities of daily living . Proportion of participant s with a score of ≥ 95 
on the Barthel Index (BI) at 1-Year . 
Improving health related quality of life . Health -related quality of life, as measured by 
[CONTACT_20367] -5D-5L at 1-Year . 
3.1.1 Primary Objective  
The primary objective is  to determine the efficacy of the neuroprotectant, nerinetide in reducing 
global disability in participant s with acute ischemic stroke (AIS). 
3.1.2 Secondary Objectives  
The secondary objectives are to determine the efficacy of nerinetide in:  
1) Reducing mortality rate  
2) Reducing worsening of stroke*  
3) Reducing functional dependence  
4) Improving neurological outcome  
* Worsening of stroke is defined as (A) progression, or hemorrhagic transformation, of the  index 
stroke as documented by [CONTACT_479430]  (a) life -threatening requiring intervention and/or 
(b) results in increased disability as gauged by a ≥[ADDRESS_615545] NIHSS during 
hospi[INVESTIGATOR_26109] (B) results in death  from the index stroke .  
3.1.3 Tertiary Objectives  
The tertiary  objectives are to determine the efficacy of nerinetide in: 
• Decreasing infarct volume  
• Improving activities of daily living  
• Reducing dependency or death  
• Improving excellent functional outcome. Improving health related quality of life  
3.1.[ADDRESS_615546] of administering a dose of 2.6 mg/kg (up to a 
maximum dose of 270 mg) intravenous infusion of nerinetide to participant  with acute stroke on 
SAEs and 90-day mortality.  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 28 of 84 3.1.5 1-Year Follow Up Analytic Sub-Trial  Objectives  
There will be a 1-Year  follow -up analytic sub -trial  to support the outcomes obtained at D ay 90.  
The primary objective is to determine the efficacy of the neuroprotectant, nerinetide in:  
• Reducing global disability in participant s with acute ischemic stroke (AIS).  
The secondary objectives are to determine the efficacy of nerinetide in:  
• Reducing mortality rate  
• Improving activities of daily living  
• Improving health related quality of life  
3.2 Outcomes  
3.2.1 Primary Efficacy Outcome  
The primary outcome is th e proportion of participant s with independent functioning on the 
modified Rankin Scale ( mRS ), as defined by a score of 0-[ADDRESS_615547] randomization.  These 
participant s are defined to be responders  (See Section 9.3.1 for further details).  
3.2.2 Secondary Efficacy Outcomes  
Secondary outcomes include:  
1) A reduction in mortality rate, as defined by [CONTACT_479412] ( proportion, expressed as a 
percentage ) for mortality over the 90 -day study period.  
2) Proportion of participants with worsening of stroke over the 90-day study period.  
3) A shift of one or more categories to reduced functional dependence analyzed across the 
whole distribution of outcomes on the mRS at Day [ADDRESS_615548] randomization.  
4) Proportion of participants with good neurological outcome, as defined by a score of 0-[ADDRESS_615549] randomization.  
3.2.3 Tertiary Outcomes  
The following tertiary outcomes will be assessed descriptively:  
• Volume of stroke as measured by [CONTACT_479414] (MRI preferred).    
• Proportion of participant s with functional independence in activities of daily living, as 
defined by a score of ≥ 95 on the  Barthel Index  (BI) at Day [ADDRESS_615550] randomization.  
• Proportion of participant s with reduced moderate or severe disability or death , as defined by 
a score of 4-[ADDRESS_615551] randomization.  
• Proportion of participant s with excellent functional outcome , as defined by a score of 0-[ADDRESS_615552] randomization.  
• Health -related quality of life, as measured by [CONTACT_20367] -5D-5L at Day 90 . 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 29 of 84 3.2.4 1-Year Follow Up Analytic Sub-Trial  Outcomes  
The primary outcome is  the proportion of participant s with independent functioning on the modified 
Rankin Scale (mRS), as defined by a score of 0-2 at 1-Year . 
The secondary outcomes include:  
• A reduction in mortality rate, as defined by [CONTACT_479412] (%) for mortality over the 1-Year study period.  
• The proportion of participant s with independent function on activities of daily living 
defined on the modified Barthel Index (BI) with a score of ≥ 95 at 1-Year . 
• Health -related quality of life, as measured by [CONTACT_20367] -5D-5L at 1-Year . 
3.2.5 Safety Outcomes  
The safety outcomes are the frequencies of SAEs and 90 -day mortality.  
  
Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615553] the life of the person concerned, restore good health or alleviate  
suffering. 
Participants  harboring an acute ischemic stroke who are selected for endovascular 
revascularization without intravenous or intra -arterial thrombolytic therapy will be given a single, 
2.6 mg/kg (up to a maximum dose of 270 mg) intravenous dose of nerinetide or placebo. 
Randomization will be stratified by  [CONTACT_479410]  ≤ 4.5 hours (yes/no) 
and done with  stochastic minimization to balance baseline factors within  strata.  The end of the 
main trial  is defined as the date that the last en rolled participant has completed their Day 90 
visit/contact. For the purpose of a n analytic follow -up sub-trial  component, participants will be 
contact[CONTACT_479431] 1-Year by [CONTACT_479432] .   
A total of up to 850 male and female participants  aged 18 years and older harboring AIS and who 
are selected for endovascular revascularization without intravenous  or intra -arterial  thrombolytic 
therapy will be enrolled.   
All participant s in the main trial  will be followed for 90 days (or until death if prior to 90 days).  
At Day 30 and Day 90 it is preferred that participant s will return to clinic.  If a n in-clinic visit is 
not possible the participant  can be contact[CONTACT_479417] (preferred) or by [CONTACT_756] (last 
option).  
Participant s will be followed at 1-Year for the analytic sub-trial  for further outcome assessment by 
[CONTACT_479433].  This  sub-trial  will be conducted to explore the independent functioning and quality of life at 
1-Year .   
Two database locks and corresponding reports are planned for this trial. The first report will be based on the completion of Day 90 visits for the main trial.  The second report will be following the completion of the 1-Year  follow up for the analytic sub-trial.     
4.2 Scientific Rationale for Study Design  
The rationale for the present trial  is as follows : 
1) The ESCAPE-NA1 trial (protocol NA -1-007) provided promising evidence that, in 
participant s with AIS who were selected for EVT and who did not receive thrombolysis, 
treatment with nerinetide increases functional independence and reduced stroke mortality
12. 
This was supported by a reduction in infarction volume as measured by [CONTACT_293618]. 
Since these improvements were observed in three separate domains of outcome (functional 
independence, mortality, and infarction volumes), they are unlikely to be du e to chance 
alone. The present trial  is intended to explore these findings further.  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 31 of 84 2) Participant s in ESCAPE -NA1 who receive d throm bolysis as part of their care did not benefit 
from subsequently being administered nerinetide. The  hypothesis explaining this lack of 
effect is that  nerinetide in participants  who received alteplase was cleaved by [CONTACT_479434] . Plasmin  is produced from circulating plasminogen by [CONTACT_479435] .  This hypothesis  of nerinetide cleavage was supported by 
[CONTACT_479436] a subset of participant s in ESCAPE -NA1  that showed that those 
who received thrombolysis  had reduced plasma levels of nerinetide (approximately 60% 
reduction) as compared to participant s who did not receive thrombolysis ., Because 
nerinetide is a peptide drug, it was predicted to be cleaved by [CONTACT_479437] n, though the magnitude 
of this effect in humans was unclear . Preclinical studies showed that plasmin  cleaves 
nerinetide into several fragments beginning at its N -terminus . Additional  preclinical studies 
then showed that co -administration of nerinetide with high -dose  alteplase (6x the human 
dose) can nullify the neuroprotective effectiveness of nerinetide in a rat model of embolic middle cerebral artery occlusion (eMCAO ). However, due to differences between human 
and rat fibrinoly tic systems, t he magnitude of the drug-drug interaction between alteplase 
and nerine tide, and its  impact  on the effectiveness of nerinetide in humans have not been 
anticipated from these animal  studies . Section 4.3 provides further details  regarding the 
justification of the target patient population for this trial  as a result of these preclinical and 
clinical  findings .  
3) Based on data from preclinical studies, the Phase 1 (protocol NA -1-001) safety trial , the 
Phase [ADDRESS_615554] trial
23 (protocol NA -1-002) and the Phase 3 ESCAPE -NA1 trial12 (protocol 
NA-1-007), nerinetide is expected to be have an acceptable safety profile.  
4) There is a compelling need to develop neuroprotectants in order to increase the proportion of patients who may benefit from EVT. These agents could improve the outcomes of patients 
and render more patients with AIS into candidates for endovascular or pharm acological 
recanalization treatment.  
The current trial  is intended to confirm the findings in the ESCAPE-NA1 stu dy that nerinetide 
may improve functional independence, reduce mortality, and reduce infarction volumes in 
participant s with AIS who are selected for EVT and who are not treated with thrombolytics. As 
such, it is a Phase 3, randomized, multicentre, blinded, placebo -controlled, parallel group, single -
dose design. Participant s harboring an acute ischemic stroke who are selected for endovascular 
revascularization without intravenous or intra -arterial thrombolytic therapy will be given a single, 
2.6 mg/kg (up to a  maximum dose of 270 mg) intravenous dose of nerinetide or placebo. 
Randomization will be stratified by  [CONTACT_479410]  ≤ 4.5 hours (yes/no) 
and done with  stochastic minimization to balance baseline factors  within strata.  
The current trial is timely, in that it is evaluating an intervention that may mitigate the detrimental 
effects of slowdowns in emergency stroke care workflows caused by [CONTACT_4113] -19 (see Section 
2.3.2). For example, if reperfusion is delayed  by 30 minutes , the probability of a good outcome is 
reduced by 10.6%
24 and perhaps up to 26%25. Treatment with nerinetide in patients who are not 
treated with thrombolysis  improved good outcome by a similar degree in ESCAPE -NA112. 
The main differences between this trial  (ESCAPE -NEXT) and ESCAPE -NA1 are that:  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 32 of 84 1) ESCAPE -NEXT focuses  on participant s who do not receive thrombolysis , in order to 
confirm the results in that patient population observed in ESCAPE-NA1  
2) The s econdary outcomes in ESCA PE-NEXT focus on domains of clinical benefit  other 
than functional outcome, namely mortality, rates of worsening of stroke  and neurological 
function.  
3) ESCAPE -NEXT has an analytic 1-Year  follow -up sub-trial  investigating the long -term 
effects of nerinetide treatment .  
4.[ADDRESS_615555] of care stroke treatments.   
Since t he only approved pharmacological therapy for acute ischemic stroke is  recombinant tissue 
plasminogen activator ( rtPA; alteplase), NoNO has conducted several pre -clinical  studies to 
evaluate and understand the drug-drug interaction between nerinetide and thrombolytic agents 
such as alteplase or tenecteplase. N erinetide does not have fibrinolytic activity of its own, nor 
does it interfere with the activity of alteplase or tenecteplase in humans.  It has a plasma half -life 
of about 5-[ADDRESS_615556] of a 
concentration  of 22.5 µ g/ml (intended to mimic the concentration of alteplase in humans during a 
clinical infusion)  on lowering nerinetide levels was similar in magnitude between rat and human 
plasma. When given in -vivo, t he co -administration of nerinetide with the human dose of alteplase 
(0.9 mg/Kg) resulted in a non- significant reduction of the Cmax and AUC of nerinetide . 
However, at six times the human dose (5.4mg/Kg) alteplase caused a significant lowering of the mean Cmax and AUC of nerinetide (49.5% and 44%, respectively). Details of these findings are summarized in the Investigator’s Brochure.   
NoNO’s previous Phase 3 trial (ESCAPE -NA-1) accounted for the  existing standard of care stroke 
treatments, namely the use of alteplase, and the use of different thrombectomy devices, in 
accordance with institutional standards.  In anticipation of a possible drug -drug interaction 
between nerinetide and alteplase, t he trial employed stratification based on the use of alteplase and 
the thrombectomy device, and a minimization  approach randomization in a 1:1 ratio for nerinetide 
vs. placebo .  The ESCAPE-NA1  stud y provided significant evidence supporting an interaction 
between the use of alteplase and the efficacy of nerinetide. In the no- alteplase stratum, nerinetide 
was associated with improved outcomes, and in the alteplase stratum there was no observed benefit with the absolute risk difference slightly (non-significantly)  favoring placebo. The 
biological plausibility of treatment effect modification by [CONTACT_479438], as well as by [CONTACT_479439] -vivo in rats. Details of these 
findings  are summarized in the Investigator’s Brochure .   
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 33 of 84 Due to the clear  and non-arbitrary findings of a drug-drug interaction between thrombolytics and 
nerinetide, it was decided that the current ESCAPE-NEXT study would focus its design on participants who are not treated with alteplase.  Current stroke treatment guidelines
26 recommend 
the use of thrombolysis only up to 4.5 hours after stroke onset , wherea s the enrollment window 
for ESCAPE -NEXT is up to 12 hours. Additionally, a large proportion of stroke patients who 
present within the 4.5 hour window of alteplase do not qualify for thrombolysis  due to various 
reasons27-29. Therefore, it is anticipated  that the ESCAPE-NEXT trial will not interfere with 
clinical decisions made by [CONTACT_172276] , while addressing a substantial and important 
portion of patients with AIS who are selected for EVT.  
Because of this important distinction between subjects in the alteplase stratum vs the no -alteplase 
stratum  in the previous ESCAPE -NA-1 study, the current study (ESCAPE -NEXT) is designed to 
address a population of adults 18 years and older harboring an acute ischemic stroke who are selected for endovascular revascularization without prior treatment with intravenous or intra -
arterial thrombolytic therapy.  
4.4 Justification for Dose  
Nerinetide 2.6 mg/kg, up to a maximum of 270 mg (or matching placebo volume) is administered as a single approximately [ADDRESS_615557] scan suite.  The 2.6 mg/kg dose was chosen for this clinical trial 
because of : 
1) the safety profile observed in the previous Phase 1, 2 and 3 clinical trials,  
2) the observed capacity of this dose of nerinetide to reduce stroke tissue damage and to 
improve neurological function in humans and non-human primates and  
3) the capacity of this dose to reduce stroke tissue damage and improve neurological damage 
in human participant s undergoing endovascular repair of brain aneurysms  as demonstrated 
in the phase 2 trial .  
4) the capacity of this dose to improve functional independence (mRS 0-2) as demonstrated in the Phase [ADDRESS_615558] report will be based on the completion of Day 90 visits for the main trial .  The second report will be following 
the completion of the 1-Year  follow up for the analytic sub-trial.    
Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615559] care for their acute stroke patients .  
Patients who are deemed by [CONTACT_479440], or are 
administered a thrombolytic prior to screening for any reason, will not be enrolled in ESCAPE - NEXT.  If the patient is not selected for treatment with a thrombolytic the treating 
physician may consider the patient as a candidate for the trial.  
5.1 Inclusion Criteria  
1) Acute ischemic stroke (AIS)  selected  for emergency  endovascular treatment . 
2) Age 18 years or greater.  
3) Onset (last -know n-well) time to randomization time within 12 hours.  
4) Disabling stroke defined as a baseline National Institutes of Health Stroke Score (NIHSS ): 
a. NIHSS > 5 for internal carotid artery ( ICA) and M1-middle cerebral artery ( MCA ) 
occlusion ; or 
b. NIHSS > 10 for M2-MCA occlusion. 
5) Confirmed symptomatic intracranial occlusion at one or more of the following locations: Intracranial carotid I/ T/L, M1 or M2 segment MCA .  Tandem extracranial carotid and 
intracranial occlusions are permitted.  
6) Pre-stroke (24 hours prior to stroke onset) independent functional status in activities of daily 
living with modified Barthel Index (BI) ≥ 95. Patient must be living without requiring nursing care.  
7) Qualifying imaging performed less than 2 hours prior to randomization.  
8) Consent process completed as per national laws and regulation and the applicable ethics 
committee requirements.   
5.2 Exclusion Criteria  
1) Treat ed with a tissue plasminogen activator (e.g., alteplase or tenecteplase) within 24 hours 
before randomization  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 35 of 84 2) Determination  by [CONTACT_1963] , based on current treatment guidelines  and medical 
evidence, that  treatment with a plasminogen activator is indicated.  
3) Large  core of established infarction defined as ASPECTS 0 -4. 
4) Absent  or poor collateral circulation on qualifying imaging (e.g., c ollateral score of 0 or 1). 
5) Any intracranial hemorrhage on the qualifying imaging.  
6) Planned use of an endovascular device not having approval or clearance by [CONTACT_479415].  
7) Endovascular thrombectomy procedure is completed as defined by [CONTACT_479441] 2c/3 
reperfusion or completion of groin / arterial closure.  
8) Clinical history, past imaging or clinical judgment suggest ing that the intracranial occlusion is 
chronic or there is suspected intracranial dissection such that there is a predicted lack of success with endovascular intervention.  
9) Estimated or known weight > 120 kg (264 lbs). 
10) Pregnancy/Lactation ; female, with positive urine or serum beta human chorionic gonadotropin 
(β-hCG) test , or breastfeeding.  
11) Known prior receipt of nerinetide for any reason, including prior enrolment in th is ESCAPE -
NEXT trial.  
12) Severe known renal impairment defined as requiring renal replacement therapy (hemo - or 
peritoneal dialysis).  
13) Severe or fatal comorbid illness that will prevent improvement or follow up.  
14) Inability to  complete follow -up treatment to Day 90.  
15) Participation in another clinical trial investigating a drug, medical device, or a medical procedure in the [ADDRESS_615560] of care screening methods at the acute stroke 
hospi[INVESTIGATOR_307]. All participant s will undergo an acute clinical assessment, blood laboratory assessment 
and baseline brain imaging .  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 36 of 84 If the participant  remains eligible after completion of routine stroke screening, the patient will be 
consented (as required) and enrolled into the trial .  A participant  is considered randomized the 
moment the randomization process is completed on -line.  Participant s who are randomized but do 
not receive study drug will still be followed through the 90-day study period.  
5.5.[ADDRESS_615561] to 
randomization time <= [ADDRESS_615562] of care use of imaging. 
Patients will be included if they meet the following qualifying imaging criteria:  
• Non-contrast CT scan or MR-DWI scan with  ASPECTS > 4, AND;  
• A proven anterior circulation intracranial occlusion (ICA, M1, M2) defined by [CONTACT_440121] 
(preferred) or MRA;  
Patients will be excluded if they meet the following imaging criteria:  
• Direct or indirect evidence of poor pi[INVESTIGATOR_479357]:  
Direct pi[INVESTIGATOR_479358]  
1. mCTA evidence of poor pi[INVESTIGATOR_479359] – Tan score of 0 or 1  
2. spCTA evidence of poor pi[INVESTIGATOR_479360]–Tan score of 0 or 1 
3. dynamic mCTA (derived from CTP imaging acquisition) may be used if mCTA or spCTA is not available.  
Indirect pi[INVESTIGATOR_479358]  
1. If mCTA cannot be done collaterals may be assessed/inferred based upon perfusion 
imaging (CT perfusion or MR perfusion). As a guide if there is a match deficit (estimated core = estimated penumbra) collaterals are poor.  If there is a mismatch (estimated penumbra > estimated core) AND estimated  core <70 cc, we infer that pi[INVESTIGATOR_479361].  
If there is discordance between mCTA and the allowable alternate modalities, mCTA 
criteria should be used.  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 37 of 84 5.5.2 Consent Process  
Participants or their legally authorized representative will be required to sign a statement of informed consent that meets the requirements of applicable national laws and regulation and the ethics committee.  
The investigator or his/her representative will explain the nature of the trial  to the participant  or 
his/her legally authorized representative and answer all questions regarding the trial. 
The medical record must include a statement describing under which process consent was obtained, and the timing of the consent and regained capacity consent . The authorized person 
obtaining the informed consent must also sign the informed consent form (ICF ). 
See Appendix 10.[ADDRESS_615563] regained capacity.   Site staff will make ongoing efforts until: (1) regained 
capacity consent is obtained from participant  as soon as it is possible and reasonable , (2) death, or 
(3) completion of the Day [ADDRESS_615564]'s LAR or family member . 
Amendment of the ICF  
In the event that new information is available and the ICF is amended, and i f required by [CONTACT_479442]/or Ethics Committees , participant s must be re-consented to the most 
current version of the ICF(s) during their participation in the trial . A copy of each ICF(s) must be 
provided to the participant  or the participant ’s legally authorized representative.  
Note: Electronic consent tools may be used for initial and regained capacity consent, as permitted under national laws and regulations and the applicable Independent R eview Boards/Ethics 
Committee.  
5.5.3 Physical Examinations  
To support the assessment of inclusion and exclusion criteria and medical history, a stroke 
focused physical examination at baseline will include, at a minimum, assessments of the Neurological, Cardiovascular, Respi[INVESTIGATOR_479362]. Investigators should pay special attention to clinical signs related to previous strokes.   
  
Version: 6.0  Protocol NA -1-009 
Date: 01 June  2022 NoNO Inc.  
Confidential Page 38 of 846 STUDY INTERVENTIONS  and CONCOMITANT THERAPY  
6.1 Study Intervention Administration 
Nerinetide was formulated at 20 mg/ml under current Good Manufacturing Practices by 
[INVESTIGATOR_2993] 50 mM sodium phosphate buffer with 0.45% sodium 
chloride (NaCl), potential hydrogen (pH) 7.0.  This formulation was dispensed aseptically into 20 
mL single use vials with snap cap lids (13.5 mL) intended for a single-dose intravenous infusion 
of nerinetide.  
Placebo consists of the same buffer used for nerinetide with slightly higher NaCl content to adjust 
for equivalence of osmolality between drug product and placebo.  It is supplied in identical vials containing 13.5 mL of 50 mM sodium phosphate pH 7.0 (0.55% NaCl).  After dilution into the saline bag, the drug has been demonstrated to be stable for at least 5 hours. 
Formulated nerinetide and placebo will be provided to clinical trial sites  in sterile, single-use 
individually labeled vials (serum vials) each with a unique five-digit identification number  and 
will be stored at the clinical trial site at 2 to 8°C in a secure location with restricted access.  
Table 6-1: Study Interventions  
Nerinetide  Placebo  
Test Product Name  [CONTACT_479409] ( NA-1) Placebo  
Type Drug  Drug  
Dose Formulation  Vial  Vial  
Unit Dose 
Strength(s)  2.6 mg/kg  Placebo  
Dosage Level(s)  Single  Single  
Route of 
Administration  IV Infusion  IV Infusion  
Use Investigational  Placebo  
Sourcing  Provided centrally by [CONTACT_479443] a 
20 m L vial.  Vials will be package d in 
boxes of  multiple vials  labeled as 
required per country requirements.  Study Intervention will be provided in 
a 20 mL vial. Vials will be package d in 
boxe d of multiple vials  labeled as 
required per country requirements.  
6.2
 Preparation/ Handling/ Storage/ Accountability 
Only participant s enrolled in the trial  may receive study intervention and only authorized site staff 
may supply or administer study intervention.  Study drug dosing will be carried out by, or under the supervision of, the investigator  who is supervising the care of the participant  for the planned or 
ongoing endovascular reperfusion procedure.  
As soon as the participant  is deemed eligible for the trial, the investigator (or delegate) will log into 
the central randomization website to receive the assign ed vial number . 
Dose timing starts at the time of infusion onset.  Study drug is intended to  be administered as soon 
as possible after randomization  (i.e., 15 minutes ).  
Confidential Business Information 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 39 of 84 A syringe for each individual participant ’s dosing will be prepared by [CONTACT_479444]:   
• for participant s weighing less than 105 kg:  (2.6 mg/kg x participant  weight in kg)/(20 
mg/ml).  This will determine the number of mL to pull up into the syringe.   
• for participant s weighing 105-120 kg the full volume of one  vial (13.5mL , equivalent to 
270 mg of nerinetide ) will be used.  
Estimated or actual weight can be used to calculate the study drug dosage.  
The syringe containing study drug will be injected into the intravenous port of a 50 or 100 mL 
drip bag of 0.9% normal saline that has been labeled with the randomization number .  The bag 
will be mixed by [CONTACT_479445].  Study drug should be infused into the participant  as soon as practical . 
Dosing will be performed by [CONTACT_479446] b ag of study drug to the participant  
through an intravenous  catheter inserted into a vein in the upper or lower extremity and using a 
standard infusion pump. Dosing will be carried out evenly over the course of 10 ± 1 minutes. The entire volume (treatment dose) of the intravenous  bag must be administered.  
After the dose administration, a minimum of [ADDRESS_615565] be stored in a secure, temperature controlled  (2 to 8 °C), and monitored 
(manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff.   Temperatures will be monitored using a device that 
can continuously monitor and record temperature readings.  
The investigator is responsible for study drug accountability, reconciliation, and record maintenance (i .e., receipt, reconciliation, and final disposition records).  Any expi[INVESTIGATOR_5697], lost, 
damaged or out -of-specification study drug must be properly documented and reported to the 
Sponsor.  Further guidance and information for the final disposition of unused study drug are 
provided in the  Operating Guideline.  
6.2.2 Disposition of Study Drug Supplies 
After study drug preparation, any remaining material in the vial will be labeled as “used,” and the volume removed will be documented  (value in mL).  Vials labeled as “used” will be retained in a 
separate storage container than the unused vials.  Used vials will be disposed of on site, once the monitor (CRA ) has completed the study drug monitoring and accountability .  Unused vials will be 
disposed of on site  or returned to the sponsor after they have been monitored by [CONTACT_47662]’s representative. Destruction of unused vials at the study  site will be documented and 
conducted in accordance with the site’s policies and procedures.  
  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 40 of 84 6.3 Measures to Minimize Bias: Randomization and Blinding  
All participant s will be centrally assigned to a randomized study intervention (i.e., ner inetide or 
placebo) using an Interactive Web Response System (IWRS). T he login information and 
directions for the IWRS will be provided to each site.   The IWRS website will allocate  the 
participant  number and vial number.  
Treatment allocation  will be assigned using 1:1 randomization (nerinetide: placebo)  with a 
stratification based  on time from stroke onset to randomization of ≤ 4.5 hours  (yes/no) and a 
randomized minimization algorithm to minimize the contribution of imbalances in baseline factors  (age, sex,  baseline NIHSS score, baseline ASPECT score, occlusion location , time from 
qualifying imaging to randomizatio n, and site). Randomization will be conducted c entral ly, using 
a web -based algorithm with treatment assignment allocated by [CONTACT_169993] -based real -time interaction 
with the site. Randomized allocation will be fully concealed by [CONTACT_479447] -time 
allocation based upon random number generation and blinded by [CONTACT_479448].  All vials will have a unique vial number.  
The purpose of minimization on the variables is to balance these variables across treatments  and 
within strata to ensure a reduced chance that any observed effect size of nerinetide vs. placebo is confounded by [CONTACT_479449] . This randomized minimization 
method from Zhao et al, called the minimal sufficient  balance method
32, will be used to ensure 
that the participant s entered into the trial will be balanced between control (placebo) and active 
treatment (ner inetide)  arms . 
All participant s, investigators, their clinical staff, local and central laboratories, the clinical 
coordinating centre, the data management group, and the sponsor staff and delegates will be blinded to the randomization codes.  
6.3.1 Procedure for Breaking the Randomization Code  
In case of an emergency, the investigator has the sole responsibility for determining if the unblinding of a participant ’s intervention assignment is warranted. Participant  safety must always 
be the first consideration in making such a determination. If the investigator decides that unblinding is warranted, the investigator should make every effort to contact [CONTACT_77775] a participant ’s intervention assignment unless this could delay emergency treatment of 
the participant . If a participant ’s intervention assignment is unblinded, the sponsor must be 
notified within [ADDRESS_615566] unblinding of the specific participant . The 
randomization provider will respond in writing to the investigator only with the unblinded patient 
treatment allocation.  
Only the investigator requesting the unblinding will receive the unblinding information.  The 
Investigator is requested to maintain the blind as far as possible. The actual treatment allocation 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 41 of 84 should not be disclosed to the participant  and/or other site personnel unless, in the judgement of 
the investigator, this information is required for the participant ’s safety. The actual treatment 
allocation must not be disclosed to study personnel on site not involved in the participant ’s 
medical care, to monitors or the sponsor. 
In order to fulfill expedited regulatory reporting requirements, the Sponsor may be required to 
unblind the participant  if the SAE meets the criteria for reporting to health authorities.  The 
Sponsor’s independent third party will initiate the request that the participant ’s treatment group be 
unblinded.  In this case, the code will be broken only for the participant (s) in question. The 
information resulting from code -breaking (i.e., the participant ’s treatment  allocation ) will not be 
communicated to either the Investigator or th e Sponsor. 
Otherwise, randomization data will be kept strictly confidential, accessible only to authorized persons, until the time of unblinding after data base lock at the time of interim analysis and at end 
of the study (Day 90). For the ongoing 1- Year  follow up, site staff conducting the assessments 
will remain blinded until after the 1-Year  follow up database lock . 
6.4 Study Intervention Compliance  
Study drug will be dispensed under the instructions of the investigator or designee  and under 
medical supervision.  The date and time of dose administered will be recorded in the source documents and in the CRF.  The dose of study drug and study participant  identification will be 
confirmed at the time of dosing by a member of the study site staff other than the person administering the study drug.  T he investigator may terminate study drug administration at his/her 
discretion.  
6.5 Dose Modification  
Not applicable in this single -dose trial.  
6.6 Continued Access to Study Intervention after the End of the Study  
Not applicable in this single -dose trial . 
6.7 Treatment of Overdose  
For this trial , any dose of study drug greater than 150% of the planned dose  will be considered an 
overdose. 
The sp onsor does not recommend specific treatment for an overdose . In the event of an overdose, 
the investigator should:  
1) Contact [CONTACT_479450] ([EMAIL_9234]) immediately.  
2) Closely monitor the participant  for any AE s/SAE s and laboratory abnormalities for at least 
1 day.  
3) Document the quantity administered  in the CRF. 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 42 of 84 6.8 Concomitant Therapy  
There are no restricted medications once a participant is enrolled in this trial.  Any medication or 
vaccines (including over- the-counter or prescription medicines) that the participant  is receiving at 
the time of enrollment (within 24 hours  prior) or receives up to D ay [ADDRESS_615567]  be recorded along 
with:  
• Dates of administration including start and end dates , medications that were ongoing at the 
last contact [CONTACT_472975] a stop date or confirmed as ongoing.  
• Indication for use . 
6.8.1 Rescue Medicine/Treatment  
[IP_ADDRESS] Early Study Drug Cessation  
The intervention is the intravenous administration of 2.6 mg/kg  (up to a maximum of 270 mg) of 
nerinetide  over a 10 ± 1 minute intravenous infusion to participant  undergoing endovascular 
mechanical thrombolysis/thrombectomy.  It is expected that dosing will be completed before the 
endovascular procedure is completed. However, if dosing is ongoing during the endovascular procedure, dosing will not be stopped in the event of an adverse intra -procedural event deemed to 
be a compli cation of the endovascular intervention.  
The investigator  may terminate drug administration at his/her discretion.  
[IP_ADDRESS] Treatment of Hypotension  
If hypotension (systolic < 80 mmHg; or any level of decreased BP that the physician deems to be clinically relevant) is observed in a participant , the hospi[INVESTIGATOR_479363], at his/her 
discretion, to administer any medication that they deem to be required for the participant ’s health 
and safety.  
There is no specific treatment requirement related to treating hypotension that may be observed in participant s with stroke who are also receiving nerinetide . Treatment of hypotension in this setting 
may include all or some of the following, as appropriate, and at the hospi[INVESTIGATOR_479364]’s discretion.  
First, the physician will determine if hypotension is symptomatic.   Asymptomatic participant s 
may be observed for spontaneous recovery. 
• Treatment, if required, should include fluid resuscitation with crystalloid fluid  (e.g., 0.9% 
saline) and/or vasopressors, if needed.  
• Consider treatment with antihistamine agents (diphenhydramine 50 mg IV, ranitidine 50mg IV) and corticosteroids (e.g., Decadron™ ; 10 mg IV) if the reaction is severe.    
• Consider using subcutaneous or intravenous epi[INVESTIGATOR_238].  
• If bronchospasm or laryngospasm are important additional symptoms, consider treatment 
with inhaled racemic epi[INVESTIGATOR_238].  
Specific amounts and doses of intravenous fluids or other drugs administered are left to the 
medical judgment of the hospi[INVESTIGATOR_479364].  
Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615568] medical care as per local practice.  If 
hypotension as defined above occurs, the hypotension and its treatment are to be recorded as an AE in the CRF.  
6.9 Endovascular Intervention  and Stroke Care  
EVT should be conducted as per the local protocol and in compliance with the current treatment 
guidelines such as those published by [CONTACT_14808]  (AHA). 
All acute stroke participant s should receive the best standard of care according to current 
treatment  guideline and any national guidelines  (e.g., Canadian best practices guidelines for acute 
stroke care , European Stroke Organization , etc. ).  All participant s are expected to be admitted to 
hospi[INVESTIGATOR_479365].  All participant s are expected to receive expert stroke 
unit care and then rehabilitation according to their clinical need  through the full 90 days. 
  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 44 of 84 7 DISCONTINUATION of STUDY INTERVENTION and PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
7.1 Discontinuation of Study Intervention  
In rare instances, it may be necessary for a participant  to permanently discontinue (definitive 
discontinuation) study intervention. If study intervention is definitively discontinued, the participant  will remain in the trial and be evaluated to Day 90.  
7.2 Participant  Discontinuation/Withdrawal from the Trial  
Participation in this clinical trial may be discontinued for any of the following reasons:  
• Administrative reasons (uncooperative, noncompliant, etc.)  
• Participant ’s decision not to participate any further  
• If it is in the participant ’s best interest, per the qualified/principal or sub -investigator  
If the participant  or legally authorized representative ( LAR ) withdraws consent, participant  data 
will be included in the analysis up to the date of the consent withdrawal and this withdrawal of 
consent will be documented in the CRF.  
If the LAR has originally provided consent and the participant  subsequently declines consent, this 
will be deemed to be a withdrawal of consent. The investigator and sponsor would continue to 
have access to data that have already been collected.  
A participant  may not withdraw use of his or her data that have already been collected, this is in 
alignment with the FDA guidance document “ Data Retention When Participant s Withdraw from 
FDA -Regulated Clinical Trials ”, which is based on the importance of avoiding selection biases 
that could compromise the analysis of the overall trial.  
Otherwise, all randomized participant s will continue to be followed according to protocol 
requirements and follow -up data will be included in the analysis.  Criteria for removal of 
participant s will be recorded and reported.  
7.[ADDRESS_615569] to follow -up if he or she repeatedly fails to return for scheduled 
visits /contacts  and is unable to be contact[CONTACT_9298].   The following actions must be taken 
if a participant  fails to return to the clinic or if they cannot be contact[CONTACT_479451] a required 
study visit:  
• The site must attempt to contact [CONTACT_479452] /contact  [CONTACT_479453]/or should continue 
in the trial . 
• Before a participant  is deemed lost to f ollow up, the investigator or designee must make 
every effort to regain contact [CONTACT_6635]  (at a minimum 3 telephone 
calls/contacts ). These contact [CONTACT_13140] ’s study  
record.  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 45 of 84 • Should the participant  continue to be unreachable, he/she will be considered to have 
withdrawn from the trial.  
• Site personnel will attempt to collect the vital status of the participant  within legal and 
ethical boundaries for all participant s randomized, including those who did not get study 
intervention. Public sources may be searched for vital status information.   If vital status is 
determined as deceased, this will be documented and the participant  will not be considered 
lost to follow -up. Sponsor personnel will not be involved in any attempts to collect vital 
status information.  
  
Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615570].  
Procedures conducted as part of the participant ’s routine clinical management (e.g., blood count) 
and obtained before signing of the ICF may be utilized for baseline purposes provided the procedures met the protocol -specified criteria and were performed within the time frame defined 
in the Schedule of Activities . 
8.1 Efficacy Assessments  
Planned time points for all efficacy  assessments are provided in the Schedule of Activities . 
8.1.1 The Modified Rankin Scale  
The primary endpoint used in this trial will be global disability, as measured by [CONTACT_352802], at Day 90. The mRS is a valid and reliable clinician -reported measure of global disability that has been 
widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke
33, 34. mRS scores range from 0 to 6, with 0 indicating no residual symptoms; 5 indicating 
bedbound, requiring constant care; and [ADDRESS_615571] dose mRS will be obtained at Day 6 (or discharge), Day 30 and Day 90 and at the 1-Year  
follow up.  Premorbid mRS status may be obtained at any time, but ideally at the Day 1 or 2 visit .  
The mRS will only be scored by [CONTACT_479454] (via www.healthcarepoint.com ) in the 
use of this scale.   An Electronic Clinical Outcome Assessment  (eCOA) tool may be used to 
conduct this assessment.  
8.1.2 Mortality Rate  
Mortality status will be obtained at all visits  during the 90 -day study period  and at the 1-Year  follow 
up. 
8.1.3 Worsening of Stroke  
Worsening of stroke is defined as (A) progression, or hemorrhagic transformation, of the  index 
stroke as documented by [CONTACT_479430]  (a) life -threatening requiring intervention and/or 
(b) results in increased disability as gauged by a ≥[ADDRESS_615572] NIHSS during 
hospi[INVESTIGATOR_26109] (B) results in death  from the index stroke .  
8.1.[ADDRESS_615573] 
brain images (MRI preferred) in nerinetide versus placebo control participant s will be calculated  
from the Day 2 /[ADDRESS_615574] volumes will be determined from 
the Day 2 /[ADDRESS_615575] and MRI data will be detailed in the Imaging 
Adjudication Charter.  
Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615576] -EVT  (2 Hours), Day 2, Day 6 (or discharge ), Day [ADDRESS_615577] this assessment.  
8.1.6 Barthel Index  
The BI is an index of functional independence
36 that is a valid measure of activities of daily living 
when employed in stroke trials37.  Modified BI scores range from 0 to 100, with higher scores 
indicating greater independence in activities of daily living and mobility. The BI will be scored at  
Baseline (pre -morbid), Day 30 and Day 90 and at the 1-Year  follow up, by [CONTACT_479455].   Note that the original Barthel Index was a scale from 0 -20.  The modified Barthel 
index simply multiplies the original scale by 5  to provide a 100-point score .  
8.1.7 EQ-5D-5L 
The EQ -5D-5L is a generic instrument for describing and valuing health. It is based on a 
descriptive system that defines health in terms of five dimensions: Mobility, Self -Care, Usual 
Activities, Pain/Discomfort, and Anxiety/Depression38. Each dimension has five response 
categories corresponding to: no problems, slight, moderate, severe and extreme problems39. The 
version of the instrument selected for the trial is interviewer administered  either in-person, or by 
[CONTACT_479456] . The respondents will also rate their overall health on the day of the 
interview on a 0–100 visual analogue scale (EQ -VAS). The EQ -5D-5L will be administered at the 
Day [ADDRESS_615578] this assessment.  
8.2 SAFETY ASSESSMENT S 
Planned time points for all safety assessments are provided in the Schedule of Activities . 
8.2.1 Vital Signs  
Blood pressure and heart rate  will be taken  at Baseline (pre-dose), at the completion of drug 
infusion and Day 2.  Results taken from standard of care assessment/timepoints may be used. Temperature will be taken at baseline (if available per standard of care ) and Day 2.  Clinically 
significant findings post -dose will be reported as AEs.  
8.2.2 Clinical Safety Laboratory Assessments  
Blood work will be taken at baseline and at  Day 2  including: CBC (hemoglobin, platelets and 
hematocrit), electrolytes (sodium, potassium, chloride), serum creatinine and serum glucose and assessed by [CONTACT_12082].  Results from local standard of care testing may be used. A central lab will not be used.   Due to the s hort time-period from arrival at hospi[INVESTIGATOR_479366], t he 
results of the baseline blood work are  not required prior to randomization.  Baseline results from 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 48 of 84 primary hospi[INVESTIGATOR_307] (within 8 hours) are accepted, if written documentation is available .  Clinically 
significant laboratory findings from the Day 2  sample (post dose) will be reported as AEs . 
8.2.[ADDRESS_615579] (urine or serum point -
of-care pregnancy test) must be completed  at baseline prior to inclusion into the trial . 
8.3 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Safety Reporting 
The definitions of an AE or SAE can be found in Appendix 3: Adverse Events: Definitions and 
Procedures for Recording, Evaluating, Follow -up, and Reporting.  
AEs will be reported by [CONTACT_2299]  (or, when appropriate, by a healthcare provider, caregiver, 
surrogate, or the participant ’s legally authorized  representative).  The investigator and any 
qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE and remain responsible for following up AEs that are serious, considered related to the study interventio n or study procedures, or that caused the participant  to 
discontinue the  trial. 
Adverse events of special interest  (AESIs)  include any AEs which occur within 2 hours of end of 
study drug infusion and which fall under the  standardized MedDRA queries of “Angioedema”, 
“Anaphylactic reaction”, and “Anaphylactic shock” as well as a list of MedDRA terms relating to “Hypotension”.  
The method of recording, evaluating, and assessing causality of AE s, AESI  and SAE s and the 
procedures for completing and transmitting SAE reports are provided in Appendix [ADDRESS_615580] a fatal outcome will be collected to Day 90, see the 
Schedule of Activities . 
All AE will be collected from the start of study drug administration until Day 30   at the time 
points specified in the Schedule of Activities . 
Medical occurrences that begin before the start of study intervention but after enrolment into the 
trial will be recorded on the Medical History section of the electronic case report form ( CRF ) not 
the AE section . 
All SAEs  will be recorded and reported to the s ponsor or designee immediately, without undue 
delay , under no circum stances later than 24 hours  following the knowledge  of such an event , as 
indicated in Appendix 3. The investigator will submit any updated SAE data to the sponsor within 24 hours of it  being available.  
8.3.2 Method of Detecting AEs  and SAE s 
Care will be taken not to introduce bias when detecting AEs and/or SAEs . Open-ended and 
non-leading verbal questioning of the participant  is the preferred method to inquire about 
AE occurrence s.  A consistent methodology of eliciting AEs at all participant  evaluation 
timepoints will be used.  Non -directive questions include:  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 49 of 84 • How have you felt since your last clinical visit/hospi[INVESTIGATOR_2345]?  
• Have you had any new or changed health problems since you were last here?  
• Have you had any unusual or unexpected worsening of your underlying medical condition or overall health?  
• Have there been any changes in the medicines you take since your last clinical visit/hospi[INVESTIGATOR_7954]?  
AE identification while the participant  is admitted to the acute stroke hospi[INVESTIGATOR_479367].  For follow 
up visits after discharge from the acute stroke hospi[INVESTIGATOR_479368]  (or LAR if the participant  is 
not able to respond to the questions) will be asked about the occurrence of AEs since the last contact, and if available, from records at the acute stroke hospi[INVESTIGATOR_307].  
Diagnosis versus signs and symptoms for the purpose of AE reporting: if known at the time of 
reporting, a diagnosis should be reported rather than individual signs and symptoms (e.g., record only pneumonia rather than pyrexia, coughing, shortness of breath).  However, if a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis it is acceptable to report the information that is ultimately available.  
8.3.3 Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each participant  
at subsequent visits/contacts. All SAEs  will be followed until resolution, stabiliz ation , the event is 
otherwise explained, or the participant  is lost to follow -up (as defined in Section 7.3 ). Further 
information on follow -up procedures is given in Appendix 3.  
AEs that were ongoing at the last contact [CONTACT_472975] a stop date or confirmed as ongoing.  AE collection will continue until Day 30, and SAE to Day [ADDRESS_615581] . 
Investigators are not obligated to actively seek AE or SAE a fter conclusion of the study 
participation . However, if the investigator learns of any SAE, including a death, at any time after a 
participant  has been discharged from the study, and he/she considers the event to be reasonably 
related to the study intervention  or study participation, the investigator must promptly notify the 
sponsor.  
8.3.4 Regulatory Reporting Requirements for SAEs  
Prompt notification by [CONTACT_238977] s ponsor of a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participant s and the safety of a study 
intervention  under clinical investigation are met.  
The s ponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention  under clinical investigation. The 
sponsor will comply with country-specific regulatory requirements relating to safety reporting to 
the regulatory authority, Institutional Review Boards (IRB)/Independent E thics Committees 
(IEC), and investigators.  
Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615582] be prepared by [CONTACT_479457] (S[LOCATION_003]R) according to local regulatory requirements and s ponsor policy and 
forwarded to investigators as necessary.  
The Sponsor’s Drug Safety Department will notify the Investigators in writing of the occurrence of any reportable SAEs.  The Sponsor or delegate will be responsible for reporting S[LOCATION_003]Rs to any Central Ethics Committees in compliance with local current legislation.  The Investigators will be 
responsible for informing the ir local  ethics committees of any reportable SAEs as per their local 
requirements.  
An investigator who receives an investigator safety report describing a SAE or other specific safety information ( e.g., summary or listing of SAE s) from the s ponsor will review and then file it 
along with the Investigator’s Brochure and will notify the IRB/IEC, if appropriate according to local requirements.  
8.3.5 Pregnancy  
Details of all pregnancies in female participant s and female partners of male participant s will be 
collected after the start of study intervention and until  Day 30.  
If a pregnancy is reported, the investigator should inform the sponsor within 24 hours  of learning 
of the pregnancy and should follow the procedures outlined in Section 10.4 (Appendix 4: 
Collection of Pregnancy Information).  
Pregnancy itself is not considered an AE, but any complications during pregnancy are to be considered as AEs, and in some cases, could be considered SAEs. Spontaneous abortions, fetal death, stillbirth, and congenital anomalies reported in the baby [CONTACT_479458], 
and the information should be provided to the Sponsor regardless of when the SAE occurs (e.g., 
even after the end of the trial).  
8.4 Pharmacokinetics  
Blood samples of approximately 5 mL will be collected for measurement of plasma 
concentrations of nerinetide as specified in the Schedule of Activities . Samples  will be collected 
from up to 100 participant s enrolled  in Canada and the US . A total of five  5 mL blood samples 
will be drawn during the Baseline Visit  (V1).  Time (T)  =0 being the initiation of dosing of study 
drug or placebo.  Samples should be drawn at the following timepoints:  
Sample 1: post randomization & prior to start of study drug administration  
Sample 2: 10 minutes from start of study drug administration (Time =  within 1 min of study 
drug completion)  
Sample 3: 20 minutes from start of study drug administration (Time = 15 to 25 min)  
Sample 4: 30 minutes from start of study drug administration (Time = 26 to 45 min)  
Sample 5: 60 minutes from start of study drug administration (Time =  46 to 120 min)  
Sample collection method should be the least invasive to the participant  and may be combined 
with routine blood sampling.  Instructions for the collection and handling of biological samples 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 51 of 84 will be provided by [CONTACT_456]. The actual date and time (24-hour clock time) of each sample will be recorded.  
Each plasma sample will be divided into 2 aliquots (1 each for primary and a back-up ).  The 
samples will be handled per guidelines/instructions provided by [CONTACT_456].  During storage, PK tubes will be kept in a freezer at -10°C or colder.  
The plasma samples will be processed for pharmacokinetics  analyses.  Appropriate firewall s will 
be put in place to prevent unblinding.  Results of the analysis will not be provided to the sponsor until after database lock. Genetic analyses will not be performed on these samples. Participant  
confidentiality will be maintained.  Samples may be stored for a maximum of  15 years (or 
according to local regulations) following the last participant ’s Day 90 visit at a facility selected by 
[CONTACT_479459]:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 52 of 84 9 STATISTICS  
9.1 Sample Size Determination  
The primary estimand will be the adjusted difference in the mRS response (i.e., mRS score of 0 -2) 
proportions between treatment conditions (nerinetide vs. placebo) in the target patient population at Day 90. Participants with mRS score of [ADDRESS_615583] and 95% confidence interval estimate for the primary estimand will be 
provided by [CONTACT_479460], 2011
40 discussed in FDA’s most recent draft guidance 
Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products41, 
adjusting for the stratification covariate of time from stroke onset to randomization ≤ 4.5 hours 
(yes/no) and the randomized minimization factors (age, sex, baseline NIHSS score, baseline ASPECT score, occlusion location, time from qualifying imaging to randomization and pooled site), and an interaction term of treatment by [CONTACT_479410]. If the interaction term is not significant at the level of 0.05, it will be removed from the model.  
Up to 850 male and female participants  aged 18 or older harboring AIS and who are selected for 
endovascular revascularization without intravenous or intra -arterial thrombolytic therapy will be 
enrolled.  
Based on results of ESCAPE -NA1 and assuming a 50% overall responder rate for the placebo 
group, there will be approximately 91.3% power to detect an 11.4% absolute effect difference between response rate (proportion of responders, with Day 90 mRS in the ra nge 0 to 2) with 
nerinetide and placebo, at alpha level 0.025 one-sided (0.05 2-sided), using the planned sample size of 850 evaluable subjects, randomized 1:1, per group [EaST v6.5, 2022].  
This sample size was calculated taking into account a dropout/non -evaluable rate of 2% with a lag 
to primary endpoint assessment of 4 months, estimated accrual rate of 50 participants per month, target effects 0.5 vs 0.6114 and a single interim analysis for early superiority stoppi[INVESTIGATOR_479369] O'Brien-Fleming alpha spending function boundary at 60% information (510 evaluable 
participants).   The interim analysis is planned to take place at 60% information (primary 
endpoint), i.e. when approximately [ADDRESS_615584] reached their primary endpoint assessment. The cumulative alpha spent at the interim analysis is 0.004 and final analysis 0.025, one -sided (0.05 2-sided); the stoppi[INVESTIGATOR_3073] Z scale are 2.668 (interim) and 
1.981 (final) and on the p-value scale 0.004 (interim) and 0.021 (final), all on the assumption that the interim is conducted at 60% information. 
See Section 9.4 for further details on the interim analysis.   
9.2 Analysis Sets  
For purposes  of analysis, the following populations are defined:  
Population  Description  
Enrolled  All participants  randomized into the trial.  
Randomly Assigned to Study 
Intervention All participants who received a dose or partial dose of study drug  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 53 of 84 Intent to Treat (I TT) All participant s randomized into the trial with groupi[INVESTIGATOR_479370], regardless of treatment actually received.  Participant  grouped 
according to the randomized (intended) treatment.  
Per Protocol  (PP) All participant s randomized and treated, with no major protocol 
deviations including: did not meet inclusion/exclusion criteria, did not 
receive planned dose volume , incorrect study drug vial, infusion more 
than 15 minutes, consent not obtained.   
Safety  All participant s randomly assigned to study intervention and who receive 
any volume of study drug .  Participant s will be analyzed according to the 
intervention  they actually received.  
The primary efficacy estimand analysis will be conducted in the ITT population.  The primary efficacy  estimand analysis will be repeated on the Per Protocol (PP) population.  An ITT analysis 
will also be conducted for the secondary endpoint  estimands , with participant  grouped according 
to the randomized (intended) treatment.    
9.[ADDRESS_615585] important estimand endpoints including primary and 
key secondary endpoints.  
9.3.1 General Considerations  
All imputed values will be determined prior to database lock and conducting primary analyses via rules documented prospectively in the final Statistical Analysis Plan for the study.   
Deceased participant  will score 6 on the mRS, 42 on the NIHSS and 0 on Barthel Index and be 
counted as non-responders.  Every effort will be made to keep missing data, particularly the Day 
90 outcome assessments, to a minimum.  
For the primary analysis, for participants who are missing the mRS at Day 90 : 
• if the participant is known to be dead at Day 90, they will be considered to be a non-
responder and the mRS will be imputed as 6 
• if the mRS  was obtained at the Da y [ADDRESS_615586] as the 
Day 90 mRS value  
• if both the Day 30 and Day 90 mRS scores are missing but the participant is documented 
to be alive at Day 90 the y will be considered to be a non-responder and the mRS will be 
imputed  as a 5  
• if both the Day 30 and Day 90 mRS scores are missing and the mortality status of the 
participant is unknown at Day 90 they will be considered to be  a non-responder and the 
mRS will be imputed as a 6.  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 54 of 84 If more than 5% subjects randomized are missing the mRS score at Day 90, additional imputation methods will be employed - details of which will be incl uded in the SAP. 
For the secondary analysis of rate of mortality, for participants for whom the morality status is not 
known at Day 90:  
• if they were alive at Day 30,  then the subject will be imputed as alive at Day 90   
• If both the Day 30 and Day 90 mortality is status is missing, the participant will be 
imputed as Dead at Day 90 .  
For other analyses involving the mRS  (other than mortality) , the same imputation approach will 
be taken as for the primary analysis.  No imputation will be done on the missing one -year follow -
up mortality data.  
A number of events may occur after study drug initiation and during the 90-day trial observation 
period that could impact data completeness, the interpretation of, or the ability to observe, each  
outcome variable. Details of handling of such events, which may or may not meet the ICH 
definition of intercurrent events (IEs)
42, will be provided in the SAP.  
Participants  who are missing NIHSS or BI endpoint data at Day [ADDRESS_615587], provided that this score was obtained at the D ay 30 visit or later. Otherwise, 
the missing NIHSS or BI will be imputed to the median score obtained at Day 90 in the trial.  
Sensitivity analyses using various imputation techniques will be specified prospectively in the SAP before the database lock for the interim analysis if more than 5% of participant s randomized 
are missing the primary endpoint.  
Unless otherwise noted, categorical data will be summarized for each treatment group using counts and percentages, with the denominator for percentages being the number of participant s in 
the population of interest. Unless otherwise noted, continuous data will be summarized for each treatment group using the number of observations (n), mean, standard deviation (SD), median, minimum, and maximum. Some continuous data will be reported as  the median, interquartile 
range (IQR), minimum and maximum according to the clinical meaning of the data.  
Percentages will be rounded to one decimal place, except 0% and 100% will be displayed without any decimal places. Minima and maxima will be rounded to the precision of the original value; means and medians will be rounded to one decimal place greater than  the precision of the original 
value; SDs will be rounded to two decimal places greater than the precision of the original value. P-values will be reported to four decimal places (0.xxx x), with values less than 0.00 01 presented 
as <0.0001. 
Inferential analyses will generally include statistics such as 2 -sided 95% confidence intervals (CI), 
and p-value s. Unless stated otherwise, all statistical tests will be one -sided  0.025 (2- sided 0.05). 
In order to avoid sparse sites (sites with fewer than 10 randomized participant s) sites within a 
geographic region (Canada/[LOCATION_003]/Rest of World) with fewer than 10 randomized participant s will 
be pooled into a single pooled site for use in efficacy analyses.  
The software used for all summary statistical analyses will be SAS
® (SAS Institute,  Inc.) version 
9.4 or later . 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 55 of 84 9.3.2 Efficacy Analysis 
The primary and secondary efficacy estimand  analyses will be conducted on the intent -to-treat 
(ITT) population, defined as all participant s randomized into the trial with groupi[INVESTIGATOR_479371], regardless of treatment actually received.    Two additional  analyses to the 
primary analysis will be conducted: (1) the primary analysis reapplied to the Per Protocol  
population ; (2) a re -randomization analysis to demonstrate that minimization did not bias the 
primary endpoint analysis .  
In order to protect the overall trial false positive rate, the primary efficacy estimand analysis  and 
secondary efficacy estimand  analys es will be analyzed in a fixed sequence, stoppi[INVESTIGATOR_479372] (and accepting the null hypothesis) at the first failed hypothesis test in the sequence. The fixed sequential order is:  
1) Primary efficacy estimand analysis.  
2) Secondary efficacy estimand analyses , as specified in the order presented in Table 9-1 
below. 
Table 9-1: Statistical Analysis Methods  
Endpoint  Statistical Analysis Methods  
Primary  Overall proportion participant s experiencing a favorable functional outcome 
90-days post -randomization, defined as 0 to 2 on the mRS . 
The pi[INVESTIGATOR_479373]-sided 0.025 (2-sided 0.05) significance level overall (for the trial), 
adjusted for the interim analysis per the O’Brien -Fleming boundary spending 
function. It will use the method of Ge et al, [ADDRESS_615588] 
error and 95% confidence interval will be reported. P -value for the primary 
endpoint will be calculated based on the estimates reported by [CONTACT_479461], 
201140 method.  
The pi[INVESTIGATOR_479374] a logistic regression model with fixed effects including the treatment group, the stratification covariate of time 
from stroke onset to randomization ≤ 4.5 hours (yes/no) and the randomized 
minimization factors  (age, baseline NIHSS score, occlusion location, time 
from qualifying imaging to randomization, baseline ASPECT score, sex, and 
pooled site), and an interaction term of treatment by [CONTACT_479462]. If the interaction term is not signi ficant at the level of 0.05, it 
will be removed from the model. The odds ratios along with the 95% CI will be reported in addition to the primary Ge et al, [ADDRESS_615589] (i.e. estimation of unadjusted treatment effects).  
Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615590] error, 95% CI and the Wald test statistics will be reported.  
An additional analysis will be conducted in which the primary analysis is reapplied to the per protocol population with observed cases only.  
Three separate efficacy analysis timepoints are planned for this trial. The first analysis will be at the interim analysis planned at 60% information on the primary endpoint. The second analysis timepoint will be based on the completion of Day [ADDRESS_615591] analysis will be following the completion of the 1-Year follow up. 
Secondary  The secondary endpoints with binary outcomes (mortality rate, worsening of 
stroke and NIHSS responder) will be assessed via the same analysis as the primary analysis  (i.e, the logistic regression based, with the odds ratios along 
with the 95% CI and two sample proportion test)  
All tests will be conducted with one -sided  significance level of  0.025  (2-sided 
0.05) . A fixed sequence multiple testing procedure will control the overall experiment -wise error rate for the trial (see below). It pre -specifies that, with 
all tests conducted at the same pre-specified significance level, the primary endpoint will be tested f irst, and all subsequent tests are considered failed and 
deemed exploratory if conducted, in the order specified (primary analysis first, 
secondary analysis second, etc.), after the first test which fails. The mRS shift 
analysis will only be conducted as part of the fixed sequence testing sequence provided that the proportional odds assumption is found to be valid on testing. If it is found to be invalid, the remaining secondary endpoints will be deemed 
to analyzed in the fixed testing sequence specified without the mRS shift 
analysis; i.e. it will be  removed from the fixed sequence testing sequence.  
Mortality rates,  defined as the number of deaths observed divided by [CONTACT_479463] 90-day study period, will be 
compared  between nerinetide and placebo control participant s on the ITT set . 
Results will be summarized and tabulated. , Mortality analysis will be 
additionally supported using time -to-death survival function analysis, both 
unadjusted shown using Kaplan-Meier analysis  and adjusted via Cox 
proportional hazards regression.  
Worsening of Stroke  is determined as the number of participants 
experiencing at least one worsening of stroke divided by [CONTACT_479464] 90-day period in that treatment group, between nerinetide and placebo control participants.  Results will be summarized and tabulated.  
“mRS shift analysis”  The primary analysis of the ordinal mRS scores will 
employ a proportional odds model (POM) to test the hypothesis that, among randomized subjects, those who are treated with nerinetide will show a shift in their mRS score distribution at 90 days relative t o the mRS distribution of the 
placebo subjects. The magnitude of the shift will be estimated as the common 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 57 of 84 odds ratio (95% CI). Modified Rankin scores of 5 and 6  (bed-bound with 
severe disability, and death) will be collapsed into a single category representing severely limited functioning. An adjusted POM will be used to derive the common odds of improvement (i.e. the nerinetide vs. placebo “shift” in mRS score di stributions). 
Adjustment of the treatment effects will 
include the same set of variables as used for the  logistic regression model for 
the primary estimand.  Deceased participants will be included with  a mRS 
score of 6.   
Since the analysis of the ordinal mRS scores will employ a proportional odds 
model (POM), if test of the proportional odds assumption shows the 
assumption to be invalid, this secondary analysis will be removed from the 
fixed sequence testing procedure and conducted as an exploratory analysis 
instead . 
NIHSS scores at Day 90  will be dichotomized into 0 -2 (indicating a good 
neurological outcome) versus >2 (indicating otherwise). Deceased participant s 
will be included with a NIHSS score of 42.  The proportion of participants  
achieving a good neurological outcome at Day [ADDRESS_615592] brain imaging in the nerinetide 
versus placebo control participant s.  Total volume will be assessed  using an 
unadjusted two-tailed Student’s t -test and supported by [CONTACT_479465] a linear regression that includes the stratification and minimization variables . A cubic root transformation will be performed if 
needed. Results will be reported with confidence intervals for the unadjusted 
and adjusted treatment effect between treatment groups.  
Barthel, Day 90 mRS≤1, Day [ADDRESS_615593] include the following:   
• Time from stroke onset to randomization (≤4.5 hours vs. > 4.5 hours)  
• Age (<80 years vs ≥ 80 years of age)  
• Age (<65 years vs ≥ 65 years of age)  
• Sex (men vs. women)  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 58 of 84 • Ethnicity (Hispanics vs non -Hispanic)  
• Race (White, Asian, Black, Other)  
• Baseline stroke severity (NIHSS > Median  vs. NIHSS <= Median ) 
• Baseline occlusion location (MCA vs. ICA) 
• Baseline ASPECT score (5 -7 vs. 8-10)  
• Time from qualifying imaging to study drug initiation (greater than vs. less than the median).  
• Time from onset of stroke symptoms to start of study drug (greater than  
vs. less than the median) .  
• Degree of reperfusion (TICI 2b-3 vs. TICI <2b) 
• Subjects weighing between 105 -120 kg. vs. ≤ 105 kg. 
•  Subjects receiving a thrombolytic treatment  post-randomization vs. those 
that do not.  
• Subjects diagnosed with COVID -[ADDRESS_615594] active COVID -19 infection at presentation vs. 
those that do not. 
• Subjects who received a thrombolytic as a rescue medication vs. those that do not  
• Subjects in whom there was a reported AE of recurrent stroke vs. those 
in who there was not  
Additional sub-groups may be examined.  
Sub-group analysis results will also be reported by [CONTACT_479466][INVESTIGATOR_479375] -by-
stratification interaction term is significant at the 0.05 level in the adjusted 
logistic regression of the primary analysis.  
[IP_ADDRESS] Adjustment for Covariates   
Adjustment will be conducted as described in Table 9 -1. Full details will be sp ecified in detail in 
the SAP.  
[IP_ADDRESS] Outcome Analysis for 1-Year Sub-Study   
The outcomes of the 1 -Year Sub-Study are intended to be supportive of the 90-day outcomes of  
the main study. The analysis population will be comprised of participants with a valid consent  
for the 1-year sub-study in the relevant jurisdiction. Missing data will be imputed as per  
Section 9.3.1. A summary table will specify the differences between the population analyzed in  
the main study and the 1 -year sub-study, including deaths, losses to follow -up and withdrawal of  
consent.  
The primary outcome is the proportion of subjects with independent functioning on the modified Rankin Scale (mRS), as defined by a score of 0-2) at 1 year.  
The secondary outcomes include:  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 59 of 84 • A reduction in mortality rate, as defined by [CONTACT_479412] (%) for mortality over the 1-year  study 
period.  
• The proportion of subjects with independent function on activities of daily living defined on 
the modified Barthel Index (BI) with a score of ≥ 95 at 1 year.  
• Health -related quality of life, as measured by [CONTACT_20367] -5D-5L at 1 year.  
9.3.3 Analyses of Safety  
All safety analyses will be performed on the Safety Population.  The main analyses will be 
frequency of SAEs and 90-day mortality.   
Endpoint  Statistical Analysis Methods  
Serious Adverse 
Events  The frequency of SAEs will be summarize d using the Medical Dictionary 
for Regulatory Activities (MedDRA) Version 23.1.  
SAEs leading to 
death  The frequency of fatal S AEs will be summarize d using the Medical 
Dictionary for Regulatory Activities (MedDRA) Version 23.1.  
Adverse Events  The frequency of AEs will be summarize d using the Medical Dictionary for 
Regulatory Activities (MedDRA) Version 23.1.  
Vital Signs  Absolute values and changes for vital signs from pre -dose to Day 2 will be 
documented. The maximum deviation of BP from Baseline between drug and placebo control groups (systolic and diastolic) to Day 2  will be 
analyzed.  
Lab Safety  Absolute values for laboratory results  will be summarized descriptively.    
Prior and 
Concomitant Medications  Prior and concomitant medications will be summarized using the WHO 
Drug Dictionary.  
9.3.4 Pharmacokinetics  
Descriptive statistics will be calculated for plasma concentrations and for all PK parameters (nerinetide ). In addition, dose proportionality and linearity of dose dependent PK  parameters will 
be investigated. Individual and mean plasma concentration versus time curves will be plotted on linear and semi -logarithmic scales. Plasma concentration versus time curves will be labelled 
appropriately with treatment regimen and batch numb er. 
Actual sampling time-points will be recorded and used for PK calculations. If data permit, the following PK parameters for nerinetide will be calculated at the end of the study by [CONTACT_479467] s with PK samples:  
• AUC
0–t: Area under the concentration -time curve from time zero to time of last measurable 
concentration  
• AUC 0–inf: Area under the concentration -time curve from time zero to infinity  
• Cmax: Maximum plasma concentration observed after dosing  
• Tmax: Time to occurrence of C max 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 60 of 84 • t½: Terminal elimination half -life 
Samples with no detectable nerinetide will be excluded from analysis (placebo).  
9.[ADDRESS_615595] complete the Day 90 fol low-up, at 60% information on the primary endpoint. The planned sample 
size is 850 pa rticipants randomized 1:1, allowing for a single interim analysis at 60%  information 
(when about [ADDRESS_615596] primary endpoint assessments)  with O’Brien-Fleming alpha-
spending function stoppi[INVESTIGATOR_479376].     
. The cumulative alpha spent 
at the interim analysis is 0.004 and final ana lysis 0.025, 1-sided; the stoppi[INVESTIGATOR_3073] Z 
scale are 2.668 (interim) and 1.981 (final) and on the p-value scale 0.004 (interim) and 0.021 
(final), all on the assumption that the interim is conducted at 60% information .  
These calculations were performed by [CONTACT_479468] a dropout/non- evaluable rate of 2% 
with 4 month lag to primary endpoint assessment, estimated accrual rate of 50 participants per 
month, target effects 0.5 vs 0.6114 and a single interim analysis for early superiority stoppi[INVESTIGATOR_479377] O'Brien -Fleming alpha spending function boundary at 60% information (510 evaluable 
participants). [EaST v6.5, 2022].  
The IDMC  may recommend  stoppi[INVESTIGATOR_479378] O -F boundary.  The IDMC Charter will provide further details on the rationale 
for, and how, these recommendations will be communicated.   
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 61 of 84 10 SUPPORTING DOCUMENTATION and OPERATIONAL CONSIDERATIONS  
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  
10.1.1 Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with the following:  
• Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines  
• Applicable ICH Good Clinical Practice (GCP) Guidelines  
• Applicable laws and regulations  including : Canadian Food and Drug Regulations, and 
the Canadian Tri -Council Policy Statement on Ethical Conduct for Research involving 
Humans (2), [LOCATION_002] Code of Federal Regulations (CFR; including Title 21 Parts 50, 54, 56, and 312), where applicable.  
• Applicable guidelines issued due to the COVID -19 pandemic  
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by [CONTACT_112245]/IEC before the study is initiated.  
Any amendments to the protocol will require IRB/IEC approval before implementation of changes 
made to the study design, except for changes necessary to eliminate an immediate hazard to study 
participant s. 
The investigator will be responsible for the following:  
• Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/IEC  
• Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
• Providing oversight of the conduct of the study at the site and adherence to requirements 
of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations  
10.1.[ADDRESS_615597] medical insurance system.  This will include but is not limited to:  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 62 of 84 • Admission to hospi[INVESTIGATOR_307]  
• Baseline laboratory testing, pregnancy test, baseline NCCT and CTA, baseline CTP  
• Endovascular procedure and angiography  
• Follow -up limited -sequence MR brain imaging at Day 2 /3 
• Follow -up laboratory testing (other than the mandated tests at Day 2 /3) 
• Physician fees  
• Treatment processes in the endovascular lab since they are considered standard of care  
• Stroke unit care in hospi[INVESTIGATOR_307]  
• Nursing care  
• Rehabilitation and home care if relevant  
• Outpatient clinic follow -up at 90 days (routine)  
The study fees are designed to cover the costs of study personnel, data collection, research study processes and treatments, the [ADDRESS_615598],  CRF completion, adverse event reporting, concomitant medication reporting, submission 
of imaging to the core lab  and support of remote monitoring, if applicable.  The study fees are 
inclusive of any local institutional overhead/indirect costs.  
10.1.3 Informed Consent Process  
See Section 5.5.2  for further details.  
10.1.4 Data Protection  
Participant s will be assigned a unique identifier by [CONTACT_456]. Any participant  records or 
datasets that are transferred to the sponsor will contain the identifier only; participant  names or 
any information which would make the participant  identifiable will not be transferred.  
The participant  must be informed that his/her personal study -related data will be used by [CONTACT_20004]. The level of disclosure must also be explained to the participant  who will be required to give consent for their data to be used as 
described in the informed consent   
Personal medical information may be reviewed for the purpose of verifying data recorded in the eCRF by [CONTACT_479469].  Other properly authorized persons, such as the regulatory authorities, 
may also have access to these records.  Personal medical information is always treated as confidential.   The participant  must be informed that his/her medical records may be examined by 
[CONTACT_340764], by [CONTACT_6667]/IEC members, and by i nspectors from regulatory authorities. 
All imaging, evaluation forms, reports, and other records that leave the site are identified only by [CONTACT_479470].  All records are kept in a 
locked file cabinet. Clinical information is not released without written permission of the 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 63 of 84 participant , except as necessary for monitoring by [CONTACT_479471]/IRB, Health Canada, the sponsor, or the 
sponsor’s designee. 
All study investigators at the clinical sites , monitors  and sponsor staff must ensure that the 
confidentiality of personal identity and all personal medical information of study participant s are 
maintained at all times.  Federal legislation in Canada (PI[INVESTIGATOR_15654]),  U.S (HIPAA), Europe (GDPR) 
and local legislation s must be followed.  
10.1.5 Committees Structure  
Safety reviews may be performed several times by [CONTACT_1034]’s staff in the course of the trial. 
Any questions pertaining to the reported clinical data will be submitted to the investigator for 
resolution.  Each step of this process will be monitored through the implementation of individual passwords to maintain appropriate database access and to ensure database integrity.  
[IP_ADDRESS] Independent Data Monitoring Committee  
The Independent Statistical Group  will perform the  efficacy interim analysis after approximately 
[ADDRESS_615599] 
statistic crosses the O’Brien -Fleming
43.  
Activities, mandate, responsibilities, communication structure and function of the IDMC and the Independent Statistical Group will be documented in the IDMC Charter prospectively. A  Blinding 
Plan will also be included, specifying sequestering and blinding measures planned for the trial (including analysis firewalls) to prevent operational bias from revelation outside the IDMC of any aggregate interim results on safety or efficacy by [CONTACT_2939].  
To prevent operational bias all interim results on safety and efficacy will be reported only to the IDMC, keepi[INVESTIGATOR_479379], project team, investigators and participant  blind to results by 
[CONTACT_479472]. Firewalls will be in place at the Statistical Analysis Center preparing all interim reports to protect and sequester all interim results on safety and efficacy. This will be detailed in the IDMC C harter.  
10.1.6 Dissemination of Clinical Study Data  
Study information and tabular study results will be posted on the US National Institutes of 
Health’s website www.clinicaltrials.gov  
within one year of study completion.  
10.1.7 Data Quality Assurance  
All participant  data relating to the study will be recorded on the electronic CRF unless transmitted 
to the sponsor or designee electronically (e .g., imaging ). The investigator is responsible for 
verifying that data entries are accurate and correct signing the CRF.   The investigator must 
maintain accurate documentation (source data) that supports the information entered in the CRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents.   The investigator agrees to 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 64 of 84 allow the monitor (s) direct access to all relevant documents , and to allocate his/her time and the 
time of staff to discuss findings , corrective actions  and any relevant issues. In addition to contacts 
during the study, the monitor may also contact [CONTACT_479473].  
Except for an emergency situation in which proper care for the protection, safety and well - being 
of the study participant s requires medical treatment, the study will be conducted as described in 
the approved protocol, ICH -GCP, SOPs and regulatory requirements.  All medical treatments will 
be recorded.  Any deviation(s) from the protocol will be recorded and presented in the final clinical study report.  
To ensure monitoring responsibilities are performed to the fullest extent possible, industry experienced study monitors will perform on site data verification for the trial.  All data monitored on site are verified for accuracy and completeness using source documents for all participant s. 
The sponsor will determine the extent, nature, and frequency of on-site visits that are needed to ensure that the study is being conducted in accordance with the approved protocol (and any amendments), GCP, and all applicable regulatory requirements   Monitoring details describing 
strategy (e .g., risk -based initiatives in operations and quality such as Risk Management and 
Mitigation Strategies and Analytical Risk -Based Monitoring), methods, responsibilities and 
requirements, including handling of noncompliance issues and monitoring techniques (ce ntral, 
remot e, or on-site monitoring) are provided in the Monitoring Plan . 
The sponsor or designee is responsible for the data management of this study including quality checking of the data.   The sponsor assumes accountability for actions delegated to other 
individuals (e .g., Contract Research Organizations). 
Study monitors will perform ongoing source data verification to confirm that data entered into the 
CRF by [CONTACT_1191], complete, and verifiable from source documents; that the safety and rights of participant s are being protected; and that the study is being conducted 
in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.   This review may occur at the study site or remotely.  
Any records supplied by [CONTACT_479474] e process approved by [CONTACT_479475]/EC/REB, when required.  
Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by [CONTACT_1732] 15 years after study completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the sponsor. No records may be transferred to anothe r location or party without written notification to the sponsor.  
10.1.8 Source Documents  
Source documents provide evidence for the existence of the participant  and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.   Source 
documents specification per site will be agreed prior to first participant  enrolled at the site.  
Data reported in the eCRF s must be consistent with the source documents or the discrepancies 
must be explained. The investigator may need to request previous medical records or transfer 
Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615600] be de-identified using only the unique trial specific participant identifier .  This 
process will be aligned with local ethics and privacy requirement s.  
If clinical outcome assessments  are collected  using the electronic Clinical Outcome Assessment 
(eCOA) tool data will transferred directly to the eCRF , in this case t he eCOA record will be the 
sole source document for these assessments.  
Any investigators shall supply the sponsor, upon request, with any required background data from the study documentation or clinic records. This is particularly important when errors in data transcription are suspected.  In case of special problems and/or governmental queries or requests for audit inspections, it is also necessary to have access to the complete study records, provided that participant  confidentiality is protected.  
Definition of what constitutes source data may include: participant  hospi[INVESTIGATOR_307]/clinic records, 
physician's and nurse's notes, appointment book, original laboratory reports, ECG, X -ray, 
pathology and special assessment reports, signed consent forms, consultant letters, and source worksheets.  
The Investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. These documents should be 
classified into two different separate categories: (1) Investigator's Study File; and (2) Participant  
Clinical Source Documents.  
The Investigator's Study File will contain the Protocol/Amendments, CRFs, REB/IRB and 
governmental approval with correspondence, all versions of ethics approved informed consent forms, staff curriculum vitae and authorization forms and other appropriate 
documents/correspondence, etc.  
The investigator must keep these two categories of documents on file according to local clinical trial regulation.  In Canada, all study documents for a regulated trial require storage for [ADDRESS_615601] and notify the REB/IRB  
10.1.[ADDRESS_615602] site open and  will be the study start date.  
The sponsor designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the sponsor, which may include new or emerging safety information that negatively affects the benefit/risk profile of the drug .  
Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615603] been collected and a study -site closure visit 
has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_277488]:  
• Failure of the investigator to comply with the protocol, the requirements of the REB/ IRB 
or local health authorities, the sponsor's procedures, or GCP guidelines  
• Inadequate recruitment of participant s by [CONTACT_093]  
• Discontinuation of further study intervention development  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
Investigators, the REBs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_11005]. The Investigator shall promptly inform the participant  and should assure 
appropriate participant  therapy and/or follow -up 
10.1.[ADDRESS_615604] proprietary information and to provide comments.  
The sponsor will permit any and all academic publications arising from the trial data provided that no publication containing unblinded trial data precedes publication of the overall trial results in a 
peer-review journal, and are (1) approved by [CONTACT_479476] (2) the publication 
authors notify the sponsor at least 30 days prior to submittal for publication with a copy of such proposed publication for the sponsor’s review and comment. Employees or consultants of the sponsor will only be named as authors in any such publication if the parties agree that it is appropriate under the usual conventions used by [CONTACT_479477].  Upon request of the sponsor the publication or disclosure shall be delayed for up to [ADDRESS_615605] of the executive committee and the site 
principal/qualified investigator at each of the sites.  A form al publication policy will be presented 
and developed by [CONTACT_941] t rial executive.  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 67 of 84 Authorship will be determined by [CONTACT_23531].  
10.1.11Audits and Inspections  
In accordance with the principles of ICH E6 Guideline for Good Clinical Practice, the study site may be inspected by [CONTACT_479478]/or audited by [CONTACT_479479]. Quality  Assurance 
(QA) or their designates. The investigator and relevant clinical support staff will be required to be actively involved in audits and inspections, including staff interviews, and to make all necessary documentation and data available upon reques t. 
During the course of the study and/or after it has been completed, one or more investigator site audits may be undertaken by [CONTACT_479480]. The purpose of these audits is to determine whether or not the study is being/has been conducted and monitored in compliance with 
recognized ICH E6 Guideline for Good Clinical Practice, protocol and approved amendment requirements, applicable local SOPs, and local laws and regulations. It is the responsibility of the investigator and site staff to p romptly address, by [CONTACT_479481].  any deficiencies 
stemming out of regulatory inspections and NoNO QA or delegate audits, and to ensure that agreed -upon corrective and preventive actions are implemented as soon as possible.  
An inspection by [CONTACT_479482]. If an investigator is contact[CONTACT_426] a regulatory authority for the purpose of conducting an inspection or to discuss any compliance issues, he/she is required to contact [CONTACT_479483].  
  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 68 of 84 10.2 Appendix 2: Clinical Laboratory Tests  and Imaging  
10.2.1 Clinical Laboratory Tests  
The tests detailed in Table 10-1 will be performed as per local hospi[INVESTIGATOR_136966] . 
Table 10-1: Protocol -Required Safety Laboratory Assessments  
Laboratory Tests  Parameters  
Hematology  Platelet Count  
Hemoglobin 
Hema tocrit  
Chemistry  Serum creatinine  
Serum glucose  
Electrolytes  Sodium  
Potassium  
Chloride  
Pregnancy testing  Highly sensitive (Serum or urine)  human chorionic gonadotropin (hCG) pregnancy test (as 
needed for women of childbearing potential)  
 
10.2.2 Imaging 
At baseline all participant s will undergo brain  imaging  for assessment of inclusion into the trial  as 
described in Section 5.5.1.  The Day 2 /[ADDRESS_615606] volume ( including a 
minimum of axial DWI, gradient -echo (GRE), FLAIR).  The Day 2 /[ADDRESS_615607] is allowed . 
The baseline and all brain/neurovascular imaging conducted up to the D ay 2/[ADDRESS_615608] the imaging inclusion/exclusion criteria found in Sections 5.[ADDRESS_615609] scores , 
adherence to qualifying imaging criteria, as well as, reperfusion rates  (TICI scores) and volume of 
stroke at Day  2/3.  Other brain imaging will be sent only if requested by [CONTACT_73488].  
For all interval times assessed from imaging, the time zero will be the first slice of the NCCT scan.  Imaging date and time will be collected in the CRF . 
Notes:  
Sites  that did not participate in the ESCAPE -NA1  trial will submit sample images  to the 
imaging core lab for quality  assessment .   
Baseline imaging may be completed at a hospi[INVESTIGATOR_479380].  
  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 69 of 84 10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow -up, and Reporting  
10.3.[ADDRESS_615610] a causal relationship with this treatment.  
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.  
Adverse Drug Reaction (ADR)  
In the pre -approval clinical experience with a new medicinal product or its new usages, 
particularly as the therapeutic dose(s) may not be established: all noxious and unintended responses to a medicinal product related to any dose should be considered adv
erse drug 
reactions.  The phrase "responses to a medicinal product" means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility, i.e., the relationship cannot be ruled out.  
Unexpected Adverse Drug Reaction  
An adverse reaction, the nature or severity of which is not consistent with the applicable product information (e.g., Investigator's Brochure for an unapproved investigational medicinal product).  
Events Meeting  the AE Definition  
• A new illness  
• The worsening of a concomitant illness  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator (i.e., not related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.  
Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615611] medical occurrence that, at any dose: 
a. Results in death  
All deaths occurring during the follow up to Day 90 will be reported as an SAE.  When reporting a death, the event or condition that caused or contributed to the fatal outcome should be reported as a single medical concept.  
b. Is life -threatening  
The term 'life-threatening' in the definition of 'serious' refers to an event in which the participant  
was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_1081]  
• In general, hospi[INVESTIGATOR_319850] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_256975]/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_479381], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be considered serious. 
• Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from baseline is not considered an AE.  
d. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere with or prevent everyday  life 
functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Other situations : a SAE can also be an important medical event that may not result in death, 
be life- threatening, or require hospi[INVESTIGATOR_059], but may jeopardize the participant  and may 
require medical or surgical intervention to prevent one of the outcomes listed in this 
definition : 
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may not be 
immediately life- threatening or result in death or hospi[INVESTIGATOR_228057] t he 
participant  or may require medical or surgical intervention to prevent one of the other 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 71 of 84 outcomes listed in the above definition. These events should usually be considered 
serious. 
• Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or drug a buse.
 
10.3.3 Recording and Follow -Up of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related to the event.  
• The investigator will then record all relevant AE/SAE information in the CRF.  
• It is not  acceptable for the investigator to send photocopi[INVESTIGATOR_10914] ’s medical 
records to the Sponsor in lieu of completion of the CRF pages and SAE reports . 
• There may be instances when copi[INVESTIGATOR_29482]. In this case, all participant  identifiers, with the exception of the participant  
study identification  number, will be redacted on the copi[INVESTIGATOR_12997]. 
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during the 
study and assign it to 1 of the following categories:  
• Mild: Awareness of sign or symptom but easily tolerated.  
• Moderate: Discomfort sufficient to cause interference with normal activities.  
• Severe: Incapacitating, with inability to perform normal activities.   
An AE that is assessed as severe should not be confused with a SAE. Severe is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.   An event 
is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, NOT when it is rated as severe.  
Assessment of Causality  
• The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 72 of 84 • The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.  
• The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the investigator has minimal information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.  
• The investigator may change his/her opi[INVESTIGATOR_9242] -up information 
and send a SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
AE Causality/ Relationship  
Related  A clinical event, including laboratory test abnormality, where there is a 
“reasonable possibility” that the SAE was caused by [CONTACT_5257], meaning that 
there is evidence or arguments to suggest a causal relationship.  
Possibly:  A clinical event, including laboratory test abnormality, with a reasonable time 
sequence to drug administration, but which could also be explained by [CONTACT_9153].  Information on drug withdrawal may be lacking or unclear.  
Unrelated:  This category is applicable to AEs which are judged to be clearly and 
incontrovertibly due to extraneous causes (diseases, environment, etc.) and do not meet the criteria for drug relationship listed for the above -mentioned conditions. 
Follow -up of AEs and SAEs  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_29551]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.  
• If a participant  dies during participation in the study the investigator may be requested by 
[CONTACT_479484] a copy of any post -mortem findings including 
histopathology.  
• New or updated information will be recorded in the originally completed CRF.  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 73 of 84 • The investigator will submit any updated SAE data to  the Sponsor  within 24 hours of 
receipt of the information.  
 
10.3.4 Reporting of SAEs  
SAE Reporting to the Sponsor  via an Electronic Data Collection Tool  
• The primary mechanism for reporting an SAE to the Sponsor will be the electronic data 
collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data collection tool (see next section) in order to report the event within 24 hours . 
• The site will enter the SAE data into the electronic system as soon as it becomes available.  
• After the study is completed at a given site, the electronic data collection tool will be taken off-line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant  or receives updated data 
on a previously reported SAE after the electronic data collection tool has been taken off -
line, then the site can report this information on a paper SAE form or to the Drug Safety Department at NoNO by [CONTACT_479485] . 
 [PHONE_10028]  or [EMAIL_9234]  
SAE Reporting to the Sponsor via Paper CRF  
If the eCRF system is not available, a paper SAE form should be directed within 24 hours to:  
Drug Safety at NoNO Inc.  
[EMAIL_9234]  or  
[PHONE_10029] (for fax)  
Initial notification via telephone does not replace the need for the investigator to complete and 
sign the SAE CRF pages within the designated reporting time frames.  
 
  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 74 of 84 10.4 Appendix 4: Collection of Pregnancy Information  
Male participant s with partners who become pregnant  
The investigator will attempt to collect pregnancy information  on any male participant ’s female 
partner who becomes pregnant while the male participant  is in this study. This applies only to 
male participant s who receive  study drug.  
After obtaining the necessary signed informed consent from the pregnant female partner directly, the investigator will record pregnancy information on the Pregnancy Reporting Form and submit it to the sponsor with in 24 hours  of learning of the partner’s pregnancy. The female partner will 
also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the sponsor. Generally, the follow -up will be no longer than 
4 weeks  following the estimated delivery date. Any termination of the pregnancy will be reported 
regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
Female Participant s who become pregnant  
The investigator will collect pregnancy information on any female participant  who becomes 
pregnant while participating in this study.  The initial information will be recorded on the Pregnancy Reporting Form  and submitted to the sponsor within 24 hours  of learning of a 
participant ’s pregnancy.  
The participant  will be followed to determine the outcome of the pregnancy. The investigator will 
collect follow -up information on the participant  and the neonate and the information will be 
forwarded to the sponsor. Generally, follow -up will not be required for longer than 4 weeks 
beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurring at >22 
weeks gestational age) is always considered to be an SAE and will be reported as such.  
Any post -study pregnancy related SAE considered reasonably related to the study intervention by 
[CONTACT_55901] 8.3.4 . While the 
investigator is not obligated to actively seek this information in former study participant s, he or 
she may learn of an SAE through spontaneous reporting.  
Any female participant  who becomes pregnant while participating in the study will discontinue 
study intervention but will continue to be followed to the end of the trial.  
  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 75 of 84 10.5 Appendix 5: Abbreviations  
AHA  American Heart Association  
AIS Acute Ischemic Stroke  
AE Adverse Event  
AESI  Adverse Event of Special Interest  
ASPECTS  Alberta Stroke Program Early Computerized Tomography Score  
β-hCG  Beta-human Chorionic Gonadotropin  
BI Barthel Index  
BP Blood Pressure  
CBC  Complete Blood Count  
CFR  Code of Federal Regulations  
CI Confidence Interval  
CIOMS  Council for International Organizations of Medical Sciences  
CRA  Clinical Research Associate  
CRF  Case Report Form  
CT Computed Tomography  
CTA  Computed Tomographic Angiography  
CTP Computed Tomographic Perfusion  
DWI  Diffusion Weighted Imaging  
EC Ethics Committee  
eCOA  
eCRF  Electronic Clinical  Outcome Assessment  
Electronic Case Report Form  
eMCAO  Embolic Middle Cerebral Artery Occlusion  
ESCAPE -NEXT  Extension of Stroke Care with Adjuvant neuro Protection to Endovascular 
treatment with Nerinetide EXcluding Thrombolysis  
EQ-5D-5L EuroQol  health -related quality of life  
EVT  Endovascular Thrombectomy  
FDA  Food and Drug Administration  
FLAIR  Fluid Attenuated Inversion Recovery  
GCP  Good Clinical Practice  
GDPR  General Data Protection Regulation  
HIPAA  Health Insurance Portability and Accountability Act  
HR Heart Rate  
ICA Internal Carotid Artery  
ICF Informed Consent Form  
ICH-GCP  International Conference on Harmonization -Good Clinical Practice  
IDMC  Independent Data Monitoring Committee  
IRB Institutional Review Board  
ITT Intent -to-treat 
IV Intravenous  
IWRS  Interactive Web Response System  
LAR  Legally Authorized Representative  
LVO  Large Vessel Occlusion  
MAP  Mean Arterial Pressure  
Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615612] Computed Tomography Scan  
NIHSS  National Institutes of Health Stroke Scale  
NMDA  N-methyl D -aspartate  
NMDAR  N-methyl D -aspartate Receptor  
nNOS  Neuronal Nitric Oxide Synthase  
NO Nitric Oxide  
O-F O’Brien Fleming  
pH Potential Hydrogen  
PI [INVESTIGATOR_479382]-[ADDRESS_615613] Operating Procedures  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
TICI  Thrombolysis in Cerebral Infarction Score  
tMCAO  Temporary Middle Cerebral Artery Occlusion  
[LOCATION_003]/US  [LOCATION_002] of America  
VAS  Visual Analogue Scale  
WHO  World Health Organization  
  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 77 of 84 10.6 Appendix 6: Country -specific Requirements  
10.6.[ADDRESS_615614] may be made by [CONTACT_479486]/favourable opi[INVESTIGATOR_479383]/Ethics Committee. Any decision made will hav e considered the patient’s presumed will.  
All methods of conducting the informed consent  process must comply with ICH GCP E6.  
Approval for all method(s) of obtaining informed consent as well as the forms used must be 
obtained prior to implementation.  
In the event the subject remains incapacitated, consent to continue participation in the trial should be obtained from the LAR  as soon as it is possible and reasonable.   
 
10.6.2 Addition to Remote Source Document Verification - Section 10.1.7  
Remote source data verification (rSDV) will only occur at study sites where the country regulations allow and prior approval has been granted by [CONTACT_46962], as 
applicable.    In [LOCATION_013], rSDV will not occur at study sites. 
 
  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 78 of 84 11 REFERENCES  
1. DALYs GBD, Collaborators H. Global, regional, and national disability -adjusted life-
years (dalys) for 359 diseases and injuries and healthy life expectancy (hale) for 195 
countries and territories, 1990 -2017: A systematic analysis for the global burden of 
disease study 2017. Lancet . 2018;392:1859- 1922  
2. Collaborators GBDM. Global, regional, and national age- sex-specific mortality and life 
expectancy, 1950- 2017: A systematic analysis for the global burden of disease study 
2017. Lancet . 2018;392:1684- 1735  
3. Macdonald RL. Neurosurgical operative atlas. In: MacDonalr LR, ed. Neurosurgical operative atlas . [LOCATION_001]: Thieme Verlagsgruppe; 2019:236- 240.  
4. NINDS. Stroke: Hope through research Accessed 12 June 2013;National Institutes of 
Health  
5. Fisher M. The ischemic penumbra: Identification, evolution and treatment concepts. 
Cerebrovasc Dis . 2004;[ADDRESS_615615] 1:1- 6 
6. Tymianski M. Novel approaches to neuroprotection trials in acute ischemic stroke. 
Stroke. 2013;44:2942- 2950  
7. Hachinski V. Management of hemorrhage. Brain Attack: The Clinical Handbook . 
1999:1- 4 
8. Saver JL. Time is brain --quantified. Stroke. 2006;37:263- 266  
9. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. 
Endovascular thrombectomy after large -vessel ischaemic stroke: A meta -analysis of 
individual patient data from five randomised trials. Lancet . 2016;387:1723- [ADDRESS_615616] Schering Res Found Workshop . 2004:155- 184  
11. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized 
assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med . 
2015;372:1019- 1030  
12. Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, Demchuk AM, et al. Efficacy 
and safety of nerinetide for the treatment of acute ischaemic stroke (escape- na1): A 
multicentre, double- blind, randomised controlled trial. Lancet . 2020  
13. Cui H, Hayashi A, Sun HS, Belmares MP, Cobey C, Phan T, et al. Pdz protein interactions underlying nmda receptor -mediated excitotoxicity and neuroprotection 
by [CONTACT_479487] -95 inhibitors. J Neurosci . 2007;27:9901- 9915  
14. Docagne F, Parcq J, Lijnen R, Ali C, Vivien D. Understanding the functions of 
endogenous and exogenous tissue- type plasminogen activator during stroke. Stroke. 
2015;46:314- 320  
15. Sun X, Garman D, Tymianski M. The experimental neuroprotective drug na1 does not interfere with the fibrinolytic activities of alteplase or tenecteplase. Stroke. 2019;50:1  
16. Chandler WL, Alessi MC, Aillaud MF, Vague P, Juhan -Vague I. Formation, inhibition 
and clearance of plasmin in vivo. Haemostasis . 2000;30:204- [ADDRESS_615617], Madison EL. Negative 
selectivity and the evolution of protease cascades: The specificity of plasmin for 
peptide and protein substrates. Chem Biol . 2000;7:443- 453  
Version:  6.0   Protocol NA -1-009 
Date: [ADDRESS_615618] -modifying drug- drug 
interactions between alteplase and nerinetide in acute ischemic stroke. Sci Transl 
Med. 2020;Manuscript in preparation; data on file  
19. Kaesmacher J, Mordasini P, Arnold M, Lopez- Cancio E, Cerda N, Boeckh -Behrens T, et 
al. Direct mechanical thrombectomy in tpa- ineligible and - eligible patients versus the 
bridging approach: A meta -analysis. J Neurointerv Surg . 2019;11:20- 27 
20. Coutinho JM, Liebeskind DS, Slater LA, Nogueira RG, Clark W, Davalos A, et al. 
Combined intravenous thrombolysis and thrombectomy vs thrombectomy alone for 
acute ischemic stroke: A pooled analysis of the swift and star studies. JAMA Neurol . 
2017;74:268- 274  
21. The randomized study of endovascular therapy with versus without intravenous 
tissue plasminogen activator in acute stroke with ica and m1 occlusion. ISC . 2020  
22. Cook DJT, L.; Tymianski, M. Treatment of stroke with a psd95 inhibitor in the 
gyrencephalic primate brain Nature . 2012;483:213- 217  
23. Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, Terbrugge KG, et al. Safety and 
efficacy of na -1 in patients with iatrogenic stroke after endovascular aneurysm repair 
(enact): A phase 2, randomised, double- blind, placebo -controlled trial. Lancet Neurol . 
2012;11:942- 950  
24. Khatri P, Yeatts SD, Mazighi M, Broderick JP, Liebeskind DS, Demchuk AM, et al. 
Duplicate: Time to angiographic reperfusion and clinical outcome after acute 
ischaemic stroke: An analysis of data from the interventional management of stroke 
(ims iii) ph ase 3 trial. Lancet Neurol . 2014;13:567- 574  
25. Ribo M, Molina CA, Cobo E, Cerda N, Tomasello A, Quesada H, et al. Association 
between time to reperfusion and outcome is primarily driven by [CONTACT_479488]. Stroke. 2016;47:999- 1004  
26. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: A 
guideline for healthcare professionals from the american heart association/american 
stroke a ssociation. Stroke. 2018;49:e46- e110  
27. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients 
excluded from tpa therapy? An analysis of patient eligibility. Neurology . 
2001;56:1015- 1020  
28. Madsen TE, Khoury JC, Alwell KA, Moomaw CJ, Kissela BM, De Los Rios La Rosa F, et 
al. Analysis of tissue plasminogen activator eligibility by [CONTACT_479489]/northern kentucky stroke study. Stroke. 2015;46:717- 721  
29. Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, et al. Eligibility for 
recombinant tissue plasminogen activator in acute ischemic stroke: A population -
based study. Stroke. 2004;35:e27- 29 
30. Jovin TG, Nogueira RG, Lansberg MG, Demchuk AM, Martins SO, Mocco J, et al. 
Duplicate: Thrombectomy for anterior circulation stroke beyond [ADDRESS_615619] 
known well (aurora): A systematic review and individual patient data meta- analysis. 
Lancet . 2022;399:249- 258  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 80 of 84 31. Nguyen TN, Abdalkader M, Nagel S, Qureshi MM, Ribo M, Caparros F, et al. Duplicate: 
Noncontrast computed tomography vs computed tomography perfusion or magnetic 
resonance imaging selection in late presentation of stroke with large- vessel 
occlusion. JAMA Neurol . 2022;79:22- 31 
32. Zhao W, Hill MD, Palesch YY. Minimal sufficient balance – a new strategy to balance 
baseline covariates and preserve randomness of treatment allocation. Stat Meth Med 
Res. 2012;In press  
33. Banks JL, Marotta CA. Outcomes validity and reliability of the modified rankin scale: 
Implications for stroke clinical trials: A literature review and synthesis. Stroke. 
2007;38:1091- 1096  
34. Quinn TJ, Dawson J, Walters MR, Lees KR. Reliability of the modified rankin scale: A 
systematic review. Stroke; a journal of cerebral circulation . 2009;40:3393- 3395  
35. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol . 2006;5:603-
612  
36. Mahoney FI, Barthel DW. Functional evaluation: The barthel index. Md State Med J . 
1965;14:61- 65 
37. Quinn TJ, Langhorne P, Stott DJ. Barthel index for stroke trials: Development, 
properties, and application. Stroke; a journal of cerebral circulation . 2011;42:1146-
1151  
38. Brooks R. Euroqol: The current state of play. Health Policy . 1996;37:53- 72 
39. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and 
preliminary testing of the new five -level version of eq -5d (eq -5d-5l). Qual Life Res . 
2011;20:1727- [ADDRESS_615620] Meyer. Covariate- adjusted difference in proportions from clinical 
trials using logistic regression and weighted risk differences. Drug Information 
Journal . 2011;45(4)::481- 493  
41. Adjusting for covariates in randomized clinical trials for drugs and biological products - fda draft guidance for industry. 2021  
42. ICH. Ich e9(r1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. 2019  
43. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics . 
1979;35:549- 556  
  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 81 of 84 12 INVESTIGATOR’S AGREEMENT  
 I have read the attached protocol: A Multicentre, Randomized, Double-blinded, Placebo -
controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Nerinetide in Participant s with Acute Ischemic Stroke Undergoing Endovascular 
Thrombectomy Excluding  Thrombolysis  (ESCAPE -NEXT  Trial)  (Version number in the 
header above) and agree to abide by [CONTACT_3769].  
 
I agree to comply with the current International Conference on Harmonisation Guidelines for 
Good Clinical Practice and the laws, rules, regulations and guidelines of the community, country, state or locality relating to the conduct of the clinical study.  
I also agree that persons debarred from conducting or working on clinical studies by [CONTACT_479490].  
 
   
Name [CONTACT_479530]   [INVESTIGATOR_479384]:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 82 of 84 13 ADDENDUM  
13.1 COVID -19 Considerations  
Improving Access to Stroke Care due to Changes in COVID -19  
Based on the clinical data available for nerinetide to date, treatment with nerinetide may slow the progression of ischemic brain damage, providing more time during which endovascular thrombectomy may be of benefit to the patient. This is of even greater relevance during the global COVID-19 pandemic for the following reasons:  
(a) There is a necessity to protect hospi[INVESTIGATOR_33717] , resulting in additional hospi[INVESTIGATOR_479354] e the exposure of the 
clinical stroke team to a potentially COVID -19 positive stroke patient (there is no time for 
COVID-19 testing to be completed) . 
(b)  There is a necessity to protect the patient , resulting in additional hospi[INVESTIGATOR_479355]/her from hospi[INVESTIGATOR_479356] (e.g., CT scanner) used on other patients . 
These necessities  slow down emergency stroke care workflows , potentially causing undue delays 
in the emergency stroke care of all AIS patients, not just those who may have been exposed to COVID-19. Thus, the possibility that nerinetide, by [CONTACT_479427], mitigates such delays may be of direct benefit to treated patients.  
Minimizing Risk to Participants and Staff  
The protocol includes the following adaptations to minimize risk while prioritizing the overall 
well-being and best interests of all involved in the trial.  This protocol was written considering the 
impact of COVID -19 on trial participants, site staff and sponsor staff. With these priorities in 
mind, the protocol design will still permit assessment of safety and efficacy of nerinetide.  
• Minimize the number of study visits  to align with the trial endpoints   
• Minimize the number of trial specific activities .  The trial was designed to align with 
standard of care protocols for acute stroke.  For example, obtaining data from standard of 
care assessments conducted during routine stroke care, for the collection and reporting of 
some safety outcomes (vital signs, laboratory results) and imaging outcomes. 
• Conduct visits by [CONTACT_479456] a t Day 30 and Day 90, where permitted, 
when a participant is unable to attend the site physically.  This will permit the timely collection of efficacy endpoints (mRS, NIHSS, Barthel Index and EQ -5D-5L) and safety 
data (AE and SAE collection).  If the contact [CONTACT_333336], only the NIHSS assessment will not be completed, all other assessments will be obtained.  
• Use of remote electronic consent , where permitted , to obtain initial consent from the 
LAR, who may not be able to enter the hospi[INVESTIGATOR_307], and to obtain regained capacity consent 
from participants who did not consent prior to their discharge from hospi[INVESTIGATOR_307].  
• Use of electronic Clinical Outcome Assessments (COA)  is optional f or the conduct  of 
the mRS, NIHSS, Barthel Index and EQ -5D-5L assessments at Day 30, Day [ADDRESS_615621] trial 
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 83 of 84 endpoints even if they are not permitted into the hospi[INVESTIGATOR_307], reduce data entry time and reduce the time on -site for CRAs in order to monitor the data.  
In addition to the above items included in the protocol, ongoing risk assessments and monitoring of the COVID -19 situation will be conducted by [CONTACT_479491] a site and country level. These ongoing assessments include changes to any of the following:  
• Potential impact on trial participants  
• Potential impact on trial site staff, including local or central REB/IRBs/ECs  
• Potential impact on sponsor/CRO staff conducting site monitoring and central review of data.  
The outcome of these ongoing assessments could result in site-specific or country-specific 
mitigation plans, which could include:  
• Suspension of enrollment in that site or country 
• Suspension of on-site visits by [CONTACT_479492], replacing the physical 
data capture with some remote measures (telephone or telemedicine, where permitted)  
• Suspension of on-site visits being conducted by [CONTACT_2689], replacing the monitoring with 
remote review of data and telephone contacts with the site  
• Other mitigation plans, as appropriate.  
 
  
Version:  6.0   Protocol NA -1-009 
Date: 01 June  2022   NoNO Inc.  
 
 
 Confidential  Page 84 of 84 13.2 Assessment Questionnaires 
Below is a sample of the assessment questionnaires and instructions to be used in the trial.  
Modified Rankin Scale (mRS)  Clinician Reported Outcome  
English example  
National Institute of Health Stroke Score 
(NIHSS)  Clinician Reported Outcome  
English example.   
Barthel Index  Clinician Reported Outcome  
English example.   
EQ-5D-5L Patient Reported Outcome   
[LOCATION_003] , English Interviewer Administered example  
See https://euroqol.org/  for device, country, and 
language specific versions  
 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
Co nfidential 1 Sta
tistical Analysis Plan  
A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose 
Design to Determine the Efficacy and Safety of Nerinetide in Subjects with Acute Ischemic 
Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis   
(ESCAPE -NEXT Trial)  
Protocol NA -1-[ADDRESS_615622]: Nerinetide
IND: 118,087  
Sponsor: NoNO Inc.  
Date  [ADDRESS_615623]
Toronto, Ontario, Canada M5V 1E7
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
Co nfidential 2 SIGNATURES OF APPROVAL  
Personal Protected Data
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  3 Version History  
This Statistical Analysis Plan (SAP) for the trial ESCAPE -NEXT  is based on Protocol V 5.0, 
dated  18 November 2021.  
Version  Date  Change  Rationale  
1.0 03 
May 2021 Not Applicable  Original version  
2.0 18 Nov 2021 - Updated hierarchical testing order of secondary endpoints: moved the NIHSS responder endpoint to the last. - The change in testing order of NIHSS endpoint was due to the concern of increased missingness of Day [ADDRESS_615624] statistical power.   
- NIHSS cannot be conducted over the 
phone.  Due to COVID -19 there is an 
increase in the number of Day 90 visits being conducted by [CONTACT_648]. 
- Updated the primary analysis model for all binary efficacy endpoints: a generalized linear regression model with adjust ment for baseline 
covariates and randomization stratification factor will be used  
- Changed one of supportive analyses of the primary efficacy endpoint to an unadjusted logistic regression  
- Added robust estimation of unconditional treatment effect for the pr imary efficacy endpoint 
analysis  - The updates in primary analysis model as well as the addition of unconditional treatment effect were made to be aligned with the FDA draft guidance “Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products” dated in May 2021 
 
  
Version: 2.0 
Date:  [ADDRESS_615625] of Tables  .................................................................................................................................. 6 
 Introduction ............................................................................................................................. 7 
1.1 Background  .......................................................................................................................... 7 
1.2 Trial Objectives  ................................................................................................................... 8 
1.2.1  Primary Objective  ....................................................................................................... 8 
1.2.2  Secondary Objectives  .................................................................................................. 8 
1.2.3  Tertiary Objectives  ...................................................................................................... 8 
1.2.4  Safety Objectives  ........................................................................................................ 9 
1.2.5  1- Year Follow Up Analytic Sub- Trial Objectives  ..................................................... 9 
1.3 Study Design ...................................................................................................................... 11 
1.4 Sample Size Determination  ............................................................................................... 11 
1.5 Randomization ................................................................................................................... 12 
1.6 Blinding of Main Study  ..................................................................................................... 14 
1.7 Blinding of 1- year Follow -up Study .................................................................................. 15 
1.7.1  Subjects hav ing the 1- year Follow -up While the Main Study is Blinded  ................. 15 
1.7.2  Subjects having the 1- year Follow -up After the Main Study is Unbli nded .............. 15 
1.8 Definitions  ......................................................................................................................... 15 
 ANALYSIS POPULATIONS  .............................................................................................. 17 
2.1 Intent -to-Treat (ITT) Population ....................................................................................... 17 
2.2 Safety Population ............................................................................................................... 17 
2.3 Per Protocol (PP) Population ............................................................................................. 17 
 STUDY ASSESSMENTS and DATA COLLECTION  ....................................................... 18 
3.1 The Modified R ankin Scale  ............................................................................................... 18 
3.2 Mortality  ............................................................................................................................ 18 
3.3 Worsening of Stroke  .......................................................................................................... 18 
3.4 National Institutes of Health Stroke Scale  ......................................................................... 18 
3.5 Volume  of Stroke  ............................................................................................................... 18 
3.6 Barthel Index  ..................................................................................................................... 19 
3.7 EQ-5D-5L .......................................................................................................................... 19 
Version: 2.0 
Date:  [ADDRESS_615626] Disposition  ............................................................................................................ 25 
5.2 Protocol Violations  ............................................................................................................ 25 
5.3 Treatments  ......................................................................................................................... 25 
5.4 Study Progress Time  .......................................................................................................... 26 
5.5 Demographic and Baseline Characteristics  ....................................................................... 26 
 EFFICACY ANALYSIS  ...................................................................................................... 27 
6.1 Primary Outcome Variable Analysis for Main Study ....................................................... 27 
6.1.1  Primary Estimand  ...................................................................................................... 27 
6.1.2  Statistical Hypothesis  ................................................................................................ 27 
6.1.3  Primary Efficacy Estimand Analysis  ........................................................................ 27 
6.2 Secondary Efficacy Estimand Analyses for Main Study  ................................................... 30 
6.2.1  Mortality  ................................................................................................................... 31 
6.2.2  Worsening of Stroke  ................................................................................................. 31 
6.2.3  Secondary Outcome Analysis – mRS shift analysis  ................................................. 31 
6.2.4  National Institutes of Health Stroke Scale  ................................................................ 33 
6.3 Tertiary Efficacy Outcomes Analyses for Main Study  ..................................................... 33 
6.3.1  Volume of Stroke  ...................................................................................................... 33 
6.3.2  Barthel Index  ............................................................................................................. 34 
6.3.3  Proportion of subjects with Day 90 mRS 4- 6 ........................................................... 34 
6.3.4  Proportion of subjects with Day 90 mRS ≤ 1  ........................................................... 34 
6.3.5  EQ-5D-5L ................................................................................................................. 34 
6.4 Explorator y Analyses for Main Study ............................................................................... 34 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  6 6.5 Pharmacokinetic Analyses  ................................................................................................. 35 
6.6 Outcome Analysis for 1 -Year Sub -Study  .......................................................................... 36 
6.6.1  mRS at 1 Year  ........................................................................................................... 36 
6.6.2  Mortality Rate at 1 Year  ........................................................................................... 36 
6.6.3  Barthel Index at 1 Year  ............................................................................................. 36 
6.6.4  EQ-5D-5L at 1 Year  .................................................................................................. 36 
 SAFETY ANALYSES .......................................................................................................... 39 
7.1 Adverse Events  .................................................................................................................. 39 
7.2 Vital Signs  ......................................................................................................................... 40 
7.3 Laboratory Results  ............................................................................................................. 40 
7.4 Concomitant Medications  .................................................................................................. 41 
 INTERIM ANALYSIS  ......................................................................................................... 42 
8.1 Interim Efficacy Analysis  .................................................................................................. 42 
8.2 Safety Analysis  .................................................................................................................. 44 
8.3 Independent Data Monitoring Commit tee ......................................................................... 44 
8.4 Handling of Enrollment Overage  ...................................................................................... 45 
 Supporting Documentation ................................................................................................... 46 
9.1 Appendix 1: Listing of Treatment -Emergent AEs of Special Interest (TEAESI)  ............. 46 
9.2 Appendix 2: List of Abbreviations  .................................................................................... [ADDRESS_615627] OF TABLES  
Table 1: Objectives and Endpoints  ................................................................................................. 9 
Table 2: Schedule of Activities - Main Trial  ................................................................................. 14 
Table 3: Schedule of Activities: One -Year Follow Up Telemedicine or Telephone Co ntact  ...... 14 
Table 4: Summary of Inferential Efficacy Analyses  ..................................................................... 37 
Table 5: Summary of Interim Efficacy Analyses  ......................................................................... 42 
 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  7 
 INTRODUCTION   
This document provides the details of statistical analyses planned for Protocol No. NA -1-009/ 
ESCAPE -NEXT .  In addition, it discusses the statistical issues relevant to these analyses 
(e.g., sample data to be used and missing data).  
1.1 Background  
Nerinetide (formerly termed NA -1 or TatNR2B9c) is  a synthetic, cell-permeant eicosapeptide  
(20 amino  acids) th at perturbs protein-protein interac tions  on the cytosolic surface of the cell 
membrane mediated by [CONTACT_447]-synaptic density 95 protein (PSD-95)1, an abunda nt protein 
localiz ed in post -synaptic d ensitie s of cent ral nervous s ystem neurons.  It may provide  significant 
benefit for the treatment of acute cerebral ischemia if administered to stroke patients who present 
to medical attention  before infarction is compl ete. The ra pid progression  of irreversible  brain 
injury in most  acute  strokes implie s a short window  of clinical  efficacy of any treatment, 
including nerinetide.  The ability to identify patients with salvageable b rain using the criteria used 
in the ESCAPE trial2 provide d an oppor tunity to target patients who m ay have the great est 
benefit from  neuroprotection, and to enhance further the impact of reperfusion therapi [INVESTIGATOR_014]3. This 
led to the ESCAPE -NA-1 trial which used inclusion/exclusion criteria substantially similar to 
those of ESCAPE in order to select potential responders to neuroprotection by [CONTACT_479424]. Results 
obtained from the ESCAPE -NA1 trial4 suggested that nerinetide may be effective in enhancing 
functional independence, reducing mortality, and reducing infarct volumes in participants with 
AIS who were selected for EVT provided that they had not received alteplase, a thrombolytic agent indicat ed in some stroke patients.  O ur preclinic al and clinical  data suppor t this notion.  
The rationale for the present stu dy is as follows : 
1) The ESCAPE- NA1 trial (protocol NA -1-007) provided promising evidence that, in 
participants with AIS who were selected for EVT and who did not receive the thrombolytic alteplase, treatment with nerinetide increases functional independence and reduced stroke mortality
4. This was supported by a reduction in infarction volume as mea sured by [CONTACT_479493]. Since these improvements were observed in three separate domains of outcome (functional independence, mortality, and infarction volumes), they are unlikely to be due to chance alone. The present study is intended to explore the se findings further.  
2) Participants in ESCAPE -NA1 who did receive alteplase as part of their care did not benefit 
from subsequently being administered nerinetide. This was likely due to the degradation of nerinetide by [CONTACT_479494] g plasmin, the product of pr ior alteplase administration. This 
hypothesis was supported by [CONTACT_479436] a subset of participants in the trial 
that showed that those who received alteplase had reduced plasma levels of nerinetide (approximately 60% reduction) as compared t o participants who did not receive alteplase. 
The magnitude of this reduction or its clinical impact could not have been anticipated from prior studies in animals.  
3) Nerinetide does not have thrombolytic or thrombotic properties of its own
[ADDRESS_615628] shown that 
plasmin, which has similar substrate specificity to trypsin, cleaves nerinetide into several 
fragments beginning at its N -terminus
5. It is similarly cleaved when it is combined in 
plasma with alteplase or tenecteplase, which convert plasminogen in pla sma into plasmin5. 
Version: 2.0 
Date:  [ADDRESS_615629] shown that co -administration of nerinetide with high-
dose alteplase (6x the human dose) can nullify the neuroprotective effectiveness of 
nerinetide in a rat model of embolic middle cerebral artery occlusion (eMCAO). However, 
due to its short half -life it can be administered in preclinical studies before alteplase and 
this restores its efficacy in eMCAO, and may be synergistic with alteplase5. The drug- drug 
interaction b etween nerinetide and alteplase has led to the exclusion of  participants who 
are candidates for alteplase in the ESCAPE -NEXT trial.  
4) Based on data from preclinical studies, the Phase 1 (protocol NA -1-001) safety study, the 
Phase [ADDRESS_615630] trial6 (protocol NA -1-002) and the Phase 3 ESCAPE -NA1 study4 
(protocol NA -1-007), nerinetide is expected to be have an acceptable safety profile.  
5) There is a comp elling need to develop neuroprotectants in order to increase the proportion 
of patients who may benefit from EVT. These agents could improve the outcomes of patients  and render more patients with AIS into candidates for endovascular or 
pharmacological recanalization treatment.  
6) The current study is intended to confirm the findings in the ESCAPE -NA1 trial that 
nerinetide may improve functional independence, reduce mortality, and reduce infarction volumes in participants with AIS who are selected for EVT and who are not treated with thrombolytics.  
1.2 Trial  Objectives  
1.2.1 Primary Objective  
The primary objective is to determine the efficacy of the neuroprotectant, nerinetide, in reducing global disability in subjects with major acute ischemic stroke (AIS).  
1.2.2 Seconda ry Objectives  
The secondary objectives are to determine the efficacy of nerinetide in:  
1) Reducing mortality rate  
2) Reducing worsening of stroke* 
3) Reducing functional dependence  
4) Improving neurological outcome  
* Worsening of stroke is defined as (A) progression, or hemorrhagic transformation, of the index stroke as documented by [CONTACT_479413] (a) life -threatening requiring intervention 
and/or (b) results in increased disability as gauged by a ≥[ADDRESS_615631] NIHSS during hospi[INVESTIGATOR_5478]/or ( B) results in death  from the index stroke .  
1.2.3 Tertiary Objectives  
The tertiary objectives are to determine the efficacy of nerinetide in:  
• Decreasing infarct volume  
• Improving activities of daily living  
• Reducing dependency or death  
• Improving excellent functional outcome. Improving health related quality of life  
Version: 2.0 
Date:  [ADDRESS_615632] of administering a dose of 2.6 mg/kg (up to a 
maximum dose of 270 mg) intravenous infusion of nerinetide to participant with acute stroke on SAEs and 90- day mortality . 
1.2.5  1- Year Follow Up Analytic Sub -Trial Objectives  
There will be a 1- Year follow -up analytic sub- trial to support the outcomes obtained at Da y 90.  
The primary objective is to determine the efficacy of the neuroprotectant, nerinetide in:  
• Reducing global disability in participants with acute ischemic stroke (AIS).  
The secondary objectives are to determine the efficacy of nerinetide in:  
• Reducing mortality rate  
• Improving activities of daily living  
• Improving health related quality of life  
 
Table 1: Objectives and Endpoints  
Objectives  Endpoints * 
Primary  
Reducing global disability in subjects 
with acute ischemic stroke (AIS).  The primary outcome is the proportion of participants 
with independent functioning on the modified Rankin Scale (mRS), as defined by a score of [ADDRESS_615633] randomization.  These participants are defined to be responders .
 
Secondary  
Reducing mortality rate.  A reduction in mortality rate, as defined by [CONTACT_479412] 
(proportion, expressed as a percentage) for mortality over the 90- day study period. 
Reducing worsening of stroke* *. Proportion of participants with worsening of stroke 
over the 90- day study period.  
Reducing functional dependence.  A shift of one or more categories to reduced 
functional dependence analyzed across the whole distribution of outcomes on the mRS at Day [ADDRESS_615634] randomization. 
Tertiary/Exploratory  
Decreasing infarct volume.  Volume of stroke as measured by [CONTACT_479495] (MRI preferred).  
Improving activities of daily living.  Proportion of participants with functional 
independence in activities of daily living, as defined 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  10 by a score of ≥ 95 on the Barthel Index (BI) at Day 
[ADDRESS_615635] randomization  
Improvi ng health related quality of life.  Health -related quality of life, as measured by [CONTACT_20367] -
5D-5L at Day 90.  
Safety  
To determine the safety based on 
serious adverse events (SAEs).  Proportion of subjects with serious adverse events to 
Day 90.  
90-day mortality.  Proportion of subjects alive at 90 -day. 
1 Year Follow Up  
Primary  
Reducing global disability in 
participants with acute ischemic stroke 
(AIS).  The proportion of participants with independent 
functioning on the modified Rankin Scale (mRS), as 
defined by a score of 0- 2 at 1 -year.  
Secondary  
Reducing mortality rate  A reduction in mortality rate, as defined by [CONTACT_479412] 
(%) for mortality over the 1 -year study period.  
Improving activities of daily living  The proportion of participants with independent 
function on activities of daily living defined on the 
modified Barthel Index (BI) with a score of ≥ 95 at 1-
year.  
Improving health related quality of life.  Health -related quality of life, as measured by [CONTACT_20367] -
5D-5L at 1 year.  
* Imputation for missing data up to Day 90 and for the 1 -year follow up will be conducted as per 
Section 4.3 of this SAP .   
**Worsening of stroke is defined as (A) progression, or hemorrhagic transformation, of the index 
stroke as documented by [CONTACT_479413] (a) life -threatening requiring intervention and/or 
(b) results in increased disability as gauged by a ≥[ADDRESS_615636] NIHSS during 
hospi[INVESTIGATOR_139074]/or ( B) results in death  from the ind ex stroke.  
 
  
Version: 2.0 
Date:  [ADDRESS_615637] the life of the person 
concerned, restore good health or alleviate suffering. 
Participants harboring an acute ischemic stroke who are selected for endovascu lar 
revascularization without intravenous or intra -arterial thrombolytic therapy will be given a 
single, 2.6 mg/kg (up to a maximum dose of 270 mg) intravenous dose of nerinetide or placebo. 
Randomization will be stratified by [CONTACT_479496] ≤ 4.5 hours (yes/no) 
and done with stochastic minimization to balance baseline factors within strata. The end of the main trial is defined as the date that the last enrolled participant has completed their Day 90 visit/contact. For the purpose of an analytic follow -up sub- trial component, participants will be 
contact[CONTACT_479431] [ADDRESS_615638]. All subjects 
will be followed for 90 days (or until death if prior to 90 days).  Subjects who are randomized but do not receive study drug will still be followed through the 90- day study period. The end of 
the pi[INVESTIGATOR_479385] 90 visit.  
At Day 30 and Day 90 it is preferred that participants will return to clinic .  If an in -clinic visit is 
not possible the participant can be contact[CONTACT_479417] (preferred) or by [CONTACT_756] (last option).  
Participants will be followed at [ADDRESS_615639] -
randomization, defined as a score of 0 to 2 on the modified Rankin Scale (mRS). These participants are defined to be responders.  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  12 An initial target 680, and up to 1020, male and female participants aged 18 or older harboring 
AIS and who ar e selected for endovascular revascularization without intravenous or intra -arterial 
thrombolytic therapy will be enrolled.  
Based on results of ESCAPE -NA1 and assuming a 50% overall responder rate for the placebo 
group, there will be approximately 82% power  to detect an 11.4% absolute effect difference 
between response rate (proportion of responders, with Day 90 mRS in the range 0 to 2) with nerinetide and placebo, at alpha level 0.05 2- sided.  
This sample size was calculated via simulation under the assumption of 2% probability of dropout and 50 patients per month accrual during the trial (across both arms) using the Chen-DeMets -Lan  approach
7 for unblinded sample size re -estimation, and possible early stoppi[INVESTIGATOR_479386] O’Brien- Fleming alpha spending boundary at a single interim 
analysis with a maximum sample size of 1020 evaluable (inflation factor 1.5) and inflation in the “promising zone” based on conditional power between 50% and 81%, based on the observed trend at the interim and using a Wald statistic with target conditional power after sample size increase 81% (using an increase rule to be specified in the IDMC  Charter to prevent back-
calculation of interim effect sizes after the interim analysis). The interim analysis is planned to take place at 75% information (primary endpoint), i.e. when approximately [ADDRESS_615640] approximately 82% power for the primary analysis using standard Wald statistic for comparison of 2 independent proportions (EaST v6.5 2020). The cumulative alpha spent at the inte rim analysis is 0.01 and final analysis 0.025, 1- sided; the stoppi[INVESTIGATOR_479387] Z scale are 2.34 (interim) and 2.012 (final) and on the p- value scale 0.01 (interim) and 0.022 
(final), all on the assumption that the interim is conducted at 75% inform ation (EaST v6.5, 
2020). 
See Section  8 for further details on the interim analysis.  
1.5 Randomization  
Treatments (placebo vs. nerinetide) will be assigned 1:1 by [CONTACT_38658] a minimization 
algorithm administered through a secure web- based, real -time interaction with the site and the 
central server. The time of randomization on the central server will be considered baseline (i.e., time zero) for the study. Study drug is intended to be infused as soon as possible after qualifying 
imaging and randomization. Although each vial of nerinetide or placebo will have a unique 
identification number that will be linked to the randomization code generated by [CONTACT_479497], the vials will appear to be identical to those dispensing them and to the 
subjects. Thus, individuals at the sites will be blinded to the treatment assignments.  
In order to balance the treatment assignment among subjects enrolled at various times from stroke onset, t reatment  will be assigned using 1:1 randomization ( nerinetide:placebo) with a 
stratification based on time from stroke onset to randomization of less than or equal to 4.5 hours 
(yes/no) and a randomized minimization algorithm to minimize the contribution of imbalances in 
baseline factors (age, sex, baselin e NIHSS score, baseline ASPECT score, occlusion location, 
time from qualifying imaging to randomization, and site). The time of 4.5 hours was selected as it approximates the median time to randomization from the ESCAPE -NA1 trial.  
There will be 2 randomiza tion strata: 
• Comprising subjects enrolled at a time of less than or equal to 4.5 hours from stroke 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  13 symptom onset . 
• Comprising subjects enrolled at a time greater than 4.[ADDRESS_615641] -level prognostic 
variables: age, sex, baseline NIHSS scores, baseline ASPECT score, occlusion location, time 
from qualifying imaging to randomization and study site. At the time of randomization, subject age will be calculated using the central server date and time. This overall approach will ensure that the subjects entered into the trial will be matched on the seven key prognostic covariates, 
within strata and between treatment arms, thereby [CONTACT_479498]. In addition to ensuring 
a balanced analysis at the conclusion of the study, the minimization will also provide some assurance that adequate balance will be maintained at the time of interim analysis.  
The randomization of the first [ADDRESS_615642] having an equal probability of assignment to either treatment arm. Thereafter, randomization will be stratified as described 
above, with the minimization algorithm applied to achieve balance simultaneously across the covariates.  
All subjects who are randomized will be accounted for in the trial database and followed rigorously for the primary and key secondary outcomes to minimize issues of imputation/missing data. The randomization number and time will be automatically generated from the randomization website and will be transmitted to the  central trial database to create the case in 
the electronic case report form.  The randomization date, time, the stratification variable, and the [ADDRESS_615643] 
within one business day and as per the local participating site’s working practice.  
All subjects, investigators, their clinical staff, the clinical coordinating center, the data 
management group, and the sponsor staff and delegates will be blinded to the randomization 
codes. The local laboratories will also be blinded.  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  14 Table 2: Schedule of Activities - Main Trial  
Visit/Contact  V1 V2 V3 V4 V5 V6 
Day Day [ADDRESS_615644]-EVT  Day 2/3  Day 61 or 
discharge  Day 302 Day 902 
Window   (~2 h)  (18-56 h)   (±5 d)  (-21 to +7d)  
Informed consent  X      
Regained capacity informed consent3   X X X X 
History and physical examination  X      
Weight4 X      
Vital Signs (BP, HR, Temperature) 5 X X X    
Randomization/  
Study drug administration  X      
Mortality   X X X X X 
NIHSS  X X X X X X 
mRS6 X   X X X 
Barthel Index  X    X X 
EQ-5D-5L      X 
Qualifying Imaging  X      
Endovascular Procedure  X      
MRI/NCCT head7   X    
Laboratory Assessments  X8  X    
Pregnancy test9 X      
Pharmacokinetic samples10 X      
AE  Collected to Day 30   
SAE  Collected to Day 90  
Prior medications  X      
Concomitant medications  Collected to Day 6 or discharge   
1. Visit will occur at Day 6 or hospi[INVESTIGATOR_479349] 6.  
2. At Day 30 and Day 90 it is preferred that participants will return to clinic.  If a in clinic visit is not possible the participant 
can be contact[CONTACT_479417] (preferred) or by [CONTACT_756] (last option).  
3. If the original process involved anyone other than the participant  (and if required), site staff will make ongoing eff orts until: 
(1) regained capacity consent is obtained from participant, (2) death, or (3) completion of the Day 90 assessment.  
4. At baseline estimated or actual weight will be collected. If an estimated weight was collected at baseline, actual weight sho uld 
be collected as soon as feasible and prior to discharge.  
5. Vital signs (BP, HR only) will be recorded immediately before and after completion of the study drug infusion, temperature 
will be collected at baseline only if standard of care.  
6. Historical (pre -stroke) mRS score can be collected at any time.  
7. MRI head may be supplanted by [CONTACT_479421].   
8. Blood should be drawn at baseline, but results are not required prior to randomization. Results from primary hospi[INVESTIGATOR_307] (within 8 
hours) are accepted.  
9. If the participant is female and is of childbearing potential a pregnancy test (urine or serum point -of-care pregnancy test) must 
be completed and the result must be negative; this is the only mandatory laboratory test prior to randomization.  
10. PK samples will be collected from up to 100 participants: pre -dose and at 10, 20, 30 and 60 min after the start of study drug 
administration.  
d = days; h = hours  
 
 
Table 3: Schedule of Activities: One -Year Follow Up Telemedicine or Telephone [CONTACT_112684]  
[CONTACT_112684]  V7- One-Year Follow up  
Day (Window)  Day 365  (±30 d)  
Mortality , EQ-5D-5L, mRS, Barthel Index  X 
 
1.6 Blinding of Main Study  
The study is conducted in a blinded manner. All subjects, investigators, their clinical staff, the 
clinical coordinating center, the data management group, and the sponsor staff and delegates will 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  15 be blinded to the randomization codes. The local laboratories will also be blinded.  
The IDMC reports and analyses for Closed Sessions will be organized by [CONTACT_2939] 
(“unblinded”). In order to ensure confidentiality and minimize bias, the information will be provided to the IDMC by [CONTACT_479499] a group that is independent of the sponsor and the blinded project team implementing the trial. A firewall w ill be maintained 
between the IDMC and statistician (unblinded) and the project staff (blinded).  The IDMC will review safety data and other data as requested by [CONTACT_31849], in addition to the interim analysis results.  
The person responsible for the study dr ug labelling will be unblinded, as will the independent 
statistical group preparing the reports for the IDMC. The person responsible for the data management group, who manages the programming of the randomization system will be unblinded. This individual w ill be the contact [CONTACT_479500]. This individual 
will not participate in data management and will only communicate unblinded data as set out below when contact[CONTACT_479501]. 
Otherwise, randomization data will be kept strictly confidential, accessible only to authorized 
persons, until the time of unblinding after data lock at the time of interim analysis and at end of the study. 
In case of emergency, a rapid unblinding procedure is available to investigators.  If the 
investigator decides that the treatment code needs to be broken in the interest of subject safety, 
the investigator will have direct access to the study data management center to request unblinding of the specific subject. The data management center will res pond in writing to the 
investigator only with the unblinded patient treatment allocation.  
Only the investigator requesting the unblinding will receive the unblinding information. The 
investigator will promptly inform the Sponsor when a request to unblind is made and the 
circumstances involved.  Any case that is unblinded in this way will be documented in a blinded manner in central study files. 
1.[ADDRESS_615645] 
become unblinded to treatment allocation. Specifically, such study staff will be firewalled from 
the Sponsor, the IDMC, t he unblinded statistician, and the coordinating investigators.  
1.8 Definitions  
Baseline: A subject’s baseline value for a given endpoint or parameter is defined as his/her latest measurement taken prior to study drug administration. 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  16 Prior and Concomitant Medi cations:  Prior medications are defined as those taken within 24 
hours prior to randomization. Concomitant medications are defined as those taken during study 
drug administration or after study drug has been administered through to Day 6 (or discharge). All prior and all concomitant medications will be recorded on the electronic case report form.  
Randomization: The time of randomization is defined as the time randomization occurred on the central server and this time is considered time zero for the study. A ll time windows are 
calculated from the time of randomization.  
Study Day : Day 1 is the date of randomization. As the study drug is intended to be administered 
as soon as possible after randomization (i.e., 15 minutes), this will also be the day of treatment initiation date. Study day is calculated relative to Day 1.  
Treatment -Emergent Adverse Event: All AEs will be collected from the start of study drug 
administration until Day 30. All SAEs will be collected from the start of study drug 
administration until Day 90. A treatment -emergent adverse event (TEAE) is one that first occurs 
or worsens in severity or frequency after study drug administration has begun through to and 
including the Day 30.  SAEs are collected through the last study visit. Those AEs that start at the same time and date as the study drug administration and those that first occur or worsen after the start of study drug administration will be considered TEAEs.  
AEs with partial or missing dates will be handled as follows: 
• If the start day and/ or month of the AE is missing the AE will be considered treatment-
emergent.  
• If the start date is completely missing then the AE will be considered treatment- emergent.  
  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  17 
 ANALYSIS POPULATIONS  
This study is designed to address a population of adults 18 years and older harboring an acute 
ischemic stroke who are selected for endovascular revascularization without intravenous or intra -
arterial thrombolytic therapy who will receive a single, 2.6 mg/kg (up to a maximum dose of 270 
mg) intravenous dose of nerinetide or placebo.  
2.1 This is a global trial being  conducted under the same protocol  at clinical sites  in 
different countries  in accordance with the national legislation of the country in which 
the trial is carried out . Following the completion of the study and provided that the 
requirements of 21CFR 312.120 are met , data from all study  sites will be pooled for 
the purpose of analyses in th is statistical analysis plan .Intent -to-Treat (ITT) 
Population  
The primary efficacy analysis will be conducted on the ITT population, defined as all subjects randomized into the trial with groupi[INVESTIGATOR_479388], regardless of treatm ent 
actually received. Deceased subjects will be included in the ITT population with a mRS score of 6, NIHSS of 42 and Barthel Index of 0. An ITT analysis will also be conducted for the secondary endpoints, with subjects grouped according to the randomized (intended) treatment.  
2.2 Safety Population  
The safety population comprises all subjects receiving any amount of study drug. In safety analyses, subjects will be grouped according to treatment actually received.  
2.3 Per Protocol (PP) Population  
The primary analy sis will be repeated on the Per Protocol (PP) population, defined to be all 
subjects randomized and treated, with no major protocol deviations. We define “major protocol 
deviations” as those with the potential to bias, confound, or otherwise obscure the tr eatment 
effect estimates or which involve ethical standards. This population will be determined via a blinded review of protocol deviations at the end of the trial before database lock and unblinding. 
Missing data due to death during the study will not exc lude a patient from the PP population (i.e. 
death is not considered a major protocol violation). Prior to unblinding, the imaging from each subject at the time of inclusion will be adjudicated to 
determine whether they have met the criteria for endovascular intervention and the imaging inclusion criteria, and hence for the trial.  This will include review of baseline NCCT, CTA and if performed CTP or MRP. Subjects who do not meet the imaging criteria outlined in the trial inclusion/exclusion criteria will b e reviewed in a blinded fashion as described above to 
determine if they met the criteria . 
Participants will be excluded from the per -protocol analysis for the following violations :  
• did not meet inclusion/exclusion criteria,  
• did not receive planned dose volume,  
• incorrect study drug vial,  
• infusion more than 15 minutes,  
• consent not obtained (including incorrect Deferral of Consent where applicable).  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  18 
 STUDY ASSESSMENTS AND DATA COLLECTION 
Study procedures and their timing are summarized in the Table 2: Schedule of Activities .   
3.1 The Modified Rankin Scale  
The primary endpoint used in this trial will be global disability, as measured by [CONTACT_352802], at Day 
90. The mRS is a valid and reliable clinician -reported measure of global disability that has been 
widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke
9,10. mRS scores range from 0 to 6, with 0 indicating no r esidual symptoms; 5 indicating 
bedbound, requiring constant care; and [ADDRESS_615646] dose mRS will be obtained at Day 6 (or discharge), Day 30 and Day 90 and at the One -
Year follow up.  Premorbid mRS status may be obtained at any time, but i deally at the Day 1 or 
2 visit.  The mRS will only be scored by [CONTACT_479454] (via www.healthcarepoint.com) in the use of this scale.  An Electronic Clinical Outcome Assessment (eCOA) tool may be used to conduct this assessment. 
3.2 Mortality  
Mortality status will be obtained at all visits during the 90 -day study period and at the One -Year 
follow up. Specifically, it will be assessed at Day 6 or discharge and at Days 30 and 90. Mortality 
rate is  defined as the number of deaths observed divided by [CONTACT_479502] 90- day study period between nerinetide and placebo control subjects . 
3.3 Worsening of Stroke  
Worsening of stroke is defined as (A) progression, or hemorrhagic transformation, of the index 
stroke as documented by [CONTACT_479413] (a) life -threatening requiring intervention 
and/or (b) results in increased disability as gauged by a ≥[ADDRESS_615647] NIHSS during hospi[INVESTIGATOR_5478]/or ( B) results in death  from the index stroke .  
3.[ADDRESS_615648]- EVT (2 Hours), Day 2, Day 6 (or discharge), Day 
[ADDRESS_615649] this assessment. The NIHSS scores will be dichotomized into 0-2 (indicating a good neurological outcome) versus >2 (indicating otherwise).  
3.5 Volume of Stroke  
All subjects will undergo a follow -up brain MRI [including a minimum of axial DWI, gradient -
echo (GRE), FLAIR] at Day 2 (18 to 56 hours from the time of randomization) .  The Day [ADDRESS_615650] of care imaging procedure; if MR is unavailable, then NCCT is allowed. The D ay 2 MR (and where MR is unavailable, CT) will be used to assess infarct volume. Infarct 
volume determinations will be conducted before database lock.  
Version: 2.0 
Date:  [ADDRESS_615651] 
brain images (MRI preferred) in nerinetide versus placebo control participants will be calculated 
from the Day 2/[ADDRESS_615652] volumes will be determined from the Day 2/[ADDRESS_615653] and MRI data will be detailed in the Imaging 
Adjudication Charter.   
3.6 Barthel Index  
The BI is an index of functional independence
12 that is a valid measure of activities of daily 
living when employed in stroke trials13.  Modified BI scores range from 0 to 100, with higher 
scores indicating greater independence in activities of daily living and mobility. The BI will be scored at Baseline (pre- morbid), Day [ADDRESS_615654] this assessment. 
3.7 EQ-5D-5L 
The EQ -5D-5L is a generic instrument for describing and valuing health. It is based on a 
descriptive system that defines health in terms of five dimensions: Mobility, Self -Care, Usual 
Activities, Pain/Discomfort, and A nxiety/Depression
14. Each dimension has five response 
categories corresponding to: no pr oblems, slight, moderate, severe and extreme problems15. The 
version of the instrument selected for the trial is interviewer administered either in -person, or by 
[CONTACT_479456]. The respondents will also rate their overall health on the day of the 
interview on a 0–100 visual analogue scale (EQ -VAS). The EQ- 5D-5L will be administered at 
the Day [ADDRESS_615655] this assessment. 
  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  20 
 MISSING DATA AND DATA TRANS FORMATION 
4.1 Statistical Methods  
The software used for all summary statistical analyses will be SAS® (SAS Institute,  Inc.) version 
9.[ADDRESS_615656]. Unless otherwise noted, continuous data will be summarized for each 
treatment group using the number of observations (n), mean, standard deviation (SD), media n, 
minimum, and maximum. Some continuous data will be reported as the median, interquartile 
range (IQR), minimum and maximum according to the clinical meaning of the data.  
Percentages will be rounded to one decimal place, except 0% and 100% will be displayed 
without any decimal places. Minima and maxima will be rounded to the precision of the original 
value; means and medians will be rounded to one decimal place greater than the precision of the 
original value; standard deviations  will be rounded to two dec imal places greater than the 
precision of the original value. P -values will be reported to four decimal places (0.xxxx), with 
values less than 0.0001 presented as <0.0001.  
Inferential analyses will generally include statistics such as 2 -sided 95% confidence intervals 
(CI), and p -values.  
The overall significance level for in this trial will be at two -sided 0.05. The type I error and the 
efficacy boundary for the final analysis will be adjusted accordingly based on the actual alpha 
spent at the inter im analysis (details in Section 8 ).  
In order to protect the overall trial false positive rate, the primary efficacy analysis and secondary 
outcome analyses will be analyzed in a fixed sequence, stoppi[INVESTIGATOR_479389] (and accepting the null hypothesis) at the first failed hypothesis test in the 
sequence. The fixed sequential order is:  
1) Primary estimand  
2) Secondary estimands , as specified in the order presented in Section 4.2. 
4.[ADDRESS_615657]. Therefore, the primary and secondary estimands will be focusing on the 
composite strategy. More specifically, death will be incorporated as part of the primary and 
secondary estimands as described below  and in Section 4.3. 
The primary estimand will be the difference in the mRS response ( i.e., mRS  score of 0 -2) 
proportions between treatment conditions  (nerinetide vs. placebo)  in the target patient population 
at Day 90 . Deaths occurr ing over the Day 90 period  will be considered  as non- response .   
The secondary estimand s are defined below:   
• The diffe rence in mortality rate over the 90 -day period between treatment conditions in the 
target patient population.  
• The difference in worsening of stroke proportions between treatment conditions in the 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  21 target patient population over the 90- day period. Death meets the definition of worsening 
of stroke.  
• The dif ference in showing a shift in mRS categorie s between treatment conditions in the 
target patient population at Day  90. D eath occurr ing prior to Day [ADDRESS_615658] mRS score (score of 6).  
• The difference in NIHSS response (i.e., score of 0- 2) proportions between treatment 
conditions in the target patient population at Day 90. Death occurring prior to Day 90 will 
be considered as non- response. 
4.3 Missing Data  
Every effort will be made to keep missing data, particularly the Day 90 outcome asse ssments, to 
a minimum.  However, some missing data may be inevitable due to, for example, loss to follow -
up.  
All imputed values will be determined prior to database lock and conducting primary analyses 
via the rules documented prospectively in this Statis tical Analysis Plan for the study.  
To incorporate death as part of the estimand definition  following the composite strategy, 
deceased participant will be assigned a score 6 on the mRS, 42 on the NIHSS and 0 on Barthel Index and be counted as non- responder s. In addition, deceased participants are considered as 
experiencing worsening of stroke. Thus, there will be no missing mRS, NIHSS , BI or worsening 
of stroke  data due to death.    
No imputation is planned for safety data. Efficacy outcomes will be imputed using a data -
informed imputation as follows:  
4.3.1 Imputation of Mortality and Worsening of Stroke  
For the analysis of rate of mortality, for participants for whom the mortality status is not known at Day 90:  
• if they were alive at Day 30, then the subject will be imputed as alive at Day 90   
• if both the Day 30 and Day 90 mortality is status is missing, the participant will be imputed 
as Dead at Day 90.  
Worsening of stroke data will be imputed similarly :  
• if it’s unknown whether the subject  experienced worsening of stroke by [CONTACT_2006] [ADDRESS_615659] will be imputed as not experiencing worsening of stroke at Day 90.  
• if both worsening of  stroke status is unknown at both Day [ADDRESS_615660] will 
be imputed as experiencing worsening of stroke at Day 90.  
No imputation will be done on the missing one -year follow -up mor tality  data.  
4.3.2 Imputation of mRS Score  
Deceased subjects will be assigned scores of 6 on the mRS.  
Single  Imputation (SI): To follow the composite strategy, the following approach will be used 
to impute missing mRS data at Day 90 : 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  22 • if the participant is known to be dead at Day 90, they will be considered to be a non-
responder and the mRS will be imputed as 6 
• if the mRS was obtained at the Day 30 assessment or later  and the participant is documented 
to be alive or the mortality status is unknown at Day 90, the Day 30 (or later) assessment  
will be carried forward as the Day 90 mRS value  
• if both the Day 30 and Day 90 mRS scores are missing but the participant is documented 
to be alive at Day 90 they will be considered to be a non- responder and the mRS will be 
imputed as a 5  
• if both the Day 30 and Day 90 mRS scores are missing and the mortality status of the participant is unknown at Day 90 they will be considered to be a non -responder and the 
mRS will be imputed as a 6.  
If more than 5% subject s randomized are missing the mRS score at Day 90 , additional 
imputation methods will be employed as follow s: 
Multiple I mputation  (MI) : The multiple imputation method assumes a Missing -At-Random 
(MAR) mechanism, which is a reasonable assumption for missingness not due to death. For the MI model, 50 imputa tions will be generated using PROC MI of SAS
®. Imputation will be 
performed using the Fully Conditional Specification (FCS) logistic regression model . For each of 
the 50 datasets, missing mRS responders status (yes or no) will be imputed using a logistic regression model including treatment group, the mRS responder status at prior post -
randomization visits, baseline mRS score, randomization stratification factor (time from stroke 
onset to randomization≤4.5 hours (yes /no)), age, sex, baseline NIHSS score, ba seline ASPECT 
score, occlusion location, time from qualifying imaging to randomization. The seed to be used in 
all MI model is 20201009. The choice of 50 imputations is generally considered sufficient to 
provide accurate and stable imputed results given the amount of missingness expected in this trial
21. 
Analysis of t he primary outcome will then be performed for each of the relevant MI datasets. 
The results of the 50 analyses will be transformed into a normal statistic and combined into a single analysis using PR OC MIANALYZE.  Details see Section 6.1.3. 
Example SAS code  for PROC MI  is as follows:  
PROC MI DATA=ADMRS1 OUT=ADMRS2 SEED=20201009 NIMPUTE=50 NOPRINT; 
CLASS TRTP RANDTIME SEX BNIHSS BASPECT OCCLOC BASEMRS MRS2 
MRS4 MRS5 MRS6; 
FCS LOGISTIC(MRS4 = TRTP AGE RANDTIME SEX BASPECT OCCLOC 
BASEMRS / DETAILS); 
FCS LOGISTIC(MRS5 = TRTP AGE RANDTIME SEX BASPECT OCCLOC 
BASEMRS MRS4 / DETAILS); 
FCS LOGISTIC(MRS6 = TRTP AGE RANDTIME SEX BASPECT OCCLOC 
BASEMRS MRS4 MRS5 / DETAILS); 
VAR TRTP AGE SEX BNIHSS BASPECT OCCLOC RANDTIME IMA_TIME 
BASEMRS MRS2 MRS4 MRS5 MRS6; 
RUN; 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  23 In above code, TRTP represents the randomized treatment group,  BASEMRS = Baseline mRS 
score, MRS4 – MRS 6 represents the binary mRS responder status  at Day 6/discharge (Visit 4) , 
Day 30 (Visit 5) , Day 90 (Visit 6)  respectively, BNIHSS = Baseline NIHSS score, BASPECT is 
the baseline ASPECT score (5 -7 or 8 -10), OCCLOC is the baseline occlusion location, 
RANDTIME is the time from stroke onset to randomization ≤ 4.5 hours (yes/no), IMA_TIME is the time from qualifying imaging to randomization. 
The imputatio n models may be modified based on the actual data if there is an issue in model 
convergence.  
Tippi[INVESTIGATOR_47863] : Tippi[INVESTIGATOR_479390] (MNAR) 
assumption will be performed as sensitivity analysis to assess the assumptions about the missing 
primary endpoint data. The tippi[INVESTIGATOR_479391] a specified sequence of shift parameters that modify the imputed log odds  of mRS response  to non- response  in the nerinetide 
group, as follows:  
1. Missing mRS responder status will be imputed [ADDRESS_615661]  with missing response status is more likely to be a non- responder; a positive  
adjustment assumes the subject with missing response status is more likely to be a responder. The MNAR statement with the ADJUST option in PROC MI will be used to apply the shif t parameter.  
2. Each of the 50 completed datasets applying the shift parameters will be analyzed using the primary analysis method as described in Section 6.1.3. 
3. The results from the 50 completed datasets will be combined for inference using PROC MIANALYZE.  
4. Repeat steps 1 -3, with adjustment by a different shift parameter to the imputed log odds 
in the nerinetide group, as following: S1 = 0 (no shift), - 0.2, - 0.4, - 0.6, - 0.8, - 1.0, - 1.2, -
1.4, - 1.6, - 1.8, and - 2.0. 
The shift parameters that result in a reversed study conclusion (i.e. from statistically significant 
to non- significant) will be flagged. Alternate series of shift parameters may be applied based on 
the actual data.  
The missing mRS data at one -year follow -up will be handled according to below : 
• If subjects are known to be dead before or at one -year follow -up visit, mRS will be assigned 
a score of 6 and counted as non- responders.  
• Other missing data not due to death will be imputed by [CONTACT_479503].  
4.3.3 Imputation of NIHSS and BI data  
No missing NIHSS or BI data due to death. Deceased participants will be assigned scores 42 on 
the NIHSS and 0 on the Barthel Index (BI) and be counted as non -responders.  
Missing NIHSS or BI data at Day [ADDRESS_615662] 
(LOCF) imputation as follows: 
LOCF:  Participants who are missing NIHSS or BI endpoint data at Day [ADDRESS_615663] 
Version: 2.0 
Date:  [ADDRESS_615664], provided that this score was obtained at the D ay 30 visit or later. 
Otherw ise, the missing NIHSS or BI will be imputed to the median score obtained at D ay 90 in 
the trial.  
For missing BI data at one -year follow -up visit:  
• If the subjects are known to be dead before or at one -year follow -up visit, BI will be 
assigned a score of 0.  
• Other m issing  BI data not due to death will be imputed to the median score obtained at one -
year follow -up in the trial.  
4.4 Data Transformation  
No transformation of the data is planned other than for volume of stroke. Note that stroke 
volume data are often d ispersed and highly non- normal and may be normalized with a cubic root 
transformation. No data transformation is planned for the primary analysis.  
4.5 Pooling of Sites  
In order to avoid sparse sites (sites with fewer than 10 randomized subjects) and the potent ial for 
too many levels for the explanatory variable of “site”, sites within a geographic region ( North 
America/Europe/Rest of World) with fewer than [ADDRESS_615665] remaining unpooled site (s) from 
that geographic region. If the resulting pooled site still has fewer than [ADDRESS_615666] pooled site from another geographic region. The process of pooling sites will be reviewed and finalized before the unblinding of the main trial for the  Day 
90 analysis (i.e. first database lock as described in Section 1.3) .  
If more than one batch of nerinetide is used in the clinical trial, data from all subjects from all sites in the trial, regardless of the nerinetide batch  administered, will be pooled for the purpose of 
analyses in this statistical analysis plan . Data from d ifferent batches will be pooled following the 
demonstration of equivalent quality of the clinical trial material based on the established release and stability testing of the nerinetide drug product batches used in the trial.  
4.6 Pooling of Data from the Two Time -to-Randomization Strata  
Since the randomization will be stratified by [CONTACT_479410] ≤4.5 hours (yes/no), the assess ment  for treatment -by-stratification variable interaction to examine for effect 
modification  will be performed via a log -binomial generalized linear model as described in 
Section 6.1.3. In addition, homogeneity of the randomization stratification factor will be tested via Breslow -Day statistic
22. If there is no evidence for effect modification, then we will report 
the data for the entire cohort only.  If there is evidence for effect modificati on, the  effect size for 
the primary, secondary and tertiary outcomes will be additionally reported by [CONTACT_64264]. 
  
Version: 2.0 
Date:  [ADDRESS_615667] disposition will be summarized and tabulated for ITT, PP and Safety populations. The 
summaries will include the number and percentage of subjects that completed the study and 
those that terminated early from the study (i.e., left the study prior to the Day 90 visit).  Early terminations will be categorized by [CONTACT_479504].  Death will not be 
considered early termination.  A  tabulation of the number and percentage of subjects randomized 
will be summarized by [CONTACT_479505]. 
Disposition will be  listed by [CONTACT_400420].  
5.2 Protocol Violations  
Protocol violations used to exclude subjects from the per -protocol analysis will be derived from 
the data collected in the case report form . Protocol violations will be determined during a data 
review meeting prior to database lock. Participants will be excluded from the per -protocol 
analysis for the following violations:  
• Enrollment did not comply with inclusion/exclusion criteria  
• Subjects who did not receive a per -protocol dose including: did not r eceive planned dose 
volume, received an incorrect study drug vial, or received the study drug infusion over 
more than 15 minutes. 
• Consent not obtained (including incorrect Deferral of Consent where applicable).  
The number and percentage of subjects in the ITT population with protocol violations will be 
summarized by [CONTACT_6654].  These p rotocol violations will be listed by 
[CONTACT_400420].  
5.3 Treatments  
Per protocol, an int ravenous  solution of nerinetide 20mg/ml will be given to subje cts with a body 
weight < 105 kg to achieve a final target dose of nerinetide 2.6 mg/kg. Subjects weighing 105-
120 kg will each receive a total dose of 270 mg of study drug (i.e., the entire 13.5 ml contained in the study drug vial). 
  
At the time of randomization, the dose will be calculated based on actual known weight (e.g., 
using an in- hospi[INVESTIGATOR_479392]) or on the subject’s estimated weight.  If the dosing weight was 
estimated , actual weigh t will be obtained by [CONTACT_2006] 5.  Discrepancies between the weight  estimate 
and actual weight obtained may result in some subjects not receiving the correct actual dose.  
Site staff  will record the total volume of nerinetide solution received by [CONTACT_479506] .  The 
following measures of the timeliness of the interventions and of exposure will be computed as follows.   
1) Number and percentages of subjects who received any nerinetide  
2) Descriptive statistics for:  
• Time from stroke symptom onset to start of nerinetide infusion (minutes)  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  26 • Time from randomization to start of nerinetide infusion  (minutes)  
• Time from NCCT to start of nerinetide infusion  (minutes)  
• Duration of study drug infusion (minutes)  
• Duration of study drug infusion (ca tegorical): < 9 minutes, 9 -11 minutes, > 11 minutes  
• Actual administered volume of study drug (mL)  
• Dosing compliance (%)  
• Dosing compliance is calculated as actual administered volume of study drug divided by 
[CONTACT_479507] * 100. The baseline calculated volume of 
study drug is the calculated volume based on the estimated or actual body weight at the 
time of randomization as recorded on the C ase Report Form , 
• Number and percentages of subjects compliant with study drug, a subject is considered 
compliant with study drug if the percent dosing compliance is ≥ 75% and ≤  125%  of 
planned volume . 
All measures will be summarized for the ITT population; individual exposures will be listed by [CONTACT_400420].   
5.4 Study Pro gress Time  
The following study progress time parameters will be summarized by [CONTACT_479508]. 
• Time from Stroke Onset to study drug infusion start (minutes)  
• Time from ESCAPE -NEXT hospi[INVESTIGATOR_479393] (mi nutes)  
• Time from to study drug infusion start to initial reperfusion * (minutes)  
• Time from ESCAPE -NEXT hospi[INVESTIGATOR_274492] (days)  
• Time in repatriation hospi[INVESTIGATOR_307] (days)  
• Time in inpatient rehabilitation (days)  
*time of initial reperfusion is defined as the time logged for the first mTICI score.  
5.[ADDRESS_615668] demographic and baseline characteristics will be summarized with descriptive statistics for each treatment group. Demographic variables include, but are not limited to: age, sex, race -
ethnicity, weight at time of dosing (in kg), and weight as determined in hospi[INVESTIGATOR_307] (in kg).  Baseline characteristics include but are not limited to: age, sex, baseline NIHSS score, baseline ASPECT score, occlusion location, time from stroke symptom onset to randomization (hours), time from stroke symptom onset to randomization ≤4.5 hours  (yes/no) , time from qualifying imaging to 
randomization, unwitnessed stroke onset (yes/no), stroke -on-awakening (yes/no), and site. The 
summaries will be provided for the ITT , Per Protocol and Safety populations. Inferential 
statistics (i.e., p -values or CI) will not be provided for these data with the exception of the results 
of a Fisher’s Exact Test which will be performed for the st ratification variable “ Time from 
Stroke Onset to Randomization ≤ 4.5 hours ” (yes/no)” in order to assess balance across treatment 
groups.  Demographics will be listed by [CONTACT_400420].  
Relevant past medical history as well as prior and concomit ant medications will be summarized 
and listed.   
Version: 2.0 
Date:  [ADDRESS_615669] 
modification (details below).  If there is no evidence for effect modification, then we will report 
the entire cohort only.  If there is evidence for effect modification, we will additionally report resul ts by [CONTACT_64264]. 
Efficacy analyses are summarized in  Table 4: Summary of Inferential Efficacy Analyses . 
6.1 Primary Outcome Variable Analysis for Main Study  
6.1.1 Primary Estimand 
The primary estimand is defined as the difference in the mRS response (i.e. mRS score of 0- 2) 
proportions between treatment conditions (nerinetide vs. placebo) in the target patient population at Day 90 . Death occurr ing prior to Day 90 will be considered as non- respon se.   
6.1.2 Statistical Hypothesis  
The primary hypothesis is:  
H
0: πnerinetide  = π placebo   VS Ha: πnerinetide  ≠ π placebo  
Where π nerinetide  and π placebo  are the nerinetide and placebo population proportions of responders, 
defined as subjects whose Day 90 mRS score is ≤ 2. 
6.1.3 Primary Efficacy Estimand Analysis  
Primary statistical analysis for primary estimand  
The prim ary analysis for the primary estimand will be conducted in the ITT population according 
to the randomized treatment.  Missing data will be imputed following the single  imputation 
approach in Section 4.3.2. The primary hypothesis to be tested is that administration of nerinetide will result in an increase 
in the proportion of mRS responders (as def ined by a score of 0 -2) at Day 90.  
The pi[INVESTIGATOR_479394] 2- sided 0.05 
significance level overall (for the trial), adjusted for the interim analysis per the O’Brien -Fleming 
boundary spending function.  
The pi[INVESTIGATOR_479395] a multivariable generalized linear model 
(GLM) using a binomial distribution with a log link to provide adjusted relative risk  (log-
binomial regression). Adjustment will include the stratification covariate of  time from stroke 
onset to randomization ≤4.5 hours (yes/no) and the randomized minimization (age, sex, baseline 
NIHSS score, baseline ASPECT score, occlusion location, time from qualifying imaging to 
randomization and pooled site) .  
The main effects p rimary analysis will be su pported by a further analysis in which the GL M used 
for the pi[INVESTIGATOR_479396] (treatment by [CONTACT_190081]). If the interaction term is significant at the 0.05 level, we will additionally 
Version: 2.0 
Date:  [ADDRESS_615670] error variance  will be used to provide adjusted relative risk . 
Example SAS code for the log- binomial regression model as follows:  
PROC GENMOD DATA = ADMRS; 
CLASS TRTPN RANDTIME SEX BASPECT OCCLOC SITEGR1; 
MODEL CRIT1FN(event=”1”) = TRTPN RANDTIME AGE SEX BNIHSS 
BASPECT OCCLOC IMA_TIME SITEGR1 / DIST = BINOMIAL LINK=LOG; 
ESTIMATE “NA-1 vs. placebo” TRTPN 1 -1 / exp; 
RUN; 
Example SAS code for the Poisson regression model:  
PROC GENMOD DATA = ADMRS; 
CLASS TRTPN RANDTIME SEX BASPECT OCCLOC SITEGR1 USUBJID; 
MODEL CRIT1FN = TRTPN RANDTIME AGE SEX BNIHSS BASPECT 
OCCLOC IMA_TIME SITEGR1 / DIST = POISSON LINK=LOG; 
REPEAT SUBJECT=USUBJID / TYPE=IND; ESTIMATE “NA-1 vs. Placebo” TRTPN 1 -1 / exp; 
RUN; 
Where CRIT1FN is a n umeric variable to indicate binary mRS responder status (1 = responder, 0 
= non- responder), TRTPN is a numeric variable for treatment group (1 = nerinetide group, 2 = 
placebo), USUBJID is the subject ID.  
The conditional treatment effect  (i.e. relative risk ) along with the 95% CI, as well as the 
corresponding Wald test statistics and p- value estimated from the above model will be reported. 
Actual proportions with and without independent functioning (i.e. mRS responders and non-
responders)  will be reported.  
In addition, the unconditional treatment effect will be estimated and reported following below 
steps : 
1. Run the primary analysis model ( adjusted log- binomial regression ) as described above . 
2. For each subject, compute the model -based prediction of the probability of mRS response 
under nerinetide in both the nerinetide group and placebo group using each subject’s 
specific baseline covariates ( i.e. as specified  in the primary analysis model)  
3. Estimate the average response under nerinetide by [CONTACT_85719] (ac ross all subjects in the ITT 
population) the probabilities estimated in Step [ADDRESS_615671]’s specifi c 
baseline covariates  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  29 5. Estimate the average response under placebo by [CONTACT_85719] (across all subjects in the ITT 
population) the probabilities estimated in Step 4  
6. The estimates of average mRS responses rates in the two treatment groups from Steps 3 
and 5 wil l be used to estimate the relative risk (i.e. unconditional treatment effect ) 
The 95% CI of the unconditional treatment effect will be constructed using a nonparametric 
bootstrap resampling, with [ADDRESS_615672] as the unit of resampling. Resampling will be done independently for the nerinetide and placebo subjects. For each resample, Steps 1- 6 
will be repeated. The 95% CI of the unconditional treatment effect will then be determined from the distribution of resample relative risks.  
Sensitivity a nalyses for the primary estimand  
Sensitivity analyses in the ITT population will be conducted in which missing values are not imputed, i.e. observed cases (OC). In addition, the following analyses will be also be performed depending on the amount of missingness  observed : 
• If ≤ 5% of participants randomized are missing the Day 90 mRS assessment, a sensitivity analysis will be performed for the primary estimand by [CONTACT_479509] 90 mRS assessments. Participants who are known to be dead before or at Day 90 will also be included as non- responders.  
• If more than 5% participants randomized are missing the Day 90 mRS assessment : 
o  a sensitivity analysis will be performed for the primary estimand with missing data 
imputed by [CONTACT_51866]  (refer to Section 4.3.2)  
o A tippi[INVESTIGATOR_479397]:  
1. For each of the multiple imputed datasets, the primary analysis mode l, i.e. adjusted log-
binomial  regression , will be performed. The log (relative risk)  and the standard errors  will 
be obtained.  
2. The point estimate of the log ( relative risk ) and standard errors obtained from Step 1 will 
be passed to PROC MIANALYZE to generate a combined result. The combined log 
(relative risk ), relative risk  and associated 95% CI and the resulting p -value will be 
reported.  
Supportive analyses for the primary estimand  
Additional supportive analyses will be conducted in addition to the primary and sensitivity 
analysis to provide additional insights into the understanding of the treatment effect. 
The primary analysis will be s upported by a Cochran- Mantel -Haenszel test to evaluate the 
association between treatment and the primary outcome stratified by [CONTACT_479510] ( time from stroke onset to randomization ≤4.5 hours (yes/no).  
Homogeneity of the random ization stratification variable will be tested via Breslow -Day 
statistics.  The common relative risk (nerinetide/placebo) over all strata with its 95% CI and p -
value will be reported.  
Example SAS code for the Cochran -Mantel -Haenszel test is as follows :  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  30 PROC FREQ DATA = ADMRS; 
TABLES RANDTIME*TRTP*CRIT1FL / CMH; 
RUN; 
A further supportive analysis will be an unadjusted two- sample comparison of binomial 
proportions via Wald test from logistic regression stratif ied on the randomization stratification 
factor (time from stroke onset to randomization ≤ 4.5 hours (yes/no))  to match the 
randomization. Estimated proportions (% responders) will be reported with binomial confidence 
intervals.  
Example SAS code for the logistic regression test is as follows: 
PROC LOGISTIC DATA = ADMRS; 
 CLASS TRTP (PARAM=REF REF=’Placebo’); 
 STRATA RANDTIME; 
 MODEL CRIT1FL(EVENT=”Y”) = TRTP; 
 ODDSRATIO TRTP / CL=WALD DIFF=ALL; 
RUN; 
Where CRIT1FL is the binary mRS responder status (yes/no).  
Two additionally supportive analyses to the primary analysis will be conducted: (1) the primary 
analysis reapplied to the Per Protocol population with observed cases (OC) only; (2) a re -
randomization analysis to demonstrate that minimization did not bias the primary endpoint analysis. The later test will consist of rerunning the randomization 5,000 times on the original 
subjects’ data and then performing the primary endpoint analysis on each of the re -randomized 
data sets. This will yield a distribution of 5,[ADDRESS_615673]. The p- value from the 
actual primary analysis will be compared to the distribution of randomization p- values. If (for 
example) the minimization was unbiased and actual p -value was 0.01, we would expect P=0.[ADDRESS_615674] percentile of the distribution of the 5000 p- values. A variant of t his 
methodolog y was successf ully used to validate the minimization in  the E SCAPE2 and 
ESCAPE -NA14 trials.  
Baseline, Day 6/Discharge , Day [ADDRESS_615675] . 
6.2 Secondary Efficacy Estimand Analyses for Main Study  
The primary analysis for the secondary estimands  with binary endpoint s will be based on the ITT 
population following the same methods as the primary estimand, and reported as described for each estimand including reporting by [CONTACT_479511][INVESTIGATOR_479398] 0.05 level . 
Missing data will be imputed according to Section 4.3. 
Binary secondary endpoints include: mortality rate, NIHSS responder and worsening of stroke.  
For the secondary estimand of the “mRS shift analysis” , the first step in the  analysis will be an 
adjusted analysis with mRS score 5 and 6 combined, using a proportional odds model to derive 
the common odds of improvement (“shift”) along the mRS scale. The mRS shift analysis will 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  31 only be conducted provided that the proportional odds assumption is found to be valid on testing. 
If it is found to be invalid, the remai ning secondary endpoints will be deemed to be protected. 
Adjustment will include the same variables as the primary outcome analysis.  
All tests will be conducted with two -sided level of significance alpha = 0.05 (overall for the in 
trial), adjusted for the interim analysis per the O’Brien -Fleming boundary spending function. A 
fixed sequence multiple testing procedure will control the overall experiment -wise error rate for 
the trial (see below). It pre -specifies that, with all tests conducted at the same pre- specified 
significance level, the primary endpoint will be tested first, and all subsequent tests are considered failed and deemed exploratory if conducted, in the order specified (primary analysis first, key secondary analysis second, etc.), after the fir st test which fails. All tests that follow the 
first failed test, are considered exploratory.  The secondary endpoints, and the order they are to be tested, are as they are listed in Table 1: Objectives and Endpoints . 
Sensitivity analysis of the secondary estimands will be conducted in ITT population with missing data not imputed.  
Additional analysis details of each outcome along with the supportive analy ses of the secondary 
estimands are specified in each section below.  
6.2.1 Mortality  
Mortality rates, defined as the number of deaths observed divided by [CONTACT_479512] 90- day study period between nerinetide and placebo control participants . 
Results will be summarized and tabulated .  
In addition to the primary and sensitivity  analysis, m ortality analysis will be additionally 
supported using:  
• Time-to-death survival function analysis, both unadjusted using Kaplan -Meier analysis and 
adjusted via Cox proportional hazards regression.  Subjects who are known to be alive or 
the mortality status is unknown at study completion/discontinuation will be censored at the date of completion/discontinuation. 
• Unadjusted logistic  regression as described for the primary estimand  
Mortality status scores will be listed by [CONTACT_400420].  
6.2.[ADDRESS_615676] one worsening of stroke divided by [CONTACT_479513] 90- day period in that 
treatment group, between neri netide and placebo control participants.  Results will be summarized 
and tabulated. The unadjusted logistic regression  method will be used as a supportive analysis. 
The alpha protected secondary analysis of Worsening of Stroke as currently designed will also be supported by a further analysis in which the imaging requirement is waived, in order to include in this supportive analysis any cases in which the stroke worsened so rapi[INVESTIGATOR_479399]. 
6.2.3 Secondary Outcome Analysis – mRS shift analysis  
The prim ary analysis of the ordinal mRS scores will employ a proportional odds model (POM) 
to test the hypothesis that, among randomized subjects, those who are treated with nerinetide will 
show a shift in their mRS score distribution at 90 days relative to the mRS distribution of the 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  32 placebo subjects. The magnitude of the shift will be estimated as the common odds ratio (95% 
CI). Modified Rankin scores of 5 and 6 (bed-bound with severe disability, and death) will be 
collapsed into a single category representing sever ely limited functioning. A n adjusted POM will 
be used to derive the common odds of improvement (i.e. the nerinetide vs. placebo “shift” in mRS score distributions). Adjustment will include the same variables as the primary outcome analysis.  The mRS shift analysis will only be conducted provided that the proportional odds assumption is found to be valid on testing. Deceased participants will be included with a mRS score of 6.   
For the purpose of clarity, since the analysis of the ordinal mRS scores will em ploy a 
proportional odds model (POM), if test of the proportional odds assumption shows the assumption to be invalid, this key secondary analysis will not be performed  and the remaining 
secondary outcomes will be deemed to be protected. 
Example SAS code fo r POM testing as follows: 
PROC LOGISTIC DATA=ADMRS; 
CLASS TRTP RANDTIME SEX BASPECT OCCLOC SITEGR1 / PARAM=GLM; 
MODEL AVAL = TRTP RANDTIME AGE SEX BNIHSS BASPECT OCCLOC 
IMA_TIME SITEGR1; 
EFFECTPLOT INTERACTION(X=TRTP SLICDBY=AVAL) / POLYBAR; 
ODDSRATIO TRTP / CL=WALD DIFF=ALL; 
RUN; 
Where “AVAL ’ is the collapsed mRS scale values ranging from 0 to 5 (level 5 = 5+6 mRS 
combined) . 
When SAS fits the POM, it runs a global test for a shift across all 6 mRS categories in the 
nerinetide group relative to the placebo; this is the test of the proportional odds (PO) assumption. The proportional odds assumption will be checked via the score test at an alpha- level of 0.15 and 
also using graphical methods to view the cumulative log odds for each mRS score. If the assumption holds, the POM estimates a single fixed odds ratio for the 5 cumulative binary endpoints defined as follows:  
1) The proporti on of subjects with mRS = 0 vs. the proportion with mRS>0  
2) The proportion of subjects with mRS ≤ 1 vs. the proportion with mRS>1  
3) The proportion of subjects with mRS ≤2 vs. the proportion with mRS>2  
4) The proportion of subjects with mRS ≤3 vs. the proportion w ith mRS>3  
5) The proportion of subjects with mRS ≤4 vs. the proportion with mRS>[ADDRESS_615677]’s being in the higher functioning category of t he dichotomy 
to a control subject’s odds, will remain the same over the entire span of the mRS scale. Thus, there is no advantage to estimating ORs singly for any of the above dichotomies. If the PO assumption holds, none of them will be significantly diff erent from the common odds ratio. This 
is analogous to the proportional hazard assumption of the Cox regression model, which posits a constant ratio of treatment vs. control hazard rates at every time point in a study. 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  33 Note that the model tests and estimates associated with endpoints “b” and “c” are the more 
commonly used (and less efficient) mRS dichotomies that represent “good” vs. “poor” functioning. Thus, in addition to providing a statistically powerful test for a treatment vs. placebo shift across all  the mRS scores, the POM subsumes the more common dichotomous mRS 
analyses that efficacy decisions in stroke trials are often based on (Agresti 2007; Nunn 2016)
16,17. 
The results of the PO assumption tests, the common odds ratio estimate (with Wald 95% CIs) and corresponding Wald test statistics will be summarized in a table. Actual proportions in each category of the collapsed mRS scale with corresponding stacked bar charts will also be presented.  
6.2.4 National Institutes of Health Stroke Scale  
The NIHSS scores will be dichotomized into 0- 2 (indicating a good neurological outcome) 
versus >2 (indicating otherwise). The proportion of subjects achieving a good neurological 
outcome at Day [ADDRESS_615678] to the fixed sequence multiple testing procedure to control the overall expe riment- wise error rate for the trial 
as was done for the secondary analyses. These efficacy outcomes will be reported as described for each outcome including reporting by [CONTACT_479514][INVESTIGATOR_479398] 0.05 level . 
The tertiary efficacy endpoints include the:  
• Volume of stroke as measured by [CONTACT_479414] (MRI preferred).    
• Proportion of participants with functional independence in activit ies of daily living, as 
defined by a score of ≥ 95 on the Barthel Index (BI) at Day [ADDRESS_615679] randomization. 
• Proportion of participants with reduced moderate or severe disability or death, as defined by a score of [ADDRESS_615680] randomization.  
• Proportion of participants with excellent functional outcome, as defined by a score of 0- [ADDRESS_615681] randomization.  
• Health -related quality of life, as measured by [CONTACT_20367] -5D-5L at Day 90.  
6.3.1 Volume of Stroke  
Total volume will be assessed using an adjusted analysis comprising of a linear regression that includes the stratification and minimization variables , and supported by [CONTACT_479515]- tailed 
Student’s t -test. A cubic root transformation will be performed if needed. Results will be 
reported with confidence intervals for the unadjusted and adjusted treatment effect between treatment groups.  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  34 Stroke volume will be listed by [CONTACT_479516] t. 
6.3.2 Barthel Index  
The BI scores will be dichotomized at 0- 90 (indicating otherwise) versus 95- 100 (indicating 
independent functioning with activities of daily living). The proportion of subjects with 
independent functioning with activities of daily living at Day [ADDRESS_615682]. 
6.3.3 Proportion of subjects with Day 90 mRS 4- 6 
The Day 90 mRS score will be dichotomized at mRS ≥ 4 (indicating moderate, severe disability 
or death) vs. mRS < 4 (indicating otherwise). The proportion of subjects with based on this 
dichotomy on D ay 90 in nerinetide versus placebo control subjects will be analyzed as the 
primary analysis described for the primary estimand . Results will be summarized and tabulated.  
6.3.4 Proportion of subjects with Day 90 mRS ≤ 1  
The Day 90 mRS score will be dichotomized at mRS≤1 (indicating freedom from disability) vs. 
mRS>1 (indicating otherwise). The proportion of subjects with freedom from dependence/disability based on this dichotomy on Day 90 in nerinetide versus placebo cont rol 
subjects will be analyzed  using the same method as the primary analysis for the primary 
estimand . Results will be summarized and tabulated.  
6.3.5 EQ-5D-5L 
For the EQ -5D-5L, the difference between nerinetide and placebo control subjects in the 
distribution of  the EQ -VAS score at Day 90 will be summarized descriptively and modeled as a 
continuous variable. An analysis of covariance (ANCOVA) model will be fit to the EQ -VAS 
endpoint with the nerinetide/placebo treatment indicator variable and the stratification variables and covariates used in the supportive primary and secondary efficacy analyses. ANCOVA results will be summarized in a table.  Least squared means, standard error and 95% CI will be reported.  
The five dimensions of EQ -5D-5L (Mobility, Self -Care, Usu al Activities, Pain/Discomfort, and 
Anxiety/Depression) will be summarized using frequency counts and percentages separately by [CONTACT_1570].  
Day [ADDRESS_615683] include the following:  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  35 • Age (<80 years vs ≥ 80 years of age)  
• Age (<65 years vs ≥ 65 years of age)  
• Sex (men vs. women)  
• Ethnicity (Hispanics vs non- Hispanic)  
• Race (White, Asian, Black, Other)  
• Baseline stroke severity (NIHSS > Median vs. NIHSS <= Median)  
• Baseline occlusion location (MCA [including M1 and M2]  vs. ICA)  
• Baseline ASPECT score (5 -7 vs. 8- 10) 
• Time from qualifying imaging to study drug initiation (greater  than vs. less than the 
median).  
• Time from onset of stroke symptoms to start of study drug greater than vs. less than the 
median).  
• Degree of reperfusion (TICI ³ 2b vs. TICI <2b)  
• Subjects weighing between 105- [ADDRESS_615684] sizes will be estimated as subgroup -specific odds ratios (±95% CIs) as follows. Separate 
logistic regression models for the primary/secondary endpoint s, with treatment group and the 
stratification variables and covariates used in the minimization algorithm as predictors, will be fit 
to each of the subject subgroups (e.g., a model will be fit to males and a second model will be fit to females). The estima ted (nerinetide/placebo) odds ratios, with 95% confidence intervals will 
be the nerinetide effect size estimates for each of the subgroups (e.g., for males and for females) and will be displayed in the forest plots.  
6.[ADDRESS_615685] 
noncompartmental methods for all subjects with PK samples: 
• AUC0 –t: Area under the concentration- time curve from time zero to time of last 
measurable concentration 
• AUC0 –inf: Area under the concentration- time curve from time zero to infinity  
• Cmax: Maximum plasma concentration observed after dosing  
• Tmax: Time to occurrence of Cmax  
• t½: Terminal elimination half -life 
Samples with no detectable nerinetide will be excluded from analysis (placebo).  
Descriptive  statistic s will be calculated for nerinetide pl asma concent rations a nd for all PK 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  36 param eters (AUC 0-t, AUC 0-∞, Cmax, Tmax, t½). 
PK results at all timepoints will be listed for the Nerinetide arm by [CONTACT_1130].  
6.6 Outcome Analysis for 1- Year Sub -Study  
The outcomes of the 1 -Year Sub -Study are intended to be supportive of the 90- day outcomes of 
the main study. The analysis population will be comprised of participants with a valid consent 
for the 1 -year sub- study in the relevant jurisdiction. Missing data will be imputed as per Section 
4.3 except that for subjects who are successfully contact[INVESTIGATOR_530] (i.e., not deceased) but who cannot complete the telephone interview (e.g., due to dysphasia, a language barrier, or incapacity) will have their outcomes estimated by [CONTACT_20679]. A summary table will specify the differences 
between the population analyzed in the main study and the 1- year sub- study, including deaths, 
losses to follow -up and withdrawal of consent.  
The primary outcome i s the proportion of subjects with independent functioning on the modified 
Rankin Scale (mRS), as defined by a score of 0 -2) at 1 year.  
The secondary outcomes include:  
• A reduction in mortality rate, as defined by [CONTACT_479412] (%) for mortality over the 1 -year 
study period. 
• The proportion of subjects with independent function on activities of daily living defined 
on the modified Barthel Index (BI) with a score of ≥ 95 at 1 year.  
• Health -related quality of life, as measured by [CONTACT_20367] -5D-5L at 1 year.  
6.6.1 mRS at 1 Yea r 
The mRS will be assessed as per the protocol. It will be dichotomized, analyzed and reported as 
in the primary efficacy analysis.  
6.6.2 Mortality Rate at 1 Year  
Mortality at 1 year will be assessed as per the protocol  (from family or legally authorized 
representative or from hospi[INVESTIGATOR_1097] ). It will be analyzed and reported as described in Section 
6.2.1. 6.6.3 Barthel  Index at 1 Year  
The Barthel Index will be obtained as per the protocol  from trial participants at 1 year. It will be 
dichotomized, analyzed and reported as for the primary analysis.  
6.6.4 EQ-5D-5L at 1 Year  
The EQ -5D-5L will be obtained by [CONTACT_116622]- person interview from trial participants at 1 
year. EQ -5D-VAS will be  analyzed and reported as described in Section 6.3.5. 
 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  37 Table 4: Summary of Inferential Efficacy Analyses  
Endpoint  Primary Analysis * Sensitivity Analysis * Supportive Analysis * 
Primary  Day-90 mRS 
Responder  
(≤2 vs. >2)  Adjusted log- binomial 
regression model , ITT, SI  
Estimation of 
unconditional treatment 
effect will also be reported.  - Adjusted log- binomial regression model , 
ITT, OC  
- Adjusted log- binomial regression model , 
ITT with Day 90 completers only (if missingness ≤ 5%)  
- Adjusted log- binomial regression model , 
ITT, MI (if missingness > 5%) 
- Adjusted log- binomial regression model , 
ITT, Tippi[INVESTIGATOR_47863] (if 
missingness > 5%)  - Primary analysis w ith the interaction term  
added ( treatment by [CONTACT_457178] ) 
- Adjusted log- binomial regression model , ITT, 
Re-randomization  
- CMH, ITT, SI 
- Unadjusted logistic regression , ITT, SI  
- Adjusted log- binomial regression model , PP, 
OC 
Secondary  Day-90 Mortality  Adjusted log- binomial 
regression model , ITT  
Missing data imputed based on Day 30 status  Adjusted log- binomial regression model , 
ITT, OC  Mortality Rate:  
-  Unadjusted logistic regression , ITT, Missing 
data imputed based on Day 30 status  
- Adjusted log- binomial regression model, PP, 
OC 
Time to Death (Days):  
- Kaplan Meier, ITT, OC  
- Cox proportional hazard regression, ITT, OC  
Worsening of Stroke  Adjusted log- binomial 
regression model , ITT, 
Missing data  imputed 
based on Day 30 status  Adjusted log- binomial regression model , 
ITT, OC  - Unadjusted logistic regression , ITT, Missing 
data imputed based on Day 30 status  
-  Adjusted log- binomial regression model  PP, 
OC 
Day-90 mRS shift 
(Ordinal)  POM, ITT, SI - POM, ITT, OC  
- POM, ITT with Day 90 completers only  POM, PP, OC  
Day-90 NIHSS 
Responder (≤2 vs. >2)  Adjusted log-binomial 
regression model , ITT, 
LOCF  Adjusted log- binomial regression model , 
ITT, OC  - Unadjusted logistics regression, ITT , LOCF  
- Adjusted log- binomial regression model , PP, 
OC 
Tertiary  Stroke volume  Linear regression , ITT, OC  N/A Student’s t -test, ITT, OC  
Day-90 Barthel 
Responder (<95 
vs.≥95)  Adjusted log- binomial 
regression model , ITT, OC  N/A N/A 
Day-90 mRS Adjusted log- binomial N/A N/A 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  38 Endpoint  Primary Analysis * Sensitivity Analysis * Supportive Analysis * 
Responder (≤3 vs. ≥4)  regression model,  ITT, SI  
Day-90 mRS 
Responder (≤1 vs. >1)  Adjusted log- binomial 
regression model , ITT, SI  N/A N/A 
Day 90 EQ -VAS  ANCOVA, ITT, OC  N/A N/A 
1 Year  mRS Responder (≤2 
vs. >2)  Adjusted log -binomial 
regression model , ITT, MI  N/A N/A 
Day-90 Mortality  Adjusted log-binomial 
regression model , ITT, OC  N/A N/A 
Barthel Index  Adjusted log- binomial 
regression model , ITT  N/A N/A 
EQ-VAS  ANCOVA, ITT, OC  N/A N/A 
*For analyses using the a djusted log-binomial regression model, a Poisson model with robust variance will be used if the log- binomial model fails to converge  
Version: 2.0 
Date:  [ADDRESS_615686] one AE, having an AE in each body system and preferre d term, by 
[CONTACT_479517]. The frequencies and incidences of AEs occurring in subjects in the drug and placebo control groups will be summarized within treatment group by 
[CONTACT_67503] (MedDR A) System Organ Class (SOC). The 
frequencies and incidences of discontinuations due to AEs occurring in subjects in the nerinetide 
and placebo control groups will be summarized within treatment group. 
If a given subject had more than one AE mapped to the s ame preferred term, then that subject 
will be counted only once within that preferred term. A listing of Adverse Events of Special Interest (AESIs) can be found in Appendix 9.[ADDRESS_615687] had more than one AE mapped 
to the same preferred term, then that AE will be counted once according to the maximal level of severity (Severe, Moderate, Mild). 
When rep orting TEAEs by [CONTACT_78487], if a given subject had more than one 
AE mapped to the same preferred term, then that AE will be counted once according to the 
highest level of relatedness (Related, Possibly, Unrelated).  
The following summar ies (tables) of AEs and TEAEs will be provided by [CONTACT_6227] (percentage) 
of subjects for each treatment group:  
• Overview of Adverse Events  
• TEAEs (with a start date 0 -30 days) by [CONTACT_53189]  
• Serious TEAEs (with start date 0 -90 days) by [CONTACT_479518]  
• All TEAEs resulting in death by [CONTACT_479518]  
• Event rate (%) for Serious TEAEs over the 90 -day study period between nerinetide and 
placebo control subjects will be compared by a logistic regression model similar  to that of 
the primary analysis.  
• All TEAEs occurring in at least 5% of subjects in either treatment arm, by [CONTACT_479518].  
• All TEAEs by [CONTACT_764] (Severe, Moderate, Mild) by [CONTACT_479518].   Missing severity gra des will be assumed as ‘severe’.  
• All TEAEs by [CONTACT_78487] (Related, Possibly, Unrelated) by [CONTACT_479518].  Missing relationships will be assumed as ‘related’.  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  40 • Serious TEAEs (with start date 0 -90 days) by [CONTACT_3773] p to study treatment (Related, 
Possibly, Unrelated) by [CONTACT_479518].  Missing relationships will 
be assumed as ‘related’.  
• All TEAEs resulting in discontinuation of treatment, by [CONTACT_479519] 
• TEAESIs (onset [ADDRESS_615688] as 
defined in Appendix 1:  Listing of Treatment- Emergent AEs of Special Interest 
(TEAESI) ) by [CONTACT_479520]:  
• All AEs by [CONTACT_479518]  
• All SAEs by [CONTACT_479518]   
• All TEAEs leading to death by [CONTACT_479518]  
• All SAEs related to study drug by [CONTACT_479518]  “Related” will 
include Related, Possibly and missing relationship 
• All TEAESIs by [CONTACT_479518]  
• All TEAEs resulting in discontinuation of treatment 
7.2 Vital Signs  
A summary (tabl e) of b lood pressure (systolic and diastolic) will be reported  at Baseline/Visit 1 , 
immediately pre dose  (Visit 1) , post dose  (Visit 1), Visit 2 (Post EVT) and at Visit 3 (Day 2/3). 
Absolute values and changes from Baseline (Visit 1) to post dose (Visit 1) , Visit 2 (Post EVT) 
and at Visit 3 (Day 2/3)  will be summarized descriptively .  
A summary (table) of heart rate will be reported at Baseline /Visit 1  (pre-dose) , Visit 2  (Post 
EVT) and at Visit 3 ( Day 2 /3). Absolute values and changes from pre -dose to Post EVT and Day 
2 will be summarized descriptively .  
A summary (table) of t emperature will be reported Baseline/Visit 1 (pre -dose), Visit 2 (Post 
EVT) and at Visit 3 (Day 2/3). Absolute values and changes from pre -dose to Post EVT and Day 
2 will be summarized descriptively .  
 A listing of all vital signs will be provided. 
7.3 Laboratory Results  
A summary (table) of c omplete blood count  (Platelets , hematocrit  and hemoglobin), electrolytes 
(sodium, potassium and chlor ide) and chemistry (serum creatinine and serum glucose) will be 
reported at Baseline and Day 2 . 
Absolute values and change from baseline values for laboratory results will be summarized 
descriptively. Inferential statistics (ie, p -values or CI) will not be provided for these data.  
A listing of all laboratory results as well as abnormal lab values post -dose will be provided. 
 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  41 7.4 Concomitant  Medications  
All concomitant medications collected on the C ase Report Form  with a start date prior to the date 
of Visit 4 ( Visit will occur at Day 6 or hospi[INVESTIGATOR_479349] 6 ) will be summarized 
by [CONTACT_479521] [ADDRESS_615689] listings . 
  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  42 
 INTERIM  ANALYSIS  
There will be an unblinded interim analysis and sample size re -estimation (SSRE) conducted in 
this trial when approximately 510 participants (75% information based on initial sample size) 
completed their 90- day study visit (that is when [ADDRESS_615690] either completed Day 90 
visit or discontinued from the study prior to Day 90 visit).  
The interim analysis will be conducted by [CONTACT_353660] s tatistician in the independent Statistical 
Group. An IDMC will review the interim efficacy and SSRE results. Depending on enrollment rates, it may be necessary to perform the interim analysis before 75% 
information to ensure sample size re -estimation is completed before the study has been fully 
enrolled.  
8.[ADDRESS_615691] complete the Day 90 follow -up, at 75% information on the primary endpoint. The interim 
efficacy analysis will be conducted on the ITT popula tion, following the same methods as the 
study final analysis described in Table 5  below.  
Table 5: Summary of Interim Efficacy Analyses  
Endpoint  Analysis  
Primary  Day-90 mRS Responder  
(≤2 vs. >2)  Adjusted log- binomial regression model , ITT, SI  
Secondary  Day-90 Mortality   Adjusted log-binomial regression model , ITT  
Missing data imputed based on Day 30 status  
Worsening of Stroke  Adjusted log- binomial regression model , ITT, Missing data 
imputed based on Day 30 status  
Day-90 mRS shift (Ordinal)  POM, ITT, SI 
Day-90 NIHSS Responder 
(≤2 vs. >2)  Adjusted log- binomial regression model,  ITT, LOCF  
 
The planned initial sample size is of 680 evaluable participants randomized 1:1, allowing for a 
single interim analysis at 75% information (when about [ADDRESS_615692] primary endpoint assessments) with O’Brien -Fleming alpha -spending function stoppi[INVESTIGATOR_479400] -estimation based on 
conditional power at the same interim look using the Chen- DeMets -Lan approach
7 for unblinded 
sample size re -estimation. The trial- wise al pha (FWER) will be controlled at pi[INVESTIGATOR_22735], 1- sided 
0.[ADDRESS_615693] for comparison of 2 independent proportions
7,18 (EaST v6.5 2020), in spi[INVESTIGATOR_479401] -estimation, by [CONTACT_941] 
“promising zone” method using the Chen- DeMets -Lan approach1. The cumulative alpha spent at 
the interim analysis is 0.01 and final analysi s 0.025, 1- sided; the stoppi[INVESTIGATOR_3073] Z 
scale are 2.34 (interim) and 2.012 (final) and on the p- value scale 0.01 (interim) and 0.022 
(final), all on the assumption that the interim is conducted at 75% information (EaST v6.5, 2020). If the interim analysis is conducted at a different time point other than when 75% 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  43 information available, the type I error and the efficacy boundary for the interim and final analysis 
will be adjusted accordingly using nQuery Advisor®.  
Power calculations for the unblinded sample size re -estimation design were run  via simulation 
under the assumption of 2% probability of dropout during the trial (across both arms) using the Chen -DeMets -Lan approach
1 for unblinded sample size re -estimation with a maximum sample 
size of 1020 randomized (sample size re -estimation inflation factor 1.5) and inflation based on 
conditional power promising zone between 50% and 80% based on the observed trend at the interim and using a Wald statistic (using a sample size increase rule to be specified in the IDMC Charter to prevent back -calculation of interim effect sizes).  
The IDMC may recommend stoppi[INVESTIGATOR_479402] O -F boundary.  Additionally, the IDMC may recommend a sample size 
modification for the trial per the pre -specified re- estimation criteria which are outlined in the 
IDMC Charter , based on the interim results  provided by [CONTACT_479522] /Independent Statistical Center  to the IDMC . However, notwithstanding the O -F 
superiority critical p -value of 0.01 for stoppi[INVESTIGATOR_007] (boundary value) at the interim analysis of the 
primary efficacy outcome, the IDMC will be instructed to make a recommendation on stoppi[INVESTIGATOR_479403], and also, in support of their recommendation, to report to the Sponsor/Steering Committee whether or not the superiority boundary was crossed and how the study sample size sh ould be adjusted after the interim analyses . The IDMC Charter will provide 
further details on the rationale for, and how, these recommendations will be communicated.   
The following summary tables and analyses will be performed at the interim analysis (als o see 
Table 5 ) and provided to the IDMC  in support of consideration of stoppi[INVESTIGATOR_479404] : 
• Subject disposition ( e.g., number completed Day 90 visits) by [CONTACT_1570]  
• Subject demographics and baseline characteristics (as described in Section 5.5) by 
[CONTACT_22058] t group  
• Primary efficacy endpoint:  
o Proportion of participants with independent functioning on the modified Rankin Scale (mRS), as defined by a score of 0 -2 (mRS responder) at Day 90  
• Secondary efficacy endpoints:  
o Mortality rate over the 90 -day study period  
o Proportion of participants with worsening of stroke over the 90 -day study period 
o Shift in mRS categories at Day 90 (mRS shift analysis)  
o Proportion of participants with a score of [ADDRESS_615694] d ata listings will also be provided to support the interim tables.  
The unblinded statistician in the Independent Statistical Group will also perform the conditional 
power calculation and sample size re- estimation by [CONTACT_373105]
® (Interim Monitoring 
and Unblinded Sample Size Re -estimation Module ). The sample size increase rules will be 
provided to the unblinded statistician directly by [CONTACT_479523] , and will not be shared with any blinded study te am members  prior to database lock . The 
nQuery results, including the Wald test statistics and conditional power based on the treatment 
Version: 2.0 
Date:  [ADDRESS_615695] information time of interim analysis, sample size 
re-estimation rule s, the re- estimated new sample size (if applicable) and the conditional power 
based on the new sample size will be provide d to ID MC in a format (e.g. executive summary in a 
report or presentation slides)  as deemed appropriate by [CONTACT_63539].  
8.2 Safety Analysis  
The Independent Statistical Group will generate safety reports, which will include cumulative 
summary statistics; subject status in the study (e.g., number completed Day 90 visits); baseline characteristics; safety data, including adverse events (AEs) and serious adverse events (SAEs) by [CONTACT_275783], and discontinuations due to AEs.  The IDMC may recommend stoppi[INVESTIGATOR_479405] . 
The following safety summaries (tables) will be provided to the IDMC: 
• Overview of Adverse Events  
• TEAEs (with a start date 0 -30 days) by [CONTACT_53189]  
• Serious TEAEs (with start date 0 -90 days) by [CONTACT_479518]  
• All TEAEs resulting in death by [CONTACT_479518]  
• All TEAEs resulting in discon tinuation of treatment, by [CONTACT_479524]:  
• All AEs by [CONTACT_479518]  
• All SAEs by [CONTACT_479518]  
• All AEs leading to death by [CONTACT_479525]  
8.3 Independent Data Monitoring Committee  
Activities, mandate, responsibilities, communication structure and function of the IDMC will be documented in the IDMC Charter prospectively. This will also include a Blinding Plan specifying sequestering and blinding measures planned for the trial (including analysis firewalls) to prevent operational bias from revelation outside the IDMC of any aggregate interim results on safety or efficacy by [CONTACT_2939].  
Two versions of these safety reports will be cr eated – an open (blinded) report to be distributed 
to the Trial Executive Committee and the IDMC, and a closed (unblinded) report to be distributed only to the IDMC. The closed reports will be forwarded to the Trial Executive Committee following database lock and unblinding at the end of the study.  
The IDMC will be unblinded to safety data to ensure a detailed analysis of safety. To ensure minimization of operational bias and confidentiality of the safety data, the IDMC reports will be analyzed by [CONTACT_479526] (the “Independent Statistical Center”) that is independent of the sponsor and the blinded project team who will implement the trial. Firewalls will be maintained between these two groups. No unblinded data reports will be seen or discussed by [CONTACT_479527].  The  IDMC Charter (separate document) captures details  of the 
firewalls . 
Version: 2.0 
Date:  [ADDRESS_615696] Team,  steering 
committe e and inve stigators and will produc e the IDMC  Safety Reports as well as the Int erim 
Analysis of  Efficacy and provide  them to the IDMC  members. The reports to the IDMC  will be 
provide d prior to the meeting.  
The Independent S tatistica l Group is r esponsible  to: 
• Prepare Tables, Figures and Listings for the IDMC to re view 
• Prepare interim conditional power results and uSSR information for the IDMC to review 
(per nQuery, see S ection 8.1above ) 
• Apply the treatme nt codes to the  data to pr oduc e the partially unblinde d reports by 
[CONTACT_34689] (Group A vs Group B).  
• Perform a quality check of the results 
• Forward the  agreed-upon Tables, Figures and Listings, conditional power results and uSSR 
information  to the  IDMC  with an  Interim Report (or presentation slides with executive 
summary) for the Interim uSSR  
The Global Coordinating Investigator [INVESTIGATOR_479406]. The  IDMC  Independent Reporting Statistic ian, also a member of the Independent 
Statistical  Group, a lso attends the Open and Closed Sessions  of the IDMC  meetings and answers 
any questions  from the  IDMC  regarding the reports.  The IDMC Chair will take minutes for the 
closed sessions.  
In contrast, the  Project S tatistic ian is on the  blinded Project T eam a nd will  not pr oduce, re view or 
have access to unblind ed aggregate reports for the IDMC  during the  study.  The Project 
Statistic ian’s group will produc e the Final Study Report after final database lock and unblindi ng 
of the trial. 
8.[ADDRESS_615697] reached their 90 day follow -up. The IDMC may recommend to (1) stop the trial due to overwhelming efficacy (2) to 
complete enrollment to the originally -planned 680 participants or (3) to  increase the sample size  
based on the results of the sample -size re- estimation  up to 1020 participants .  
It is possible that, by [CONTACT_479528]  a recommendation , enrollment in the study could 
exceed the number of participants needed to adhere to the IDMC recommendation. In such an 
eventuality, the primary outcome  variable analysis for the main study and for the 1- Year Sub 
Study, as well as the S econdary Efficacy Estimand Analyses for the Main Study and for the 1-
Year Sub Study may also be performed on the  participants as per the IDMC -recommended sample 
size as needed.    
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  46 
 SUPPORTING DOCUMENTATION 
9.1 Appendix 1:  Listing of Treatment -Emergent AEs of Special Interest (TEAESI)  
Table A -1: AEs Related to Angioedema (by [CONTACT_11702] ) based on SMQ  
• Allergic oedema  
• Angioedema  
• Circumoral oedema  
• Conjunctival oedema  
• Corneal oedema  
• Epi[INVESTIGATOR_479407]  
• Eye oedema  
• Eye swelling  
• Eyelid oedem a 
• Face oedema  
• Gingival oedema  
• Gingival swelling  
• Idiopathic angioedema  
• Idiopathic urticaria  
• Laryngeal oedema  
• Laryngotracheal oedema  
• Limbal swelling  
• Lip oedema  
• Lip swelling  
• Mouth swelling  
• Oedema mouth  
• Oropharyngeal oedema  
• Oropharyngeal swelling  
• Palatal oedema  
• Palatal swelling  
• Periorbital oedema  
• Pharyngeal oedema  
• Scleral oedema  
• Swelling face  
• Swollen tongue  
• Tongue oedema  
• Tracheal oedema  • Auricular swelling  
• Breast oedema 
• Breast swelling  
• Choking  
• Choking sensation  
• Drug hypersensitivity  
• Ear swelling  
• Endotracheal intubation  
• Generalised oedema  
• Hypersensitivity  
• Laryngeal obstruction  
• Localised oedema  
• Nasal oedema  
• Nipple oedema  
• Nipple swelling  
• Oedema  
• Oedema mucosal  
• Oedema peripheral  
• Orbital oedema  
• Peripheral swelling  
• Reversible airways obstruction  
• Skin oedema 
• Skin swelling  
• Stridor  
• Suffocation feeling  
• Throat tightness  
• Tracheal obstruction  
• Tracheostomy  
• Upper airway obstruction  
• Urticaria  
• Wheezing  
Table A -2: AEs related to Hypotension (by [CONTACT_11702] ) based on MedDRA Terms  
• Blood pressure abnormal  
• Blood pressure decreased  
• Blood pressure diastolic abnormal  
• Blood pressure diastolic decreased  
• Blood pressure difference of extremities  
• Blood pressure fluctuation  
• Blood pressure immeasurable  
• Blood pressure inadequately controlled  
• Blood pressure ort hostatic abnormal  • Blood pressure orthostatic decreased  
• Blood pressure systolic abnormal  
• Blood pressure systolic decreased  
• Blood pressure systolic inspi[INVESTIGATOR_479408]  
• Labile blood pressure  
• Hypotension  
• Diastolic hypotension  
• Hypotensive transfusion reaction  
• Orthostatic Hypotension  
  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  47 Table A -3: AEs related to Anaphylactic reaction and Anaphylactic shock (by [CONTACT_39813] ) based on SMQs  
Anaphylactic reaction  Anaphylactic shock  
• Anaphylactic reaction  
• Anaphylactic shock  
• Anaphylactic transfusion reaction  
• Anaphylactoid reaction  
• Anaphylactoid shock  
• Circulatory collapse  
• Distributive shock  
• Kounis syndrome  
• Shock  
• Shock symptom  • Acute kidney injury  
• Acute respi[INVESTIGATOR_1399]  
• Asthma  
• Bronchial oedema  
• Bronchospasm  
• Cardio -respi[INVESTIGATOR_1506]  
• Dyspnoea  
• Erythema  
• Eye pruritus  
• Flushing  
• Generalised erythema  
• Hyperventilation  
• Hypoperfusion  
• Injection site urticaria  
• Jugular vein distension  
• Laryngospasm  
• Myocardial depression  
• Nodular rash  
• Ocular hyperaemia  
• Oropharyngeal spasm  
• Organ failure  
• Prerenal failure  
• Propofol infusion syndrome  
• Pruritus  
• Pruritus allergic  
• Pruritus generalised  
• Rash  
• Rash erythematous  
• Rash generalised  
• Rash pruritic  
• Renal failure  
• Respi[INVESTIGATOR_13374]  
• Respi[INVESTIGATOR_1506]  
• Respi[INVESTIGATOR_1399]  
• Sensation of foreign body  
• Tachypnoea  
• Cardiac arrest  
• Cardio- respi[INVESTIGATOR_13374]  
• Cardiovascular insufficiency  
  
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  48 9.2 Appendix 2:  List of Abbreviations   
AE Adverse Event  
AESI  Adverse Events of Special Interest  
AIS  Acute Ischemic Stroke  
ANCOVA  Analysis of Covariance  
ASPECTS  Alberta Stroke Program Early Computerized Tomography Score  
ATC   Anatomical Therapeutic Chemical  
AUC   Area under the Curve  
BI  Barthel Index  
BP  Blood Pressure  
CT  Computerized Tomography 
CTA   Computerized Tomographic Angiography  
CTP  Computerized Tomographic Perfusion  
DWI   Diffusion Weighted Imaging 
eCOA   electronic Clinical Outcome Assessment  
eMCAO  Embolic Middle Cerebral Artery Occlusion  
EQ-5D-5L EuroQol  5-dimension 5- level (quality of life)  
EVT   Endovascular Thrombectomy 
FLAIR   Fluid Attenuated Inversion Recovery  
GRE   Gradient Echo  
ICA   Internal Carotid Artery   
IDMC   Independent Data Monitoring Committee  
IND  Investigational New Drug ([LOCATION_003])  
ITT  Intent -to-Treat   
IV  Intravenous  
LOCF   Last Observation Carried Forward  
MedDRA  Medical Dictionary for Regulatory Activities  
MCA    Middle Cerebral Artery  
mCTA   Multiphase Computerized Tomographic Angiography 
MR  Magnetic Resonance  
MRI   Magnetic Resonance Imaging 
MRP   Magnetic Resonance Perfusion  
mRS   Modified Rankin Scale  
NCCT   Non-contrast  Computed Tomography Scan  
NIHSS   National Institutes of Health Stroke Scale  
OC  Observed Cases  
O-F  O’Brien -Fleming  
OR  Odds Ratio 
PK  Pharmacokinetic  
PO  Proportional Odds  
Version: 2.0 
Date:  [ADDRESS_615698]  
TICI   Thrombolysis i n Cerebral Infarction  
VAS   Visual Analogue Scale  
wt  Weight   
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  50 
 REFERENCES  
1. Aarts M, Liu Y, Liu L, et al. Treatment of ischemic brain damage by [CONTACT_479529] - PSD -95 protein interactions. Science 2002;298:846- 50. 
2. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019- 30. 
3. Tymianski M. Combining Neuroprotection With Endovascular Treatment of Acute Stroke: Is There Hope? Stroke 2017;48:1700- 5. 
4. Hill MD, Goyal M, Menon BK, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE -NA1): a multicentre, double -blind, randomised controlled 
trial. Lancet 2020.  
5. Mayor D, Xi J, Sun X, Teves L, Tymianski M. Plasm in Resistant PSD -[ADDRESS_615699] -Modifying Drug- Drug Interactions Between Alteplase and Nerinetide in 
Acute Ischemic Stroke. Science Translational Medicine 2020;In Revision.  
6. Hill MD, Martin RH, Mikulis D, et al. Safety and efficacy of NA -1 in patients with iatrogenic 
stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double -blind, 
placebo -controlled trial. Lancet Neurol 2012;11:942- 50. 
7. Chen YH, DeMets DL, Lan KK. Increasing the sample size when the unblinded inte rim 
result is promising. Statistics in medicine 2004;23:1023- 38. 
8. Zhao W, Hill MD, Palesch Y. Minimal sufficient balance -a new strategy to balance baseline 
covariates and preserve randomness of treatment allocation. Statistical methods in medical research 2015;24:989- 1002. 
9. Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007;38:1091-6. 
10. Quinn TJ, Dawson J, Walters MR, Lees KR. Rel iability of the modified Rankin Scale: a 
systematic review. Stroke; a journal of cerebral circulation 2009;40:3393- 5. 
11. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol 2006;5:603- 12. 
12. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Md State Med J 1965;14:61- 5. 
13. Quinn TJ, Langhorne P, Stott DJ. Barthel index for stroke trials: development, properties, and application. Stroke; a journal of cerebral circulation 2011;42:1146- 51. 
14. Brooks R. EuroQol: The cur rent state of play. Health Policy 1996;37:53- 72. 
15. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five -
level version of EQ -5D (EQ- 5D-5L). Qual Life Res 2011;20:1727- 36. 
16. Agresti A. An Introduction to Categorical Dat a Analysis. 2
nd Ed. ed. Hoboken, NJ: J. Wiley 
and Sons; 2007. 
17. Nunn A, Bath PM, Gray LJ. Analysis of the Modified Rankin Scale in Randomised Controlled Trials of Acute Ischaemic Stroke: A Systematic Review. Stroke Research and 
Treatment 2016:1- 7. 
18. Gao P, Ware JH, Mehta C. Sample size re -estimation for adaptive sequential design in 
clinical trials. Journal of biopharmaceutical statistics 2008;18:1184- 96. 
19. Lan KKG. Design and analysis of group sequential tests based on type -1 error sp ending rate 
function. Biometrika 1987;74:149- 54. 
20. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 
1979;35:549- 56. 
Version: 2.0 
Date:  18 November  2021  SAP NA -1-009 
NoNO Inc  
 
 Confidential  51 21.     Todd E. Bodner (2008) What Improves with Increased Missing Data Imputations?, Structural 
Equation Modeling: A Multidisciplinary Journal, 15:4, 651- 675 
22.   Breslow, N. E., and Day, N. E. (1980). The Analysis of Case -Control Studies. Statistical 
Methods in Cancer Research, IARC Scientific Publications, vol. 1, no. 32. Lyon: 
International Agency for Research on Cancer.  
 